id	sid	tid	token	lemma	pos
dpc-4151	1	1	dermatology	dermatology	NOUN
dpc-4151	1	2	:	:	PUNCT
dpc-4151	1	3	practical	practical	ADJ
dpc-4151	1	4	and	and	CCONJ
dpc-4151	1	5	conceptual	conceptual	ADJ
dpc-4151	1	6	original	original	ADJ
dpc-4151	1	7	article	article	NOUN
dpc-4151	1	8	|	|	ADV
dpc-4151	1	9	dermatol	dermatol	ADJ
dpc-4151	1	10	pract	pract	NOUN
dpc-4151	1	11	concept	concept	NOUN
dpc-4151	1	12	.	.	PUNCT
dpc-4151	2	1	2024;14(4):e2024220	2024;14(4):e2024220	NUM
dpc-4151	2	2	1	1	NUM
dpc-4151	2	3	efficacy	efficacy	NOUN
dpc-4151	2	4	and	and	CCONJ
dpc-4151	2	5	safety	safety	NOUN
dpc-4151	2	6	of	of	ADP
dpc-4151	2	7	low	low	ADJ
dpc-4151	2	8	-	-	PUNCT
dpc-4151	2	9	dose	dose	NOUN
dpc-4151	2	10	methotrexate	methotrexate	NOUN
dpc-4151	2	11	in	in	ADP
dpc-4151	2	12	generalized	generalized	ADJ
dpc-4151	2	13	and	and	CCONJ
dpc-4151	2	14	recalcitrant	recalcitrant	ADJ
dpc-4151	2	15	lichen	lichen	NOUN
dpc-4151	2	16	planus	planus	NOUN
dpc-4151	2	17	:	:	PUNCT
dpc-4151	2	18	a	a	DET
dpc-4151	2	19	retrospective	retrospective	ADJ
dpc-4151	2	20	study	study	NOUN
dpc-4151	2	21	at	at	ADP
dpc-4151	2	22	a	a	DET
dpc-4151	2	23	tertiary	tertiary	ADJ
dpc-4151	2	24	care	care	NOUN
dpc-4151	2	25	center	center	PROPN
dpc-4151	2	26	ananta	ananta	PROPN
dpc-4151	2	27	khurana	khurana	PROPN
dpc-4151	2	28	,	,	PUNCT
dpc-4151	2	29	savitha	savitha	PROPN
dpc-4151	2	30	sharath	sharath	PROPN
dpc-4151	2	31	,	,	PUNCT
dpc-4151	2	32	kabir	kabir	PROPN
dpc-4151	2	33	sardana	sardana	PROPN
dpc-4151	2	34	department	department	PROPN
dpc-4151	2	35	of	of	ADP
dpc-4151	2	36	dermatology	dermatology	NOUN
dpc-4151	2	37	,	,	PUNCT
dpc-4151	2	38	venereology	venereology	NOUN
dpc-4151	2	39	and	and	CCONJ
dpc-4151	2	40	leprosy	leprosy	NOUN
dpc-4151	2	41	,	,	PUNCT
dpc-4151	2	42	atal	atal	PROPN
dpc-4151	2	43	bihari	bihari	PROPN
dpc-4151	2	44	vajpayee	vajpayee	PROPN
dpc-4151	2	45	institute	institute	PROPN
dpc-4151	2	46	of	of	ADP
dpc-4151	2	47	medical	medical	PROPN
dpc-4151	2	48	sciences	sciences	PROPN
dpc-4151	2	49	and	and	CCONJ
dpc-4151	2	50	dr	dr	PROPN
dpc-4151	2	51	ram	ram	PROPN
dpc-4151	2	52	manohar	manohar	PROPN
dpc-4151	2	53	lohia	lohia	PROPN
dpc-4151	2	54	hospital	hospital	PROPN
dpc-4151	2	55	,	,	PUNCT
dpc-4151	2	56	delhi	delhi	PROPN
dpc-4151	2	57	,	,	PUNCT
dpc-4151	2	58	india	india	PROPN
dpc-4151	2	59	key	key	ADJ
dpc-4151	2	60	words	word	NOUN
dpc-4151	2	61	:	:	PUNCT
dpc-4151	2	62	methotrexate	methotrexate	NOUN
dpc-4151	2	63	,	,	PUNCT
dpc-4151	2	64	low	low	ADJ
dpc-4151	2	65	-	-	PUNCT
dpc-4151	2	66	dose	dose	NOUN
dpc-4151	2	67	,	,	PUNCT
dpc-4151	2	68	lichen	lichen	NOUN
dpc-4151	2	69	planus	planus	NOUN
dpc-4151	2	70	,	,	PUNCT
dpc-4151	2	71	recalcitrant	recalcitrant	ADJ
dpc-4151	2	72	,	,	PUNCT
dpc-4151	2	73	relapse	relapse	NOUN
dpc-4151	2	74	,	,	PUNCT
dpc-4151	2	75	adverse	adverse	ADJ
dpc-4151	2	76	effects	effect	NOUN
dpc-4151	2	77	citation	citation	NOUN
dpc-4151	2	78	:	:	PUNCT
dpc-4151	2	79	khurana	khurana	PROPN
dpc-4151	2	80	a	a	X
dpc-4151	2	81	,	,	PUNCT
dpc-4151	2	82	sharath	sharath	PROPN
dpc-4151	2	83	s	s	PROPN
dpc-4151	2	84	,	,	PUNCT
dpc-4151	2	85	sardana	sardana	PROPN
dpc-4151	2	86	k.	k.	PROPN
dpc-4151	2	87	efficacy	efficacy	PROPN
dpc-4151	2	88	and	and	CCONJ
dpc-4151	2	89	safety	safety	NOUN
dpc-4151	2	90	of	of	ADP
dpc-4151	2	91	low	low	ADJ
dpc-4151	2	92	dose	dose	NOUN
dpc-4151	2	93	methotrexate	methotrexate	NOUN
dpc-4151	2	94	in	in	ADP
dpc-4151	2	95	generalized	generalized	ADJ
dpc-4151	2	96	and	and	CCONJ
dpc-4151	2	97	recalcitrant	recalcitrant	ADJ
dpc-4151	2	98	lichen	lichen	NOUN
dpc-4151	2	99	planus	planus	NOUN
dpc-4151	2	100	:	:	PUNCT
dpc-4151	2	101	a	a	DET
dpc-4151	2	102	retrospective	retrospective	ADJ
dpc-4151	2	103	study	study	NOUN
dpc-4151	2	104	at	at	ADP
dpc-4151	2	105	tertiary	tertiary	ADJ
dpc-4151	2	106	care	care	NOUN
dpc-4151	2	107	centre	centre	NOUN
dpc-4151	2	108	.	.	PUNCT
dpc-4151	3	1	dermatol	dermatol	NOUN
dpc-4151	3	2	pract	pract	PROPN
dpc-4151	3	3	concept	concept	NOUN
dpc-4151	3	4	.	.	PUNCT
dpc-4151	4	1	2024;14(4):e2024220	2024;14(4):e2024220	X
dpc-4151	4	2	.	.	X
dpc-4151	4	3	doi	doi	NOUN
dpc-4151	4	4	:	:	PUNCT
dpc-4151	4	5	https://doi.org/10.5826/	https://doi.org/10.5826/	PROPN
dpc-4151	4	6	dpc.1404a220	dpc.1404a220	ADP
dpc-4151	4	7	accepted	accept	VERB
dpc-4151	4	8	:	:	PUNCT
dpc-4151	4	9	may	may	AUX
dpc-4151	4	10	6	6	NUM
dpc-4151	4	11	,	,	PUNCT
dpc-4151	4	12	2024	2024	NUM
dpc-4151	4	13	;	;	PUNCT
dpc-4151	4	14	published	publish	VERB
dpc-4151	4	15	:	:	PUNCT
dpc-4151	5	1	october	october	PROPN
dpc-4151	5	2	2024	2024	NUM
dpc-4151	5	3	copyright	copyright	NOUN
dpc-4151	5	4	:	:	PUNCT
dpc-4151	5	5	©	©	PROPN
dpc-4151	5	6	2024	2024	NUM
dpc-4151	5	7	khurana	khurana	NOUN
dpc-4151	5	8	et	et	PROPN
dpc-4151	5	9	al	al	PROPN
dpc-4151	5	10	.	.	PUNCT
dpc-4151	6	1	this	this	PRON
dpc-4151	6	2	is	be	AUX
dpc-4151	6	3	an	an	DET
dpc-4151	6	4	open	open	ADJ
dpc-4151	6	5	-	-	PUNCT
dpc-4151	6	6	access	access	NOUN
dpc-4151	6	7	article	article	NOUN
dpc-4151	6	8	distributed	distribute	VERB
dpc-4151	6	9	under	under	ADP
dpc-4151	6	10	the	the	DET
dpc-4151	6	11	terms	term	NOUN
dpc-4151	6	12	of	of	ADP
dpc-4151	6	13	the	the	DET
dpc-4151	6	14	creative	creative	ADJ
dpc-4151	6	15	commons	common	NOUN
dpc-4151	6	16	attributionnoncommercial	attributionnoncommercial	ADJ
dpc-4151	6	17	license	license	NOUN
dpc-4151	6	18	(	(	PUNCT
dpc-4151	6	19	by	by	ADP
dpc-4151	6	20	-	-	PUNCT
dpc-4151	6	21	nc-4.0	nc-4.0	NOUN
dpc-4151	6	22	)	)	PUNCT
dpc-4151	6	23	,	,	PUNCT
dpc-4151	6	24	https://creativecommons.org/licenses/by-nc/4.0/	https://creativecommons.org/licenses/by-nc/4.0/	PROPN
dpc-4151	6	25	,	,	PUNCT
dpc-4151	6	26	which	which	PRON
dpc-4151	6	27	permits	permit	VERB
dpc-4151	6	28	unrestricted	unrestricted	ADJ
dpc-4151	6	29	noncommercial	noncommercial	ADJ
dpc-4151	6	30	use	use	NOUN
dpc-4151	6	31	,	,	PUNCT
dpc-4151	6	32	distribution	distribution	NOUN
dpc-4151	6	33	,	,	PUNCT
dpc-4151	6	34	and	and	CCONJ
dpc-4151	6	35	reproduction	reproduction	NOUN
dpc-4151	6	36	in	in	ADP
dpc-4151	6	37	any	any	DET
dpc-4151	6	38	medium	medium	NOUN
dpc-4151	6	39	,	,	PUNCT
dpc-4151	6	40	provided	provide	VERB
dpc-4151	6	41	the	the	DET
dpc-4151	6	42	original	original	ADJ
dpc-4151	6	43	authors	author	NOUN
dpc-4151	6	44	and	and	CCONJ
dpc-4151	6	45	source	source	NOUN
dpc-4151	6	46	are	be	AUX
dpc-4151	6	47	credited	credit	VERB
dpc-4151	6	48	.	.	PUNCT
dpc-4151	7	1	funding	funding	NOUN
dpc-4151	7	2	:	:	PUNCT
dpc-4151	7	3	none	none	NOUN
dpc-4151	7	4	.	.	PUNCT
dpc-4151	8	1	competing	compete	VERB
dpc-4151	8	2	interests	interest	NOUN
dpc-4151	8	3	:	:	PUNCT
dpc-4151	8	4	none	none	NOUN
dpc-4151	8	5	.	.	PUNCT
dpc-4151	9	1	authorship	authorship	NOUN
dpc-4151	9	2	:	:	PUNCT
dpc-4151	9	3	all	all	DET
dpc-4151	9	4	authors	author	NOUN
dpc-4151	9	5	have	have	AUX
dpc-4151	9	6	contributed	contribute	VERB
dpc-4151	9	7	significantly	significantly	ADV
dpc-4151	9	8	to	to	ADP
dpc-4151	9	9	this	this	DET
dpc-4151	9	10	publication	publication	NOUN
dpc-4151	9	11	.	.	PUNCT
dpc-4151	10	1	corresponding	correspond	VERB
dpc-4151	10	2	author	author	NOUN
dpc-4151	10	3	:	:	PUNCT
dpc-4151	10	4	ananta	ananta	PROPN
dpc-4151	10	5	khurana	khurana	PROPN
dpc-4151	10	6	,	,	PUNCT
dpc-4151	10	7	md	md	PROPN
dpc-4151	10	8	,	,	PUNCT
dpc-4151	10	9	dnb	dnb	PROPN
dpc-4151	10	10	,	,	PUNCT
dpc-4151	10	11	mnams	mnam	NOUN
dpc-4151	10	12	,	,	PUNCT
dpc-4151	10	13	frcp(l	frcp(l	PROPN
dpc-4151	10	14	)	)	PUNCT
dpc-4151	10	15	,	,	PUNCT
dpc-4151	10	16	professor	professor	NOUN
dpc-4151	10	17	,	,	PUNCT
dpc-4151	10	18	department	department	NOUN
dpc-4151	10	19	of	of	ADP
dpc-4151	10	20	dermatology	dermatology	NOUN
dpc-4151	10	21	,	,	PUNCT
dpc-4151	10	22	venereology	venereology	NOUN
dpc-4151	10	23	and	and	CCONJ
dpc-4151	10	24	leprosy	leprosy	NOUN
dpc-4151	10	25	,	,	PUNCT
dpc-4151	10	26	atal	atal	PROPN
dpc-4151	10	27	bihari	bihari	PROPN
dpc-4151	10	28	vajpayee	vajpayee	PROPN
dpc-4151	10	29	institute	institute	PROPN
dpc-4151	10	30	of	of	ADP
dpc-4151	10	31	medical	medical	PROPN
dpc-4151	10	32	sciences	sciences	PROPN
dpc-4151	10	33	and	and	CCONJ
dpc-4151	10	34	dr	dr	PROPN
dpc-4151	10	35	ram	ram	PROPN
dpc-4151	10	36	manohar	manohar	PROPN
dpc-4151	10	37	lohia	lohia	PROPN
dpc-4151	10	38	hospital	hospital	PROPN
dpc-4151	10	39	,	,	PUNCT
dpc-4151	10	40	delhi	delhi	PROPN
dpc-4151	10	41	;	;	PUNCT
dpc-4151	10	42	phone	phone	NOUN
dpc-4151	10	43	:	:	PUNCT
dpc-4151	10	44	+919212370467	+919212370467	NUM
dpc-4151	10	45	;	;	PUNCT
dpc-4151	10	46	e	e	X
dpc-4151	10	47	-	-	NOUN
dpc-4151	10	48	mail	mail	NOUN
dpc-4151	10	49	:	:	PUNCT
dpc-4151	10	50	drananta2014@gmail.com	drananta2014@gmail.com	PROPN
dpc-4151	10	51	introduction	introduction	NOUN
dpc-4151	10	52	:	:	PUNCT
dpc-4151	10	53	methotrexate	methotrexate	NOUN
dpc-4151	10	54	(	(	PUNCT
dpc-4151	10	55	mtx	mtx	NOUN
dpc-4151	10	56	)	)	PUNCT
dpc-4151	10	57	acts	act	NOUN
dpc-4151	10	58	by	by	ADP
dpc-4151	10	59	suppressing	suppress	VERB
dpc-4151	10	60	multiple	multiple	ADJ
dpc-4151	10	61	immune	immune	ADJ
dpc-4151	10	62	pathways	pathway	NOUN
dpc-4151	10	63	involved	involve	VERB
dpc-4151	10	64	in	in	ADP
dpc-4151	10	65	the	the	DET
dpc-4151	10	66	pathogenesis	pathogenesis	NOUN
dpc-4151	10	67	of	of	ADP
dpc-4151	10	68	lichen	lichen	NOUN
dpc-4151	10	69	planus	planus	NOUN
dpc-4151	10	70	(	(	PUNCT
dpc-4151	10	71	lp	lp	NOUN
dpc-4151	10	72	)	)	PUNCT
dpc-4151	10	73	.	.	PUNCT
dpc-4151	11	1	trials	trial	NOUN
dpc-4151	11	2	assessing	assess	VERB
dpc-4151	11	3	the	the	DET
dpc-4151	11	4	efficacy	efficacy	NOUN
dpc-4151	11	5	and	and	CCONJ
dpc-4151	11	6	relapse	relapse	NOUN
dpc-4151	11	7	rates	rate	NOUN
dpc-4151	11	8	of	of	ADP
dpc-4151	11	9	methotrexate	methotrexate	NOUN
dpc-4151	11	10	in	in	ADP
dpc-4151	11	11	lp	lp	ADV
dpc-4151	11	12	are	be	AUX
dpc-4151	11	13	lacking	lack	VERB
dpc-4151	11	14	.	.	PUNCT
dpc-4151	12	1	objectives	objective	NOUN
dpc-4151	12	2	:	:	PUNCT
dpc-4151	12	3	our	our	PRON
dpc-4151	12	4	objective	objective	NOUN
dpc-4151	12	5	was	be	AUX
dpc-4151	12	6	to	to	PART
dpc-4151	12	7	analyze	analyze	VERB
dpc-4151	12	8	the	the	DET
dpc-4151	12	9	efficacy	efficacy	NOUN
dpc-4151	12	10	and	and	CCONJ
dpc-4151	12	11	safety	safety	NOUN
dpc-4151	12	12	of	of	ADP
dpc-4151	12	13	low	low	ADJ
dpc-4151	12	14	-	-	PUNCT
dpc-4151	12	15	dose	dose	NOUN
dpc-4151	12	16	methotrexate	methotrexate	NOUN
dpc-4151	12	17	in	in	ADP
dpc-4151	12	18	generalized	generalized	ADJ
dpc-4151	12	19	and	and	CCONJ
dpc-4151	12	20	recalcitrant	recalcitrant	ADJ
dpc-4151	12	21	lp	lp	ADJ
dpc-4151	12	22	patients	patient	NOUN
dpc-4151	12	23	retrospectively	retrospectively	ADV
dpc-4151	12	24	and	and	CCONJ
dpc-4151	12	25	to	to	PART
dpc-4151	12	26	assess	assess	VERB
dpc-4151	12	27	the	the	DET
dpc-4151	12	28	relapse	relapse	NOUN
dpc-4151	12	29	rates	rate	NOUN
dpc-4151	12	30	in	in	ADP
dpc-4151	12	31	patients	patient	NOUN
dpc-4151	12	32	after	after	ADP
dpc-4151	12	33	stopping	stop	VERB
dpc-4151	12	34	mtx	mtx	NOUN
dpc-4151	12	35	therapy	therapy	NOUN
dpc-4151	12	36	.	.	PUNCT
dpc-4151	13	1	methods	method	NOUN
dpc-4151	13	2	:	:	PUNCT
dpc-4151	13	3	we	we	PRON
dpc-4151	13	4	analyzed	analyze	VERB
dpc-4151	13	5	clinical	clinical	ADJ
dpc-4151	13	6	and	and	CCONJ
dpc-4151	13	7	therapeutic	therapeutic	ADJ
dpc-4151	13	8	details	detail	NOUN
dpc-4151	13	9	of	of	ADP
dpc-4151	13	10	lp	lp	NOUN
dpc-4151	13	11	patients	patient	NOUN
dpc-4151	13	12	treated	treat	VERB
dpc-4151	13	13	with	with	ADP
dpc-4151	13	14	low	low	ADJ
dpc-4151	13	15	-	-	PUNCT
dpc-4151	13	16	dose	dose	NOUN
dpc-4151	13	17	mtx	mtx	NOUN
dpc-4151	13	18	at	at	ADP
dpc-4151	13	19	our	our	PRON
dpc-4151	13	20	center	center	NOUN
dpc-4151	13	21	.	.	PUNCT
dpc-4151	14	1	the	the	DET
dpc-4151	14	2	cumulative	cumulative	ADJ
dpc-4151	14	3	dose	dose	NOUN
dpc-4151	14	4	and	and	CCONJ
dpc-4151	14	5	duration	duration	NOUN
dpc-4151	14	6	of	of	ADP
dpc-4151	14	7	mtx	mtx	NOUN
dpc-4151	14	8	was	be	AUX
dpc-4151	14	9	calculated	calculate	VERB
dpc-4151	14	10	,	,	PUNCT
dpc-4151	14	11	and	and	CCONJ
dpc-4151	14	12	the	the	DET
dpc-4151	14	13	time	time	NOUN
dpc-4151	14	14	to	to	PART
dpc-4151	14	15	achieve	achieve	VERB
dpc-4151	14	16	disease	disease	NOUN
dpc-4151	14	17	control	control	NOUN
dpc-4151	14	18	was	be	AUX
dpc-4151	14	19	noted	note	VERB
dpc-4151	14	20	.	.	PUNCT
dpc-4151	15	1	we	we	PRON
dpc-4151	15	2	analyzed	analyze	VERB
dpc-4151	15	3	duration	duration	NOUN
dpc-4151	15	4	of	of	ADP
dpc-4151	15	5	remission	remission	NOUN
dpc-4151	15	6	and	and	CCONJ
dpc-4151	15	7	time	time	NOUN
dpc-4151	15	8	after	after	ADP
dpc-4151	15	9	which	which	PRON
dpc-4151	15	10	recurrences	recurrence	NOUN
dpc-4151	15	11	were	be	AUX
dpc-4151	15	12	seen	see	VERB
dpc-4151	15	13	post	post	ADJ
dpc-4151	15	14	-	-	NOUN
dpc-4151	15	15	treatment	treatment	NOUN
dpc-4151	15	16	.	.	PUNCT
dpc-4151	16	1	results	result	NOUN
dpc-4151	16	2	:	:	PUNCT
dpc-4151	16	3	records	record	NOUN
dpc-4151	16	4	of	of	ADP
dpc-4151	16	5	42	42	NUM
dpc-4151	16	6	generalized	generalized	ADJ
dpc-4151	16	7	and	and	CCONJ
dpc-4151	16	8	recalcitrant	recalcitrant	ADJ
dpc-4151	16	9	lp	lp	ADJ
dpc-4151	16	10	patients	patient	NOUN
dpc-4151	16	11	treated	treat	VERB
dpc-4151	16	12	with	with	ADP
dpc-4151	16	13	mtx	mtx	NOUN
dpc-4151	16	14	were	be	AUX
dpc-4151	16	15	analyzed	analyze	VERB
dpc-4151	16	16	.	.	PUNCT
dpc-4151	17	1	the	the	DET
dpc-4151	17	2	starting	starting	NOUN
dpc-4151	17	3	dose	dose	PROPN
dpc-4151	17	4	of	of	ADP
dpc-4151	17	5	mtx	mtx	PROPN
dpc-4151	17	6	was	be	AUX
dpc-4151	17	7	7.5	7.5	NUM
dpc-4151	17	8	mg	mg	PROPN
dpc-4151	17	9	(	(	PUNCT
dpc-4151	17	10	n=7	n=7	PROPN
dpc-4151	17	11	)	)	PUNCT
dpc-4151	17	12	or	or	CCONJ
dpc-4151	17	13	10	10	NUM
dpc-4151	17	14	mg	mg	PROPN
dpc-4151	17	15	(	(	PUNCT
dpc-4151	17	16	n=	n=	ADJ
dpc-4151	17	17	35	35	NUM
dpc-4151	17	18	)	)	PUNCT
dpc-4151	17	19	once	once	ADV
dpc-4151	17	20	weekly	weekly	ADV
dpc-4151	17	21	,	,	PUNCT
dpc-4151	17	22	increased	increase	VERB
dpc-4151	17	23	to	to	ADP
dpc-4151	17	24	10/15	10/15	NUM
dpc-4151	17	25	mg	mg	PROPN
dpc-4151	17	26	weekly	weekly	ADV
dpc-4151	17	27	in	in	ADP
dpc-4151	17	28	patients	patient	NOUN
dpc-4151	17	29	with	with	ADP
dpc-4151	17	30	inadequate	inadequate	ADJ
dpc-4151	17	31	response	response	NOUN
dpc-4151	17	32	.	.	PUNCT
dpc-4151	18	1	ten	ten	NUM
dpc-4151	18	2	patients	patient	NOUN
dpc-4151	18	3	were	be	AUX
dpc-4151	18	4	lost	lose	VERB
dpc-4151	18	5	to	to	PART
dpc-4151	18	6	follow	follow	VERB
dpc-4151	18	7	-	-	PUNCT
dpc-4151	18	8	up	up	NOUN
dpc-4151	18	9	.	.	PUNCT
dpc-4151	19	1	complete	complete	ADJ
dpc-4151	19	2	resolution	resolution	NOUN
dpc-4151	19	3	was	be	AUX
dpc-4151	19	4	achieved	achieve	VERB
dpc-4151	19	5	in	in	ADP
dpc-4151	19	6	30/32	30/32	NUM
dpc-4151	19	7	(	(	PUNCT
dpc-4151	19	8	93	93	NUM
dpc-4151	19	9	%	%	NOUN
dpc-4151	19	10	)	)	PUNCT
dpc-4151	19	11	patients	patient	NOUN
dpc-4151	19	12	within	within	ADP
dpc-4151	19	13	a	a	DET
dpc-4151	19	14	mean	mean	ADJ
dpc-4151	19	15	duration	duration	NOUN
dpc-4151	19	16	of	of	ADP
dpc-4151	19	17	14.76	14.76	NUM
dpc-4151	19	18	weeks	week	NOUN
dpc-4151	19	19	(	(	PUNCT
dpc-4151	19	20	4	4	NUM
dpc-4151	19	21	-	-	SYM
dpc-4151	19	22	32	32	NUM
dpc-4151	19	23	weeks	week	NOUN
dpc-4151	19	24	)	)	PUNCT
dpc-4151	19	25	,	,	PUNCT
dpc-4151	19	26	and	and	CCONJ
dpc-4151	19	27	the	the	DET
dpc-4151	19	28	cumulative	cumulative	ADJ
dpc-4151	19	29	dose	dose	NOUN
dpc-4151	19	30	of	of	ADP
dpc-4151	19	31	mtx	mtx	NOUN
dpc-4151	19	32	to	to	PART
dpc-4151	19	33	achieve	achieve	VERB
dpc-4151	19	34	remission	remission	NOUN
dpc-4151	19	35	was	be	AUX
dpc-4151	19	36	153.58	153.58	NUM
dpc-4151	19	37	mg	mg	NOUN
dpc-4151	19	38	(	(	PUNCT
dpc-4151	19	39	50	50	NUM
dpc-4151	19	40	-	-	SYM
dpc-4151	19	41	375	375	NUM
dpc-4151	19	42	mg	mg	NUM
dpc-4151	19	43	)	)	PUNCT
dpc-4151	19	44	.	.	PUNCT
dpc-4151	20	1	only	only	ADV
dpc-4151	20	2	minor	minor	ADJ
dpc-4151	20	3	side	side	NOUN
dpc-4151	20	4	effects	effect	NOUN
dpc-4151	20	5	were	be	AUX
dpc-4151	20	6	noted	note	VERB
dpc-4151	20	7	in	in	ADP
dpc-4151	20	8	12/32	12/32	NUM
dpc-4151	20	9	(	(	PUNCT
dpc-4151	20	10	37.5	37.5	NUM
dpc-4151	20	11	%	%	NOUN
dpc-4151	20	12	)	)	PUNCT
dpc-4151	20	13	patients	patient	NOUN
dpc-4151	20	14	,	,	PUNCT
dpc-4151	20	15	and	and	CCONJ
dpc-4151	20	16	none	none	NOUN
dpc-4151	20	17	required	require	VERB
dpc-4151	20	18	treatment	treatment	NOUN
dpc-4151	20	19	discontinuation	discontinuation	NOUN
dpc-4151	20	20	.	.	PUNCT
dpc-4151	21	1	the	the	DET
dpc-4151	21	2	mean	mean	ADJ
dpc-4151	21	3	duration	duration	NOUN
dpc-4151	21	4	of	of	ADP
dpc-4151	21	5	remission	remission	NOUN
dpc-4151	21	6	was	be	AUX
dpc-4151	21	7	29.43	29.43	NUM
dpc-4151	21	8	months	month	NOUN
dpc-4151	21	9	(	(	PUNCT
dpc-4151	21	10	5	5	NUM
dpc-4151	21	11	-	-	SYM
dpc-4151	21	12	60	60	NUM
dpc-4151	21	13	months	month	NOUN
dpc-4151	21	14	)	)	PUNCT
dpc-4151	21	15	.	.	PUNCT
dpc-4151	22	1	conclusion	conclusion	NOUN
dpc-4151	22	2	:	:	PUNCT
dpc-4151	22	3	mtx	mtx	NOUN
dpc-4151	22	4	demonstrated	demonstrate	VERB
dpc-4151	22	5	high	high	ADJ
dpc-4151	22	6	efficacy	efficacy	NOUN
dpc-4151	22	7	and	and	CCONJ
dpc-4151	22	8	a	a	DET
dpc-4151	22	9	good	good	ADJ
dpc-4151	22	10	safety	safety	NOUN
dpc-4151	22	11	profile	profile	NOUN
dpc-4151	22	12	in	in	ADP
dpc-4151	22	13	extensive	extensive	ADJ
dpc-4151	22	14	cutaneous	cutaneous	ADJ
dpc-4151	22	15	lp	lp	NOUN
dpc-4151	22	16	and	and	CCONJ
dpc-4151	22	17	may	may	AUX
dpc-4151	22	18	be	be	AUX
dpc-4151	22	19	a	a	DET
dpc-4151	22	20	safer	safe	ADJ
dpc-4151	22	21	alternative	alternative	NOUN
dpc-4151	22	22	to	to	ADP
dpc-4151	22	23	steroids	steroid	NOUN
dpc-4151	22	24	for	for	ADP
dpc-4151	22	25	this	this	DET
dpc-4151	22	26	condition	condition	NOUN
dpc-4151	22	27	.	.	PUNCT
dpc-4151	23	1	abstract	abstract	ADJ
dpc-4151	23	2	2	2	NUM
dpc-4151	23	3	original	original	ADJ
dpc-4151	23	4	article	article	NOUN
dpc-4151	23	5	|	|	ADV
dpc-4151	23	6	dermatol	dermatol	ADJ
dpc-4151	23	7	pract	pract	NOUN
dpc-4151	23	8	concept	concept	NOUN
dpc-4151	23	9	.	.	PUNCT
dpc-4151	24	1	2024;14(4):e2024220	2024;14(4):e2024220	NUM
dpc-4151	24	2	introduction	introduction	NOUN
dpc-4151	24	3	lichen	lichen	NOUN
dpc-4151	24	4	planus	planus	NOUN
dpc-4151	24	5	(	(	PUNCT
dpc-4151	24	6	lp	lp	NOUN
dpc-4151	24	7	)	)	PUNCT
dpc-4151	24	8	is	be	AUX
dpc-4151	24	9	an	an	DET
dpc-4151	24	10	idiopathic	idiopathic	ADJ
dpc-4151	24	11	inflammatory	inflammatory	ADJ
dpc-4151	24	12	disorder	disorder	NOUN
dpc-4151	24	13	with	with	ADP
dpc-4151	24	14	a	a	DET
dpc-4151	24	15	relapsing	relapse	VERB
dpc-4151	24	16	and	and	CCONJ
dpc-4151	24	17	remitting	remit	VERB
dpc-4151	24	18	course	course	NOUN
dpc-4151	24	19	.	.	PUNCT
dpc-4151	25	1	most	most	ADV
dpc-4151	25	2	often	often	ADV
dpc-4151	25	3	the	the	DET
dpc-4151	25	4	disease	disease	NOUN
dpc-4151	25	5	is	be	AUX
dpc-4151	25	6	localized	localize	VERB
dpc-4151	25	7	and	and	CCONJ
dpc-4151	25	8	subsides	subside	VERB
dpc-4151	25	9	with	with	ADP
dpc-4151	25	10	topical	topical	ADJ
dpc-4151	25	11	therapy	therapy	NOUN
dpc-4151	25	12	;	;	PUNCT
dpc-4151	25	13	however	however	ADV
dpc-4151	25	14	,	,	PUNCT
dpc-4151	25	15	severe	severe	ADJ
dpc-4151	25	16	and	and	CCONJ
dpc-4151	25	17	recalcitrant	recalcitrant	ADJ
dpc-4151	25	18	lesions	lesion	NOUN
dpc-4151	25	19	can	can	AUX
dpc-4151	25	20	be	be	AUX
dpc-4151	25	21	seen	see	VERB
dpc-4151	25	22	in	in	ADP
dpc-4151	25	23	up	up	ADP
dpc-4151	25	24	to	to	PART
dpc-4151	25	25	20	20	NUM
dpc-4151	25	26	%	%	NOUN
dpc-4151	25	27	patients	patient	NOUN
dpc-4151	26	1	[	[	X
dpc-4151	26	2	1	1	NUM
dpc-4151	26	3	]	]	PUNCT
dpc-4151	26	4	.	.	PUNCT
dpc-4151	27	1	a	a	DET
dpc-4151	27	2	meta	meta	ADJ
dpc-4151	27	3	-	-	PUNCT
dpc-4151	27	4	analysis	analysis	NOUN
dpc-4151	27	5	on	on	ADP
dpc-4151	27	6	interventions	intervention	NOUN
dpc-4151	27	7	for	for	ADP
dpc-4151	27	8	lp	lp	ADP
dpc-4151	27	9	which	which	PRON
dpc-4151	27	10	analyzed	analyze	VERB
dpc-4151	27	11	21	21	NUM
dpc-4151	27	12	different	different	ADJ
dpc-4151	27	13	treatment	treatment	NOUN
dpc-4151	27	14	modalities	modality	NOUN
dpc-4151	27	15	reported	report	VERB
dpc-4151	27	16	low	low	ADJ
dpc-4151	27	17	or	or	CCONJ
dpc-4151	27	18	very	very	ADV
dpc-4151	27	19	low	low	ADJ
dpc-4151	27	20	quality	quality	NOUN
dpc-4151	27	21	of	of	ADP
dpc-4151	27	22	evidence	evidence	NOUN
dpc-4151	27	23	for	for	ADP
dpc-4151	27	24	all	all	DET
dpc-4151	27	25	systemic	systemic	ADJ
dpc-4151	27	26	drugs	drug	NOUN
dpc-4151	27	27	except	except	SCONJ
dpc-4151	27	28	oral	oral	ADJ
dpc-4151	27	29	steroids	steroid	NOUN
dpc-4151	28	1	[	[	X
dpc-4151	28	2	2	2	NUM
dpc-4151	28	3	]	]	PUNCT
dpc-4151	28	4	.	.	PUNCT
dpc-4151	29	1	oral	oral	ADJ
dpc-4151	29	2	corticosteroids	corticosteroid	NOUN
dpc-4151	29	3	(	(	PUNCT
dpc-4151	29	4	ocs	ocs	PROPN
dpc-4151	29	5	)	)	PUNCT
dpc-4151	29	6	are	be	AUX
dpc-4151	29	7	often	often	ADV
dpc-4151	29	8	prescribed	prescribe	VERB
dpc-4151	29	9	for	for	ADP
dpc-4151	29	10	moderate	moderate	ADJ
dpc-4151	29	11	to	to	ADP
dpc-4151	29	12	severe	severe	ADJ
dpc-4151	29	13	cutaneous	cutaneous	ADJ
dpc-4151	29	14	lp	lp	NOUN
dpc-4151	29	15	,	,	PUNCT
dpc-4151	29	16	but	but	CCONJ
dpc-4151	29	17	frequent	frequent	ADJ
dpc-4151	29	18	recurrences	recurrence	NOUN
dpc-4151	29	19	are	be	AUX
dpc-4151	29	20	noted	note	VERB
dpc-4151	29	21	after	after	ADP
dpc-4151	29	22	stopping	stop	VERB
dpc-4151	29	23	therapy	therapy	NOUN
dpc-4151	29	24	,	,	PUNCT
dpc-4151	29	25	and	and	CCONJ
dpc-4151	29	26	steroid	steroid	NOUN
dpc-4151	29	27	related	relate	VERB
dpc-4151	29	28	adverse	adverse	ADJ
dpc-4151	29	29	effects	effect	NOUN
dpc-4151	29	30	consistently	consistently	ADV
dpc-4151	29	31	develop	develop	VERB
dpc-4151	29	32	.	.	PUNCT
dpc-4151	30	1	the	the	DET
dpc-4151	30	2	latter	latter	ADJ
dpc-4151	30	3	are	be	AUX
dpc-4151	30	4	also	also	ADV
dpc-4151	30	5	frequently	frequently	ADV
dpc-4151	30	6	seen	see	VERB
dpc-4151	30	7	with	with	ADP
dpc-4151	30	8	the	the	DET
dpc-4151	30	9	use	use	NOUN
dpc-4151	30	10	of	of	ADP
dpc-4151	30	11	long	long	ADV
dpc-4151	30	12	-	-	PUNCT
dpc-4151	30	13	acting	act	VERB
dpc-4151	30	14	steroids	steroid	NOUN
dpc-4151	30	15	as	as	ADP
dpc-4151	30	16	part	part	NOUN
dpc-4151	30	17	of	of	ADP
dpc-4151	30	18	“	"	PUNCT
dpc-4151	30	19	oral	oral	ADJ
dpc-4151	30	20	mini	mini	ADJ
dpc-4151	30	21	pulse	pulse	NOUN
dpc-4151	30	22	”	"	PUNCT
dpc-4151	31	1	[	[	X
dpc-4151	31	2	3	3	NUM
dpc-4151	31	3	]	]	PUNCT
dpc-4151	31	4	.	.	PUNCT
dpc-4151	32	1	other	other	ADJ
dpc-4151	32	2	drugs	drug	NOUN
dpc-4151	32	3	in	in	ADP
dpc-4151	32	4	the	the	DET
dpc-4151	32	5	therapeutic	therapeutic	ADJ
dpc-4151	32	6	armamentarium	armamentarium	NOUN
dpc-4151	32	7	for	for	ADP
dpc-4151	32	8	the	the	DET
dpc-4151	32	9	management	management	NOUN
dpc-4151	32	10	of	of	ADP
dpc-4151	32	11	extensive	extensive	ADJ
dpc-4151	32	12	lp	lp	NOUN
dpc-4151	32	13	include	include	VERB
dpc-4151	32	14	metronidazole	metronidazole	NOUN
dpc-4151	32	15	,	,	PUNCT
dpc-4151	32	16	acitretin	acitretin	NOUN
dpc-4151	32	17	,	,	PUNCT
dpc-4151	32	18	cyclosporine	cyclosporine	NOUN
dpc-4151	32	19	,	,	PUNCT
dpc-4151	32	20	thalidomide	thalidomide	VERB
dpc-4151	32	21	[	[	X
dpc-4151	32	22	4	4	NUM
dpc-4151	32	23	]	]	PUNCT
dpc-4151	32	24	,	,	PUNCT
dpc-4151	32	25	leflunomide	leflunomide	ADJ
dpc-4151	32	26	[	[	X
dpc-4151	32	27	5	5	NUM
dpc-4151	32	28	]	]	PUNCT
dpc-4151	32	29	,	,	PUNCT
dpc-4151	32	30	griseofulvin	griseofulvin	NOUN
dpc-4151	32	31	,	,	PUNCT
dpc-4151	32	32	sulfasalazine	sulfasalazine	NOUN
dpc-4151	32	33	,	,	PUNCT
dpc-4151	32	34	enoxaparin	enoxaparin	NOUN
dpc-4151	32	35	,	,	PUNCT
dpc-4151	32	36	methotrexate	methotrexate	NOUN
dpc-4151	32	37	,	,	PUNCT
dpc-4151	32	38	dapsone	dapsone	PROPN
dpc-4151	32	39	,	,	PUNCT
dpc-4151	32	40	mycophenolate	mycophenolate	PROPN
dpc-4151	32	41	mofetil	mofetil	PROPN
dpc-4151	32	42	,	,	PUNCT
dpc-4151	32	43	azathioprine	azathioprine	NOUN
dpc-4151	32	44	,	,	PUNCT
dpc-4151	32	45	phototherapy	phototherapy	NOUN
dpc-4151	32	46	,	,	PUNCT
dpc-4151	32	47	and	and	CCONJ
dpc-4151	32	48	most	most	ADV
dpc-4151	32	49	recently	recently	ADV
dpc-4151	32	50	,	,	PUNCT
dpc-4151	32	51	jak	jak	PROPN
dpc-4151	32	52	inhibitors	inhibitor	NOUN
dpc-4151	32	53	,	,	PUNCT
dpc-4151	32	54	but	but	CCONJ
dpc-4151	32	55	most	most	ADJ
dpc-4151	32	56	have	have	AUX
dpc-4151	32	57	limited	limit	VERB
dpc-4151	32	58	and	and	CCONJ
dpc-4151	32	59	low	low	ADJ
dpc-4151	32	60	-	-	PUNCT
dpc-4151	32	61	level	level	NOUN
dpc-4151	32	62	evidence	evidence	NOUN
dpc-4151	32	63	to	to	ADP
dpc-4151	32	64	their	their	PRON
dpc-4151	32	65	credit	credit	NOUN
dpc-4151	33	1	[	[	X
dpc-4151	33	2	6,7	6,7	NUM
dpc-4151	33	3	]	]	PUNCT
dpc-4151	33	4	.	.	PUNCT
dpc-4151	34	1	methotrexate	methotrexate	NOUN
dpc-4151	34	2	(	(	PUNCT
dpc-4151	34	3	mtx	mtx	NOUN
dpc-4151	34	4	)	)	PUNCT
dpc-4151	34	5	has	have	VERB
dpc-4151	34	6	a	a	DET
dpc-4151	34	7	significant	significant	ADJ
dpc-4151	34	8	inhibitory	inhibitory	ADJ
dpc-4151	34	9	effect	effect	NOUN
dpc-4151	34	10	on	on	ADP
dpc-4151	34	11	lymphoid	lymphoid	ADJ
dpc-4151	34	12	cells	cell	NOUN
dpc-4151	34	13	[	[	X
dpc-4151	34	14	8	8	NUM
dpc-4151	34	15	]	]	PUNCT
dpc-4151	34	16	.	.	PUNCT
dpc-4151	35	1	in	in	ADP
dpc-4151	35	2	an	an	DET
dpc-4151	35	3	open	open	ADJ
dpc-4151	35	4	trial	trial	NOUN
dpc-4151	35	5	,	,	PUNCT
dpc-4151	35	6	four	four	NUM
dpc-4151	35	7	patients	patient	NOUN
dpc-4151	35	8	with	with	ADP
dpc-4151	35	9	severe	severe	ADJ
dpc-4151	35	10	erosive	erosive	NOUN
dpc-4151	35	11	lp	lp	NOUN
dpc-4151	35	12	were	be	AUX
dpc-4151	35	13	treated	treat	VERB
dpc-4151	35	14	with	with	ADP
dpc-4151	35	15	combination	combination	NOUN
dpc-4151	35	16	of	of	ADP
dpc-4151	35	17	mtx	mtx	NOUN
dpc-4151	35	18	(	(	PUNCT
dpc-4151	35	19	10	10	NUM
dpc-4151	35	20	-	-	SYM
dpc-4151	35	21	15	15	NUM
dpc-4151	35	22	mg	mg	NUM
dpc-4151	35	23	/	/	SYM
dpc-4151	35	24	week	week	NOUN
dpc-4151	35	25	)	)	PUNCT
dpc-4151	35	26	and	and	CCONJ
dpc-4151	35	27	topical	topical	ADJ
dpc-4151	35	28	corticosteroids	corticosteroid	NOUN
dpc-4151	35	29	for	for	ADP
dpc-4151	35	30	17	17	NUM
dpc-4151	35	31	months	month	NOUN
dpc-4151	35	32	and	and	CCONJ
dpc-4151	35	33	the	the	DET
dpc-4151	35	34	drug	drug	NOUN
dpc-4151	35	35	was	be	AUX
dpc-4151	35	36	found	find	VERB
dpc-4151	35	37	to	to	PART
dpc-4151	35	38	be	be	AUX
dpc-4151	35	39	safe	safe	ADJ
dpc-4151	35	40	and	and	CCONJ
dpc-4151	35	41	effective	effective	ADJ
dpc-4151	35	42	for	for	ADP
dpc-4151	35	43	the	the	DET
dpc-4151	35	44	condition	condition	NOUN
dpc-4151	36	1	[	[	X
dpc-4151	36	2	9	9	NUM
dpc-4151	36	3	]	]	PUNCT
dpc-4151	36	4	.	.	PUNCT
dpc-4151	37	1	our	our	PRON
dpc-4151	37	2	objective	objective	NOUN
dpc-4151	37	3	was	be	AUX
dpc-4151	37	4	to	to	PART
dpc-4151	37	5	analyze	analyze	VERB
dpc-4151	37	6	the	the	DET
dpc-4151	37	7	efficacy	efficacy	NOUN
dpc-4151	37	8	and	and	CCONJ
dpc-4151	37	9	safety	safety	NOUN
dpc-4151	37	10	of	of	ADP
dpc-4151	37	11	low	low	ADJ
dpc-4151	37	12	-	-	PUNCT
dpc-4151	37	13	dose	dose	NOUN
dpc-4151	37	14	mtx	mtx	NOUN
dpc-4151	37	15	in	in	ADP
dpc-4151	37	16	lichen	lichen	NOUN
dpc-4151	37	17	planus	planus	NOUN
dpc-4151	37	18	patients	patient	NOUN
dpc-4151	37	19	retrospectively	retrospectively	ADV
dpc-4151	37	20	and	and	CCONJ
dpc-4151	37	21	to	to	PART
dpc-4151	37	22	assess	assess	VERB
dpc-4151	37	23	the	the	DET
dpc-4151	37	24	relapse	relapse	NOUN
dpc-4151	37	25	rates	rate	NOUN
dpc-4151	37	26	in	in	ADP
dpc-4151	37	27	patients	patient	NOUN
dpc-4151	37	28	after	after	ADP
dpc-4151	37	29	stopping	stop	VERB
dpc-4151	37	30	mtx	mtx	NOUN
dpc-4151	37	31	therapy	therapy	NOUN
dpc-4151	37	32	.	.	PUNCT
dpc-4151	38	1	methods	method	NOUN
dpc-4151	38	2	we	we	PRON
dpc-4151	38	3	retrospectively	retrospectively	ADV
dpc-4151	38	4	analyzed	analyze	VERB
dpc-4151	38	5	records	record	NOUN
dpc-4151	38	6	of	of	ADP
dpc-4151	38	7	generalized	generalized	ADJ
dpc-4151	38	8	recalcitrant	recalcitrant	ADJ
dpc-4151	38	9	lichen	lichen	NOUN
dpc-4151	38	10	planus	planus	ADJ
dpc-4151	38	11	cases	case	NOUN
dpc-4151	38	12	who	who	PRON
dpc-4151	38	13	were	be	AUX
dpc-4151	38	14	treated	treat	VERB
dpc-4151	38	15	with	with	ADP
dpc-4151	38	16	low	low	ADJ
dpc-4151	38	17	-	-	PUNCT
dpc-4151	38	18	dose	dose	NOUN
dpc-4151	38	19	methotrexate	methotrexate	NOUN
dpc-4151	38	20	(	(	PUNCT
dpc-4151	38	21	7.5	7.5	NUM
dpc-4151	38	22	-	-	SYM
dpc-4151	38	23	15	15	NUM
dpc-4151	38	24	mg	mg	NUM
dpc-4151	38	25	/	/	SYM
dpc-4151	38	26	week	week	NOUN
dpc-4151	38	27	)	)	PUNCT
dpc-4151	38	28	at	at	ADP
dpc-4151	38	29	our	our	PRON
dpc-4151	38	30	tertiary	tertiary	ADJ
dpc-4151	38	31	center	center	NOUN
dpc-4151	38	32	during	during	ADP
dpc-4151	38	33	the	the	DET
dpc-4151	38	34	period	period	NOUN
dpc-4151	38	35	august	august	PROPN
dpc-4151	38	36	2018	2018	NUM
dpc-4151	38	37	–	–	PUNCT
dpc-4151	38	38	april	april	PROPN
dpc-4151	38	39	2023	2023	NUM
dpc-4151	38	40	,	,	PUNCT
dpc-4151	38	41	after	after	ADP
dpc-4151	38	42	obtaining	obtain	VERB
dpc-4151	38	43	ethical	ethical	ADJ
dpc-4151	38	44	clearance	clearance	NOUN
dpc-4151	38	45	from	from	ADP
dpc-4151	38	46	our	our	PRON
dpc-4151	38	47	institution	institution	NOUN
dpc-4151	38	48	[	[	X
dpc-4151	38	49	vide	vide	NOUN
dpc-4151	38	50	letter	letter	NOUN
dpc-4151	38	51	number	number	NOUN
dpc-4151	38	52	631	631	NUM
dpc-4151	38	53	(	(	PUNCT
dpc-4151	38	54	74/2022)/iec	74/2022)/iec	NOUN
dpc-4151	38	55	/	/	SYM
dpc-4151	38	56	abvims	abvim	NOUN
dpc-4151	38	57	/	/	SYM
dpc-4151	38	58	rmlh/1134	rmlh/1134	NOUN
dpc-4151	38	59	]	]	PUNCT
dpc-4151	38	60	.	.	PUNCT
dpc-4151	39	1	the	the	DET
dpc-4151	39	2	outpatient	outpatient	NOUN
dpc-4151	39	3	department	department	NOUN
dpc-4151	39	4	record	record	NOUN
dpc-4151	39	5	proformas	proforma	NOUN
dpc-4151	39	6	of	of	ADP
dpc-4151	39	7	patients	patient	NOUN
dpc-4151	39	8	with	with	ADP
dpc-4151	39	9	lp	lp	ADV
dpc-4151	39	10	treated	treat	VERB
dpc-4151	39	11	with	with	ADP
dpc-4151	39	12	methotrexate	methotrexate	NOUN
dpc-4151	39	13	were	be	AUX
dpc-4151	39	14	scanned	scan	VERB
dpc-4151	39	15	for	for	ADP
dpc-4151	39	16	clinical	clinical	ADJ
dpc-4151	39	17	and	and	CCONJ
dpc-4151	39	18	therapeutic	therapeutic	ADJ
dpc-4151	39	19	data	datum	NOUN
dpc-4151	39	20	.	.	PUNCT
dpc-4151	40	1	the	the	DET
dpc-4151	40	2	baseline	baseline	NOUN
dpc-4151	40	3	and	and	CCONJ
dpc-4151	40	4	follow	follow	VERB
dpc-4151	40	5	-	-	PUNCT
dpc-4151	40	6	up	up	ADP
dpc-4151	40	7	clinical	clinical	ADJ
dpc-4151	40	8	assessment	assessment	NOUN
dpc-4151	40	9	details	detail	NOUN
dpc-4151	40	10	were	be	AUX
dpc-4151	40	11	noted	note	VERB
dpc-4151	40	12	,	,	PUNCT
dpc-4151	40	13	and	and	CCONJ
dpc-4151	40	14	laboratory	laboratory	NOUN
dpc-4151	40	15	evaluations	evaluation	NOUN
dpc-4151	40	16	performed	perform	VERB
dpc-4151	40	17	at	at	ADP
dpc-4151	40	18	baseline	baseline	NOUN
dpc-4151	40	19	and	and	CCONJ
dpc-4151	40	20	follow	follow	VERB
dpc-4151	40	21	-	-	PUNCT
dpc-4151	40	22	up	up	NOUN
dpc-4151	40	23	were	be	AUX
dpc-4151	40	24	also	also	ADV
dpc-4151	40	25	scanned	scan	VERB
dpc-4151	40	26	.	.	PUNCT
dpc-4151	41	1	the	the	DET
dpc-4151	41	2	cumulative	cumulative	ADJ
dpc-4151	41	3	dose	dose	NOUN
dpc-4151	41	4	and	and	CCONJ
dpc-4151	41	5	duration	duration	NOUN
dpc-4151	41	6	of	of	ADP
dpc-4151	41	7	mtx	mtx	NOUN
dpc-4151	41	8	was	be	AUX
dpc-4151	41	9	calculated	calculate	VERB
dpc-4151	41	10	.	.	PUNCT
dpc-4151	42	1	times	time	NOUN
dpc-4151	42	2	to	to	PART
dpc-4151	42	3	achieve	achieve	VERB
dpc-4151	42	4	disease	disease	NOUN
dpc-4151	42	5	control	control	NOUN
dpc-4151	42	6	in	in	ADP
dpc-4151	42	7	terms	term	NOUN
dpc-4151	42	8	of	of	ADP
dpc-4151	42	9	resolution	resolution	NOUN
dpc-4151	42	10	of	of	ADP
dpc-4151	42	11	pruritus	pruritus	PROPN
dpc-4151	42	12	,	,	PUNCT
dpc-4151	42	13	cessation	cessation	NOUN
dpc-4151	42	14	of	of	ADP
dpc-4151	42	15	new	new	ADJ
dpc-4151	42	16	lesions	lesion	NOUN
dpc-4151	42	17	,	,	PUNCT
dpc-4151	42	18	and	and	CCONJ
dpc-4151	42	19	flattening	flattening	NOUN
dpc-4151	42	20	of	of	ADP
dpc-4151	42	21	lesions	lesion	NOUN
dpc-4151	42	22	were	be	AUX
dpc-4151	42	23	noted	note	VERB
dpc-4151	42	24	.	.	PUNCT
dpc-4151	43	1	finally	finally	ADV
dpc-4151	43	2	,	,	PUNCT
dpc-4151	43	3	we	we	PRON
dpc-4151	43	4	also	also	ADV
dpc-4151	43	5	analyzed	analyze	VERB
dpc-4151	43	6	the	the	DET
dpc-4151	43	7	duration	duration	NOUN
dpc-4151	43	8	of	of	ADP
dpc-4151	43	9	remission	remission	NOUN
dpc-4151	43	10	and	and	CCONJ
dpc-4151	43	11	time	time	NOUN
dpc-4151	43	12	after	after	ADP
dpc-4151	43	13	which	which	PRON
dpc-4151	43	14	recurrences	recurrence	NOUN
dpc-4151	43	15	were	be	AUX
dpc-4151	43	16	seen	see	VERB
dpc-4151	43	17	post	post	ADJ
dpc-4151	43	18	-	-	NOUN
dpc-4151	43	19	treatment	treatment	ADJ
dpc-4151	43	20	,	,	PUNCT
dpc-4151	43	21	wherever	wherever	SCONJ
dpc-4151	43	22	records	record	NOUN
dpc-4151	43	23	for	for	ADP
dpc-4151	43	24	the	the	DET
dpc-4151	43	25	same	same	ADJ
dpc-4151	43	26	were	be	AUX
dpc-4151	43	27	available	available	ADJ
dpc-4151	43	28	.	.	PUNCT
dpc-4151	44	1	results	result	VERB
dpc-4151	44	2	a	a	DET
dpc-4151	44	3	total	total	NOUN
dpc-4151	44	4	of	of	ADP
dpc-4151	44	5	42	42	NUM
dpc-4151	44	6	lp	lp	PROPN
dpc-4151	44	7	patients	patient	NOUN
dpc-4151	44	8	presenting	present	VERB
dpc-4151	44	9	with	with	ADP
dpc-4151	44	10	papules	papule	NOUN
dpc-4151	44	11	and	and	CCONJ
dpc-4151	44	12	plaque	plaque	NOUN
dpc-4151	44	13	lesions	lesion	NOUN
dpc-4151	44	14	managed	manage	VERB
dpc-4151	44	15	on	on	ADP
dpc-4151	44	16	low	low	ADJ
dpc-4151	44	17	-	-	PUNCT
dpc-4151	44	18	dose	dose	VERB
dpc-4151	44	19	methotrexate	methotrexate	NOUN
dpc-4151	44	20	were	be	AUX
dpc-4151	44	21	analyzed	analyze	VERB
dpc-4151	44	22	in	in	ADP
dpc-4151	44	23	this	this	DET
dpc-4151	44	24	study	study	NOUN
dpc-4151	44	25	.	.	PUNCT
dpc-4151	45	1	demographic	demographic	ADJ
dpc-4151	45	2	and	and	CCONJ
dpc-4151	45	3	baseline	baseline	VERB
dpc-4151	45	4	clinical	clinical	ADJ
dpc-4151	45	5	parameters	parameter	NOUN
dpc-4151	45	6	of	of	ADP
dpc-4151	45	7	the	the	DET
dpc-4151	45	8	patients	patient	NOUN
dpc-4151	45	9	are	be	AUX
dpc-4151	45	10	detailed	detail	VERB
dpc-4151	45	11	in	in	ADP
dpc-4151	45	12	table	table	NOUN
dpc-4151	45	13	1	1	NUM
dpc-4151	45	14	.	.	PUNCT
dpc-4151	46	1	the	the	DET
dpc-4151	46	2	mean	mean	ADJ
dpc-4151	46	3	age	age	NOUN
dpc-4151	46	4	of	of	ADP
dpc-4151	46	5	patients	patient	NOUN
dpc-4151	46	6	was	be	AUX
dpc-4151	46	7	32.66	32.66	NUM
dpc-4151	46	8	years	year	NOUN
dpc-4151	46	9	(	(	PUNCT
dpc-4151	46	10	6–79	6–79	ADJ
dpc-4151	46	11	years	year	NOUN
dpc-4151	46	12	)	)	PUNCT
dpc-4151	46	13	,	,	PUNCT
dpc-4151	46	14	and	and	CCONJ
dpc-4151	46	15	the	the	DET
dpc-4151	46	16	male	male	NOUN
dpc-4151	46	17	-	-	PUNCT
dpc-4151	46	18	to	to	ADP
dpc-4151	46	19	-	-	PUNCT
dpc-4151	46	20	female	female	ADJ
dpc-4151	46	21	ratio	ratio	NOUN
dpc-4151	46	22	was	be	AUX
dpc-4151	46	23	0.75:1	0.75:1	PRON
dpc-4151	46	24	.	.	PUNCT
dpc-4151	47	1	the	the	DET
dpc-4151	47	2	mean	mean	ADJ
dpc-4151	47	3	duration	duration	NOUN
dpc-4151	47	4	of	of	ADP
dpc-4151	47	5	disease	disease	NOUN
dpc-4151	47	6	was	be	AUX
dpc-4151	47	7	17.25	17.25	NUM
dpc-4151	47	8	months	month	NOUN
dpc-4151	47	9	(	(	PUNCT
dpc-4151	47	10	1–240	1–240	NUM
dpc-4151	47	11	months	month	NOUN
dpc-4151	47	12	)	)	PUNCT
dpc-4151	47	13	.	.	PUNCT
dpc-4151	48	1	the	the	DET
dpc-4151	48	2	majority	majority	NOUN
dpc-4151	48	3	of	of	ADP
dpc-4151	48	4	the	the	DET
dpc-4151	48	5	patients	patient	NOUN
dpc-4151	48	6	(	(	PUNCT
dpc-4151	48	7	35/42	35/42	NUM
dpc-4151	48	8	)	)	PUNCT
dpc-4151	48	9	had	have	AUX
dpc-4151	48	10	failed	fail	VERB
dpc-4151	48	11	or	or	CCONJ
dpc-4151	48	12	showed	show	VERB
dpc-4151	48	13	partial	partial	ADJ
dpc-4151	48	14	response	response	NOUN
dpc-4151	48	15	to	to	ADP
dpc-4151	48	16	other	other	ADJ
dpc-4151	48	17	medications	medication	NOUN
dpc-4151	48	18	,	,	PUNCT
dpc-4151	48	19	including	include	VERB
dpc-4151	48	20	topical	topical	ADJ
dpc-4151	48	21	/	/	SYM
dpc-4151	48	22	intralesional	intralesional	ADJ
dpc-4151	48	23	/	/	SYM
dpc-4151	48	24	oral	oral	ADJ
dpc-4151	48	25	steroids	steroid	NOUN
dpc-4151	48	26	,	,	PUNCT
dpc-4151	48	27	dapsone	dapsone	NOUN
dpc-4151	48	28	,	,	PUNCT
dpc-4151	48	29	and	and	CCONJ
dpc-4151	48	30	doxycycline	doxycycline	NOUN
dpc-4151	48	31	.	.	PUNCT
dpc-4151	49	1	also	also	ADV
dpc-4151	49	2	,	,	PUNCT
dpc-4151	49	3	most	most	ADJ
dpc-4151	49	4	of	of	ADP
dpc-4151	49	5	the	the	DET
dpc-4151	49	6	patients	patient	NOUN
dpc-4151	49	7	had	have	VERB
dpc-4151	49	8	extensive	extensive	ADJ
dpc-4151	49	9	lp	lp	NOUN
dpc-4151	49	10	with	with	ADP
dpc-4151	49	11	>	>	SYM
dpc-4151	49	12	20	20	NUM
dpc-4151	49	13	%	%	NOUN
dpc-4151	49	14	body	body	NOUN
dpc-4151	49	15	surface	surface	NOUN
dpc-4151	49	16	area	area	NOUN
dpc-4151	49	17	involvement	involvement	NOUN
dpc-4151	49	18	(	(	PUNCT
dpc-4151	49	19	31/42	31/42	NUM
dpc-4151	49	20	,	,	PUNCT
dpc-4151	49	21	73.8	73.8	NUM
dpc-4151	49	22	%	%	NOUN
dpc-4151	49	23	)	)	PUNCT
dpc-4151	49	24	.	.	PUNCT
dpc-4151	50	1	the	the	DET
dpc-4151	50	2	diagnosis	diagnosis	NOUN
dpc-4151	50	3	of	of	ADP
dpc-4151	50	4	lp	lp	NOUN
dpc-4151	50	5	was	be	AUX
dpc-4151	50	6	made	make	VERB
dpc-4151	50	7	based	base	VERB
dpc-4151	50	8	on	on	ADP
dpc-4151	50	9	clinical	clinical	ADJ
dpc-4151	50	10	presentation	presentation	NOUN
dpc-4151	50	11	in	in	ADP
dpc-4151	50	12	all	all	DET
dpc-4151	50	13	cases	case	NOUN
dpc-4151	50	14	.	.	PUNCT
dpc-4151	51	1	all	all	DET
dpc-4151	51	2	patients	patient	NOUN
dpc-4151	51	3	had	have	AUX
dpc-4151	51	4	undergone	undergo	VERB
dpc-4151	51	5	a	a	DET
dpc-4151	51	6	baseline	baseline	ADJ
dpc-4151	51	7	assessment	assessment	NOUN
dpc-4151	51	8	consisting	consist	VERB
dpc-4151	51	9	of	of	ADP
dpc-4151	51	10	complete	complete	ADJ
dpc-4151	51	11	hemogram	hemogram	NOUN
dpc-4151	51	12	,	,	PUNCT
dpc-4151	51	13	liver	liver	NOUN
dpc-4151	51	14	function	function	NOUN
dpc-4151	51	15	tests	test	NOUN
dpc-4151	51	16	,	,	PUNCT
dpc-4151	51	17	kidney	kidney	NOUN
dpc-4151	51	18	function	function	NOUN
dpc-4151	51	19	tests	test	NOUN
dpc-4151	51	20	,	,	PUNCT
dpc-4151	51	21	hepatitis	hepatitis	NOUN
dpc-4151	51	22	serology	serology	NOUN
dpc-4151	51	23	,	,	PUNCT
dpc-4151	51	24	hiv	hiv	PROPN
dpc-4151	51	25	,	,	PUNCT
dpc-4151	51	26	chest	chest	NOUN
dpc-4151	51	27	radiograph	radiograph	NOUN
dpc-4151	51	28	,	,	PUNCT
dpc-4151	51	29	and	and	CCONJ
dpc-4151	51	30	mantoux	mantoux	NOUN
dpc-4151	51	31	test	test	NOUN
dpc-4151	51	32	prior	prior	ADV
dpc-4151	51	33	to	to	ADP
dpc-4151	51	34	starting	start	VERB
dpc-4151	51	35	mtx	mtx	NOUN
dpc-4151	51	36	.	.	PUNCT
dpc-4151	52	1	the	the	DET
dpc-4151	52	2	starting	start	VERB
dpc-4151	52	3	dose	dose	PROPN
dpc-4151	52	4	of	of	ADP
dpc-4151	52	5	mtx	mtx	PROPN
dpc-4151	52	6	was	be	AUX
dpc-4151	52	7	7.5	7.5	NUM
dpc-4151	52	8	mg	mg	PROPN
dpc-4151	52	9	(	(	PUNCT
dpc-4151	52	10	n=7	n=7	PROPN
dpc-4151	52	11	)	)	PUNCT
dpc-4151	52	12	or	or	CCONJ
dpc-4151	52	13	10	10	NUM
dpc-4151	52	14	mg	mg	PROPN
dpc-4151	52	15	(	(	PUNCT
dpc-4151	52	16	n=	n=	ADJ
dpc-4151	52	17	35	35	NUM
dpc-4151	52	18	)	)	PUNCT
dpc-4151	52	19	once	once	ADV
dpc-4151	52	20	weekly	weekly	ADV
dpc-4151	52	21	.	.	PUNCT
dpc-4151	53	1	patients	patient	NOUN
dpc-4151	53	2	were	be	AUX
dpc-4151	53	3	also	also	ADV
dpc-4151	53	4	co	co	ADJ
dpc-4151	53	5	-	-	ADJ
dpc-4151	53	6	prescribed	prescribed	ADJ
dpc-4151	53	7	folic	folic	NOUN
dpc-4151	53	8	acid	acid	NOUN
dpc-4151	53	9	(	(	PUNCT
dpc-4151	53	10	5	5	NUM
dpc-4151	53	11	mg	mg	NOUN
dpc-4151	53	12	)	)	PUNCT
dpc-4151	53	13	supplementation	supplementation	NOUN
dpc-4151	53	14	once	once	ADV
dpc-4151	53	15	weekly	weekly	ADV
dpc-4151	53	16	,	,	PUNCT
dpc-4151	53	17	while	while	SCONJ
dpc-4151	53	18	no	no	DET
dpc-4151	53	19	topical	topical	ADJ
dpc-4151	53	20	steroids	steroid	NOUN
dpc-4151	53	21	were	be	AUX
dpc-4151	53	22	prescribed	prescribe	VERB
dpc-4151	53	23	for	for	ADP
dpc-4151	53	24	any	any	DET
dpc-4151	53	25	patient	patient	NOUN
dpc-4151	53	26	.	.	PUNCT
dpc-4151	54	1	in	in	ADP
dpc-4151	54	2	those	those	PRON
dpc-4151	54	3	who	who	PRON
dpc-4151	54	4	had	have	VERB
dpc-4151	54	5	inadequate	inadequate	ADJ
dpc-4151	54	6	response	response	NOUN
dpc-4151	54	7	(	(	PUNCT
dpc-4151	54	8	no	no	DET
dpc-4151	54	9	decrease	decrease	NOUN
dpc-4151	54	10	in	in	ADP
dpc-4151	54	11	pruritus	pruritus	PROPN
dpc-4151	54	12	,	,	PUNCT
dpc-4151	54	13	appearance	appearance	NOUN
dpc-4151	54	14	of	of	ADP
dpc-4151	54	15	new	new	ADJ
dpc-4151	54	16	lesions	lesion	NOUN
dpc-4151	54	17	,	,	PUNCT
dpc-4151	54	18	or	or	CCONJ
dpc-4151	54	19	no	no	DET
dpc-4151	54	20	flattening	flattening	NOUN
dpc-4151	54	21	of	of	ADP
dpc-4151	54	22	existing	exist	VERB
dpc-4151	54	23	lesions	lesion	NOUN
dpc-4151	54	24	)	)	PUNCT
dpc-4151	54	25	to	to	ADP
dpc-4151	54	26	the	the	DET
dpc-4151	54	27	starting	starting	NOUN
dpc-4151	54	28	dose	dose	NOUN
dpc-4151	54	29	,	,	PUNCT
dpc-4151	54	30	the	the	DET
dpc-4151	54	31	dose	dose	NOUN
dpc-4151	54	32	was	be	AUX
dpc-4151	54	33	increased	increase	VERB
dpc-4151	54	34	to	to	ADP
dpc-4151	54	35	10/15	10/15	NUM
dpc-4151	54	36	mg	mg	NOUN
dpc-4151	54	37	weekly	weekly	ADV
dpc-4151	54	38	.	.	PUNCT
dpc-4151	55	1	a	a	DET
dpc-4151	55	2	total	total	NOUN
dpc-4151	55	3	of	of	ADP
dpc-4151	55	4	12	12	NUM
dpc-4151	55	5	patients	patient	NOUN
dpc-4151	55	6	were	be	AUX
dpc-4151	55	7	prescribed	prescribe	VERB
dpc-4151	55	8	a	a	DET
dpc-4151	55	9	dose	dose	NOUN
dpc-4151	55	10	of	of	ADP
dpc-4151	55	11	15	15	NUM
dpc-4151	55	12	mg	mg	NUM
dpc-4151	55	13	/	/	SYM
dpc-4151	55	14	week	week	NOUN
dpc-4151	55	15	,	,	PUNCT
dpc-4151	55	16	while	while	SCONJ
dpc-4151	55	17	17	17	NUM
dpc-4151	55	18	received	receive	VERB
dpc-4151	55	19	a	a	DET
dpc-4151	55	20	maximum	maximum	NOUN
dpc-4151	55	21	of	of	ADP
dpc-4151	55	22	10	10	NUM
dpc-4151	55	23	mg	mg	NUM
dpc-4151	55	24	/	/	SYM
dpc-4151	55	25	week	week	NOUN
dpc-4151	55	26	,	,	PUNCT
dpc-4151	55	27	and	and	CCONJ
dpc-4151	55	28	three	three	NUM
dpc-4151	55	29	received	receive	VERB
dpc-4151	55	30	only	only	ADV
dpc-4151	55	31	7.5	7.5	NUM
dpc-4151	55	32	mg	mg	NUM
dpc-4151	55	33	/	/	SYM
dpc-4151	55	34	week	week	NOUN
dpc-4151	55	35	throughout	throughout	ADP
dpc-4151	55	36	the	the	DET
dpc-4151	55	37	treatment	treatment	NOUN
dpc-4151	55	38	course	course	NOUN
dpc-4151	55	39	.	.	PUNCT
dpc-4151	56	1	no	no	DET
dpc-4151	56	2	patient	patient	NOUN
dpc-4151	56	3	was	be	AUX
dpc-4151	56	4	prescribed	prescribe	VERB
dpc-4151	56	5	a	a	DET
dpc-4151	56	6	dose	dose	NOUN
dpc-4151	56	7	higher	high	ADJ
dpc-4151	56	8	than	than	ADP
dpc-4151	56	9	15	15	NUM
dpc-4151	56	10	mg	mg	NOUN
dpc-4151	56	11	.	.	PUNCT
dpc-4151	57	1	ten	ten	NUM
dpc-4151	57	2	patients	patient	NOUN
dpc-4151	57	3	were	be	AUX
dpc-4151	57	4	lost	lose	VERB
dpc-4151	57	5	to	to	PART
dpc-4151	57	6	follow	follow	VERB
dpc-4151	57	7	-	-	PUNCT
dpc-4151	57	8	up	up	NOUN
dpc-4151	57	9	.	.	PUNCT
dpc-4151	58	1	two	two	NUM
dpc-4151	58	2	patients	patient	NOUN
dpc-4151	58	3	were	be	AUX
dpc-4151	58	4	given	give	VERB
dpc-4151	58	5	concomitant	concomitant	ADJ
dpc-4151	58	6	isoniazid	isoniazid	NOUN
dpc-4151	58	7	for	for	ADP
dpc-4151	58	8	latent	latent	NOUN
dpc-4151	58	9	tuberculosis	tuberculosis	NOUN
dpc-4151	58	10	detected	detect	VERB
dpc-4151	58	11	on	on	ADP
dpc-4151	58	12	baseline	baseline	NOUN
dpc-4151	58	13	investigations	investigation	NOUN
dpc-4151	58	14	,	,	PUNCT
dpc-4151	58	15	while	while	SCONJ
dpc-4151	58	16	another	another	DET
dpc-4151	58	17	patient	patient	NOUN
dpc-4151	58	18	with	with	ADP
dpc-4151	58	19	a	a	DET
dpc-4151	58	20	history	history	NOUN
dpc-4151	58	21	of	of	ADP
dpc-4151	58	22	treated	treat	VERB
dpc-4151	58	23	pulmonary	pulmonary	ADJ
dpc-4151	58	24	tuberculosis	tuberculosis	NOUN
dpc-4151	58	25	five	five	NUM
dpc-4151	58	26	years	year	NOUN
dpc-4151	58	27	prior	prior	ADV
dpc-4151	58	28	,	,	PUNCT
dpc-4151	58	29	with	with	ADP
dpc-4151	58	30	radiological	radiological	ADJ
dpc-4151	58	31	sequelae	sequelae	NOUN
dpc-4151	58	32	of	of	ADP
dpc-4151	58	33	treated	treat	VERB
dpc-4151	58	34	infection	infection	NOUN
dpc-4151	58	35	but	but	CCONJ
dpc-4151	58	36	a	a	DET
dpc-4151	58	37	negative	negative	ADJ
dpc-4151	58	38	mantoux	mantoux	NOUN
dpc-4151	58	39	test	test	NOUN
dpc-4151	58	40	,	,	PUNCT
dpc-4151	58	41	was	be	AUX
dpc-4151	58	42	given	give	VERB
dpc-4151	58	43	mtx	mtx	NOUN
dpc-4151	58	44	without	without	ADP
dpc-4151	58	45	any	any	DET
dpc-4151	58	46	anti	anti	ADJ
dpc-4151	58	47	-	-	ADJ
dpc-4151	58	48	tubercular	tubercular	ADJ
dpc-4151	58	49	drugs	drug	NOUN
dpc-4151	58	50	following	follow	VERB
dpc-4151	58	51	medical	medical	ADJ
dpc-4151	58	52	consultation	consultation	NOUN
dpc-4151	58	53	.	.	PUNCT
dpc-4151	59	1	mtx	mtx	PROPN
dpc-4151	59	2	was	be	AUX
dpc-4151	59	3	tapered	taper	VERB
dpc-4151	59	4	down	down	ADP
dpc-4151	59	5	and	and	CCONJ
dpc-4151	59	6	stopped	stop	VERB
dpc-4151	59	7	in	in	ADP
dpc-4151	59	8	four	four	NUM
dpc-4151	59	9	patients	patient	NOUN
dpc-4151	59	10	and	and	CCONJ
dpc-4151	59	11	abruptly	abruptly	ADV
dpc-4151	59	12	discontinued	discontinue	VERB
dpc-4151	59	13	in	in	ADP
dpc-4151	59	14	rest	rest	NOUN
dpc-4151	59	15	of	of	ADP
dpc-4151	59	16	the	the	DET
dpc-4151	59	17	patients	patient	NOUN
dpc-4151	59	18	when	when	SCONJ
dpc-4151	59	19	complete	complete	ADJ
dpc-4151	59	20	response	response	NOUN
dpc-4151	59	21	was	be	AUX
dpc-4151	59	22	achieved	achieve	VERB
dpc-4151	59	23	.	.	PUNCT
dpc-4151	60	1	complete	complete	ADJ
dpc-4151	60	2	resolution	resolution	NOUN
dpc-4151	60	3	was	be	AUX
dpc-4151	60	4	achieved	achieve	VERB
dpc-4151	60	5	in	in	ADP
dpc-4151	60	6	30/32	30/32	NUM
dpc-4151	60	7	(	(	PUNCT
dpc-4151	60	8	93	93	NUM
dpc-4151	60	9	%	%	NOUN
dpc-4151	60	10	)	)	PUNCT
dpc-4151	60	11	patients	patient	NOUN
dpc-4151	60	12	.	.	PUNCT
dpc-4151	61	1	the	the	DET
dpc-4151	61	2	mean	mean	ADJ
dpc-4151	61	3	time	time	NOUN
dpc-4151	61	4	to	to	PART
dpc-4151	61	5	achieve	achieve	VERB
dpc-4151	61	6	complete	complete	ADJ
dpc-4151	61	7	resolution	resolution	NOUN
dpc-4151	61	8	of	of	ADP
dpc-4151	61	9	the	the	DET
dpc-4151	61	10	disease	disease	NOUN
dpc-4151	61	11	was	be	AUX
dpc-4151	61	12	14.76	14.76	NUM
dpc-4151	61	13	weeks	week	NOUN
dpc-4151	61	14	(	(	PUNCT
dpc-4151	61	15	4	4	NUM
dpc-4151	61	16	-	-	SYM
dpc-4151	61	17	32	32	NUM
dpc-4151	61	18	weeks	week	NOUN
dpc-4151	61	19	)	)	PUNCT
dpc-4151	61	20	,	,	PUNCT
dpc-4151	61	21	and	and	CCONJ
dpc-4151	61	22	the	the	DET
dpc-4151	61	23	cumulative	cumulative	ADJ
dpc-4151	61	24	dose	dose	NOUN
dpc-4151	61	25	of	of	ADP
dpc-4151	61	26	mtx	mtx	NOUN
dpc-4151	61	27	to	to	PART
dpc-4151	61	28	achieve	achieve	VERB
dpc-4151	61	29	remission	remission	NOUN
dpc-4151	61	30	was	be	AUX
dpc-4151	61	31	153.58	153.58	NUM
dpc-4151	61	32	mg	mg	NOUN
dpc-4151	61	33	(	(	PUNCT
dpc-4151	61	34	50	50	NUM
dpc-4151	61	35	-	-	SYM
dpc-4151	61	36	375	375	NUM
dpc-4151	61	37	mg	mg	NUM
dpc-4151	61	38	)	)	PUNCT
dpc-4151	61	39	(	(	PUNCT
dpc-4151	61	40	table	table	NOUN
dpc-4151	61	41	2	2	NUM
dpc-4151	61	42	)	)	PUNCT
dpc-4151	61	43	.	.	PUNCT
dpc-4151	62	1	side	side	NOUN
dpc-4151	62	2	effects	effect	NOUN
dpc-4151	62	3	were	be	AUX
dpc-4151	62	4	noted	note	VERB
dpc-4151	62	5	in	in	ADP
dpc-4151	62	6	12/32	12/32	NUM
dpc-4151	62	7	(	(	PUNCT
dpc-4151	62	8	37.5	37.5	NUM
dpc-4151	62	9	%	%	NOUN
dpc-4151	62	10	)	)	PUNCT
dpc-4151	62	11	patients	patient	NOUN
dpc-4151	62	12	,	,	PUNCT
dpc-4151	62	13	including	include	VERB
dpc-4151	62	14	headache	headache	NOUN
dpc-4151	62	15	(	(	PUNCT
dpc-4151	62	16	n=1	n=1	PROPN
dpc-4151	62	17	)	)	PUNCT
dpc-4151	62	18	,	,	PUNCT
dpc-4151	62	19	nausea	nausea	NOUN
dpc-4151	62	20	(	(	PUNCT
dpc-4151	62	21	n=2	n=2	ADV
dpc-4151	62	22	)	)	PUNCT
dpc-4151	62	23	,	,	PUNCT
dpc-4151	62	24	fatigue	fatigue	NOUN
dpc-4151	62	25	(	(	PUNCT
dpc-4151	62	26	n=2	n=2	ADV
dpc-4151	62	27	)	)	PUNCT
dpc-4151	62	28	,	,	PUNCT
dpc-4151	62	29	fever	fever	NOUN
dpc-4151	62	30	(	(	PUNCT
dpc-4151	62	31	n=1	n=1	PROPN
dpc-4151	62	32	)	)	PUNCT
dpc-4151	62	33	,	,	PUNCT
dpc-4151	62	34	decreased	decrease	VERB
dpc-4151	62	35	appetite	appetite	NOUN
dpc-4151	62	36	(	(	PUNCT
dpc-4151	62	37	n=1	n=1	PROPN
dpc-4151	62	38	)	)	PUNCT
dpc-4151	62	39	,	,	PUNCT
dpc-4151	62	40	diffuse	diffuse	VERB
dpc-4151	62	41	hair	hair	NOUN
dpc-4151	62	42	loss	loss	NOUN
dpc-4151	62	43	(	(	PUNCT
dpc-4151	62	44	n=3	n=3	NOUN
dpc-4151	62	45	)	)	PUNCT
dpc-4151	62	46	,	,	PUNCT
dpc-4151	62	47	vomiting	vomiting	NOUN
dpc-4151	62	48	(	(	PUNCT
dpc-4151	62	49	n=1	n=1	PROPN
dpc-4151	62	50	)	)	PUNCT
dpc-4151	62	51	,	,	PUNCT
dpc-4151	62	52	abdominal	abdominal	ADJ
dpc-4151	62	53	pain	pain	NOUN
dpc-4151	62	54	(	(	PUNCT
dpc-4151	62	55	n=1	n=1	PROPN
dpc-4151	62	56	)	)	PUNCT
dpc-4151	62	57	,	,	PUNCT
dpc-4151	62	58	dyspepsia	dyspepsia	NOUN
dpc-4151	62	59	(	(	PUNCT
dpc-4151	62	60	n=3	n=3	NOUN
dpc-4151	62	61	)	)	PUNCT
dpc-4151	62	62	,	,	PUNCT
dpc-4151	62	63	elevation	elevation	NOUN
dpc-4151	62	64	of	of	ADP
dpc-4151	62	65	transaminases	transaminase	NOUN
dpc-4151	62	66	(	(	PUNCT
dpc-4151	62	67	n=1	n=1	PROPN
dpc-4151	62	68	)	)	PUNCT
dpc-4151	62	69	,	,	PUNCT
dpc-4151	62	70	mood	mood	NOUN
dpc-4151	62	71	disturbances	disturbance	NOUN
dpc-4151	62	72	(	(	PUNCT
dpc-4151	62	73	n=1	n=1	PROPN
dpc-4151	62	74	)	)	PUNCT
dpc-4151	62	75	,	,	PUNCT
dpc-4151	62	76	plantar	plantar	NOUN
dpc-4151	62	77	erythema	erythema	NOUN
dpc-4151	62	78	and	and	CCONJ
dpc-4151	62	79	burning	burn	VERB
dpc-4151	62	80	(	(	PUNCT
dpc-4151	62	81	n=1	n=1	PROPN
dpc-4151	62	82	)	)	PUNCT
dpc-4151	62	83	,	,	PUNCT
dpc-4151	62	84	and	and	CCONJ
dpc-4151	62	85	thrombocytopenia	thrombocytopenia	PROPN
dpc-4151	62	86	(	(	PUNCT
dpc-4151	62	87	n=1	n=1	PROPN
dpc-4151	62	88	)	)	PUNCT
dpc-4151	62	89	.	.	PUNCT
dpc-4151	63	1	no	no	DET
dpc-4151	63	2	serious	serious	ADJ
dpc-4151	63	3	adverse	adverse	ADJ
dpc-4151	63	4	effect	effect	NOUN
dpc-4151	63	5	was	be	AUX
dpc-4151	63	6	observed	observe	VERB
dpc-4151	63	7	,	,	PUNCT
dpc-4151	63	8	and	and	CCONJ
dpc-4151	63	9	no	no	DET
dpc-4151	63	10	patient	patient	NOUN
dpc-4151	63	11	discontinued	discontinue	VERB
dpc-4151	63	12	treatment	treatment	NOUN
dpc-4151	63	13	due	due	ADP
dpc-4151	63	14	to	to	ADP
dpc-4151	63	15	a	a	DET
dpc-4151	63	16	drug	drug	NOUN
dpc-4151	63	17	-	-	PUNCT
dpc-4151	63	18	related	relate	VERB
dpc-4151	63	19	adverse	adverse	ADJ
dpc-4151	63	20	event	event	NOUN
dpc-4151	63	21	.	.	PUNCT
dpc-4151	64	1	original	original	ADJ
dpc-4151	64	2	article	article	NOUN
dpc-4151	64	3	|	|	ADV
dpc-4151	64	4	dermatol	dermatol	ADJ
dpc-4151	64	5	pract	pract	NOUN
dpc-4151	64	6	concept	concept	NOUN
dpc-4151	64	7	.	.	PUNCT
dpc-4151	65	1	2024;14(4):e2024220	2024;14(4):e2024220	NUM
dpc-4151	65	2	3	3	NUM
dpc-4151	65	3	the	the	DET
dpc-4151	65	4	mean	mean	ADJ
dpc-4151	65	5	duration	duration	NOUN
dpc-4151	65	6	of	of	ADP
dpc-4151	65	7	remission	remission	NOUN
dpc-4151	65	8	was	be	AUX
dpc-4151	65	9	29.43	29.43	NUM
dpc-4151	65	10	months	month	NOUN
dpc-4151	65	11	(	(	PUNCT
dpc-4151	65	12	5	5	NUM
dpc-4151	65	13	-	-	SYM
dpc-4151	65	14	60	60	NUM
dpc-4151	65	15	months	month	NOUN
dpc-4151	65	16	)	)	PUNCT
dpc-4151	65	17	.	.	PUNCT
dpc-4151	66	1	recurrence	recurrence	NOUN
dpc-4151	66	2	of	of	ADP
dpc-4151	66	3	lesions	lesion	NOUN
dpc-4151	66	4	was	be	AUX
dpc-4151	66	5	observed	observe	VERB
dpc-4151	66	6	in	in	ADP
dpc-4151	66	7	13/30	13/30	NUM
dpc-4151	66	8	(	(	PUNCT
dpc-4151	66	9	43.3	43.3	NUM
dpc-4151	66	10	%	%	NOUN
dpc-4151	66	11	)	)	PUNCT
dpc-4151	66	12	patients	patient	NOUN
dpc-4151	66	13	after	after	ADP
dpc-4151	66	14	a	a	DET
dpc-4151	66	15	mean	mean	ADJ
dpc-4151	66	16	duration	duration	NOUN
dpc-4151	66	17	of	of	ADP
dpc-4151	66	18	17.33	17.33	NUM
dpc-4151	66	19	months	month	NOUN
dpc-4151	66	20	(	(	PUNCT
dpc-4151	66	21	5	5	NUM
dpc-4151	66	22	-	-	SYM
dpc-4151	66	23	36	36	NUM
dpc-4151	66	24	months	month	NOUN
dpc-4151	66	25	)	)	PUNCT
dpc-4151	66	26	of	of	ADP
dpc-4151	66	27	stopping	stop	VERB
dpc-4151	66	28	mtx	mtx	NOUN
dpc-4151	66	29	(	(	PUNCT
dpc-4151	66	30	table	table	NOUN
dpc-4151	66	31	2	2	NUM
dpc-4151	66	32	)	)	PUNCT
dpc-4151	66	33	.	.	PUNCT
dpc-4151	67	1	discussion	discussion	NOUN
dpc-4151	67	2	lp	lp	NOUN
dpc-4151	67	3	is	be	AUX
dpc-4151	67	4	a	a	DET
dpc-4151	67	5	chronic	chronic	ADJ
dpc-4151	67	6	inflammatory	inflammatory	ADJ
dpc-4151	67	7	disorder	disorder	NOUN
dpc-4151	67	8	involving	involve	VERB
dpc-4151	67	9	skin	skin	NOUN
dpc-4151	67	10	,	,	PUNCT
dpc-4151	67	11	mucosae	mucosae	PROPN
dpc-4151	67	12	,	,	PUNCT
dpc-4151	67	13	nails	nail	NOUN
dpc-4151	67	14	,	,	PUNCT
dpc-4151	67	15	and	and	CCONJ
dpc-4151	67	16	scalp	scalp	NOUN
dpc-4151	67	17	.	.	PUNCT
dpc-4151	68	1	the	the	DET
dpc-4151	68	2	disease	disease	NOUN
dpc-4151	68	3	is	be	AUX
dpc-4151	68	4	often	often	ADV
dpc-4151	68	5	associated	associate	VERB
dpc-4151	68	6	with	with	ADP
dpc-4151	68	7	pruritus	pruritus	NOUN
dpc-4151	68	8	of	of	ADP
dpc-4151	68	9	varying	vary	VERB
dpc-4151	68	10	intensity	intensity	NOUN
dpc-4151	68	11	.	.	PUNCT
dpc-4151	69	1	it	it	PRON
dpc-4151	69	2	runs	run	VERB
dpc-4151	69	3	an	an	DET
dpc-4151	69	4	unpredictable	unpredictable	ADJ
dpc-4151	69	5	course	course	NOUN
dpc-4151	69	6	,	,	PUNCT
dpc-4151	69	7	and	and	CCONJ
dpc-4151	69	8	prognosis	prognosis	NOUN
dpc-4151	69	9	depends	depend	VERB
dpc-4151	69	10	on	on	ADP
dpc-4151	69	11	the	the	DET
dpc-4151	69	12	subtype	subtype	NOUN
dpc-4151	69	13	of	of	ADP
dpc-4151	69	14	lp	lp	NOUN
dpc-4151	69	15	.	.	PUNCT
dpc-4151	70	1	while	while	SCONJ
dpc-4151	70	2	spontaneous	spontaneous	ADJ
dpc-4151	70	3	resolution	resolution	NOUN
dpc-4151	70	4	is	be	AUX
dpc-4151	70	5	seen	see	VERB
dpc-4151	70	6	in	in	ADP
dpc-4151	70	7	two	two	NUM
dpc-4151	70	8	-	-	PUNCT
dpc-4151	70	9	thirds	third	NOUN
dpc-4151	70	10	of	of	ADP
dpc-4151	70	11	patients	patient	NOUN
dpc-4151	70	12	within	within	ADP
dpc-4151	70	13	18	18	NUM
dpc-4151	70	14	months	month	NOUN
dpc-4151	70	15	,	,	PUNCT
dpc-4151	70	16	oral	oral	ADJ
dpc-4151	70	17	lp	lp	NOUN
dpc-4151	70	18	may	may	AUX
dpc-4151	70	19	take	take	VERB
dpc-4151	70	20	longer	long	ADJ
dpc-4151	70	21	to	to	PART
dpc-4151	70	22	subside	subside	VERB
dpc-4151	70	23	[	[	X
dpc-4151	70	24	10,11	10,11	NUM
dpc-4151	70	25	]	]	PUNCT
dpc-4151	70	26	.	.	PUNCT
dpc-4151	71	1	the	the	DET
dpc-4151	71	2	pathomechanism	pathomechanism	NOUN
dpc-4151	71	3	of	of	ADP
dpc-4151	71	4	lp	lp	PROPN
dpc-4151	71	5	involves	involve	VERB
dpc-4151	71	6	a	a	DET
dpc-4151	71	7	complex	complex	ADJ
dpc-4151	71	8	interplay	interplay	NOUN
dpc-4151	71	9	between	between	ADP
dpc-4151	71	10	genetic	genetic	ADJ
dpc-4151	71	11	,	,	PUNCT
dpc-4151	71	12	environmental	environmental	ADJ
dpc-4151	71	13	and	and	CCONJ
dpc-4151	71	14	immunological	immunological	ADJ
dpc-4151	71	15	factors	factor	NOUN
dpc-4151	71	16	.	.	PUNCT
dpc-4151	72	1	the	the	DET
dpc-4151	72	2	immunopathogenesis	immunopathogenesis	NOUN
dpc-4151	72	3	is	be	AUX
dpc-4151	72	4	largely	largely	ADV
dpc-4151	72	5	cell	cell	NOUN
dpc-4151	72	6	-	-	PUNCT
dpc-4151	72	7	mediated	mediate	VERB
dpc-4151	72	8	,	,	PUNCT
dpc-4151	72	9	with	with	SCONJ
dpc-4151	72	10	t	t	PROPN
dpc-4151	72	11	lymphocytes	lymphocyte	VERB
dpc-4151	72	12	playing	play	VERB
dpc-4151	72	13	a	a	DET
dpc-4151	72	14	pivotal	pivotal	ADJ
dpc-4151	72	15	role	role	NOUN
dpc-4151	72	16	.	.	PUNCT
dpc-4151	73	1	among	among	ADP
dpc-4151	73	2	t	t	PROPN
dpc-4151	73	3	cell	cell	NOUN
dpc-4151	73	4	lines	line	NOUN
dpc-4151	73	5	,	,	PUNCT
dpc-4151	73	6	t	t	PROPN
dpc-4151	73	7	helper1	helper1	PROPN
dpc-4151	73	8	(	(	PUNCT
dpc-4151	73	9	th1	th1	NOUN
dpc-4151	73	10	)	)	PUNCT
dpc-4151	73	11	and	and	CCONJ
dpc-4151	73	12	t	t	X
dpc-4151	73	13	cytotoxic	cytotoxic	ADJ
dpc-4151	73	14	1(tc1	1(tc1	NUM
dpc-4151	73	15	)	)	PUNCT
dpc-4151	73	16	and	and	CCONJ
dpc-4151	73	17	th	th	NUM
dpc-4151	73	18	17	17	NUM
dpc-4151	73	19	and	and	CCONJ
dpc-4151	73	20	tc17	tc17	PROPN
dpc-4151	73	21	lymphocyte	lymphocyte	ADJ
dpc-4151	73	22	subpopulations	subpopulation	NOUN
dpc-4151	73	23	play	play	VERB
dpc-4151	73	24	important	important	ADJ
dpc-4151	73	25	roles	role	NOUN
dpc-4151	73	26	[	[	X
dpc-4151	73	27	12	12	NUM
dpc-4151	73	28	]	]	PUNCT
dpc-4151	73	29	.	.	PUNCT
dpc-4151	74	1	the	the	DET
dpc-4151	74	2	key	key	ADJ
dpc-4151	74	3	cytokines	cytokine	NOUN
dpc-4151	74	4	that	that	PRON
dpc-4151	74	5	play	play	VERB
dpc-4151	74	6	a	a	DET
dpc-4151	74	7	role	role	NOUN
dpc-4151	74	8	include	include	VERB
dpc-4151	74	9	interferon	interferon	ADJ
dpc-4151	74	10	-	-	PUNCT
dpc-4151	74	11	gamma	gamma	NOUN
dpc-4151	74	12	(	(	PUNCT
dpc-4151	74	13	ifn	ifn	PROPN
dpc-4151	74	14	-	-	PUNCT
dpc-4151	74	15	γ	γ	NOUN
dpc-4151	74	16	)	)	PUNCT
dpc-4151	74	17	table	table	NOUN
dpc-4151	74	18	1	1	NUM
dpc-4151	74	19	.	.	PUNCT
dpc-4151	75	1	demographic	demographic	ADJ
dpc-4151	75	2	and	and	CCONJ
dpc-4151	75	3	baseline	baseline	VERB
dpc-4151	75	4	clinical	clinical	ADJ
dpc-4151	75	5	parameters	parameter	NOUN
dpc-4151	75	6	of	of	ADP
dpc-4151	75	7	42	42	NUM
dpc-4151	75	8	lichen	lichen	NOUN
dpc-4151	75	9	planus	planus	ADJ
dpc-4151	75	10	patients	patient	NOUN
dpc-4151	75	11	.	.	PUNCT
dpc-4151	76	1	age	age	NOUN
dpc-4151	76	2	(	(	PUNCT
dpc-4151	76	3	years	year	NOUN
dpc-4151	76	4	)	)	PUNCT
dpc-4151	76	5	32.66	32.66	NUM
dpc-4151	76	6	(	(	PUNCT
dpc-4151	76	7	6	6	NUM
dpc-4151	76	8	-	-	SYM
dpc-4151	76	9	79	79	NUM
dpc-4151	76	10	)	)	PUNCT
dpc-4151	76	11	sex	sex	NOUN
dpc-4151	76	12	males	male	NOUN
dpc-4151	76	13	18	18	NUM
dpc-4151	76	14	(	(	PUNCT
dpc-4151	76	15	42.85	42.85	NUM
dpc-4151	76	16	%	%	NOUN
dpc-4151	76	17	)	)	PUNCT
dpc-4151	76	18	females	female	NOUN
dpc-4151	76	19	24	24	NUM
dpc-4151	76	20	(	(	PUNCT
dpc-4151	76	21	57.14	57.14	NUM
dpc-4151	76	22	%	%	NOUN
dpc-4151	76	23	)	)	PUNCT
dpc-4151	76	24	mean	mean	VERB
dpc-4151	76	25	disease	disease	NOUN
dpc-4151	76	26	duration	duration	NOUN
dpc-4151	76	27	(	(	PUNCT
dpc-4151	76	28	months	month	NOUN
dpc-4151	76	29	)	)	PUNCT
dpc-4151	76	30	17.25	17.25	NUM
dpc-4151	76	31	(	(	PUNCT
dpc-4151	76	32	1	1	NUM
dpc-4151	76	33	-	-	SYM
dpc-4151	76	34	240	240	NUM
dpc-4151	76	35	)	)	PUNCT
dpc-4151	76	36	lesions	lesion	NOUN
dpc-4151	76	37	at	at	ADP
dpc-4151	76	38	site	site	NOUN
dpc-4151	76	39	of	of	ADP
dpc-4151	76	40	trauma	trauma	NOUN
dpc-4151	76	41	10	10	NUM
dpc-4151	76	42	(	(	PUNCT
dpc-4151	76	43	23.8	23.8	NUM
dpc-4151	76	44	%	%	NOUN
dpc-4151	76	45	)	)	PUNCT
dpc-4151	76	46	number	number	NOUN
dpc-4151	76	47	of	of	ADP
dpc-4151	76	48	new	new	ADJ
dpc-4151	76	49	lesions	lesion	NOUN
dpc-4151	76	50	over	over	ADP
dpc-4151	76	51	previous	previous	ADJ
dpc-4151	76	52	2	2	NUM
dpc-4151	76	53	weeks	week	NOUN
dpc-4151	76	54	<	<	X
dpc-4151	76	55	20	20	NUM
dpc-4151	76	56	17	17	NUM
dpc-4151	76	57	(	(	PUNCT
dpc-4151	76	58	40.47	40.47	NUM
dpc-4151	76	59	)	)	PUNCT
dpc-4151	76	60	20	20	NUM
dpc-4151	76	61	-	-	SYM
dpc-4151	76	62	50	50	NUM
dpc-4151	76	63	23	23	NUM
dpc-4151	76	64	(	(	PUNCT
dpc-4151	76	65	54.76	54.76	NUM
dpc-4151	76	66	%	%	NOUN
dpc-4151	76	67	)	)	PUNCT
dpc-4151	76	68	50	50	NUM
dpc-4151	76	69	-	-	SYM
dpc-4151	76	70	100	100	NUM
dpc-4151	76	71	2	2	NUM
dpc-4151	76	72	(	(	PUNCT
dpc-4151	76	73	4.76	4.76	NUM
dpc-4151	76	74	%	%	NOUN
dpc-4151	76	75	)	)	PUNCT
dpc-4151	77	1	pruritus	pruritus	PROPN
dpc-4151	77	2	score	score	NOUN
dpc-4151	77	3	(	(	PUNCT
dpc-4151	77	4	0	0	NUM
dpc-4151	77	5	-	-	SYM
dpc-4151	77	6	10	10	NUM
dpc-4151	77	7	)	)	PUNCT
dpc-4151	77	8	<	<	X
dpc-4151	77	9	5	5	NUM
dpc-4151	77	10	7	7	NUM
dpc-4151	77	11	(	(	PUNCT
dpc-4151	77	12	16.66	16.66	NUM
dpc-4151	77	13	%	%	NOUN
dpc-4151	77	14	)	)	PUNCT
dpc-4151	77	15	≥5	≥5	NUM
dpc-4151	77	16	35	35	NUM
dpc-4151	77	17	(	(	PUNCT
dpc-4151	77	18	83.33	83.33	NUM
dpc-4151	77	19	%	%	NOUN
dpc-4151	77	20	)	)	PUNCT
dpc-4151	77	21	distribution	distribution	NOUN
dpc-4151	77	22	of	of	ADP
dpc-4151	77	23	lesions	lesion	NOUN
dpc-4151	77	24	localized	localize	VERB
dpc-4151	77	25	11	11	NUM
dpc-4151	77	26	(	(	PUNCT
dpc-4151	77	27	26.19	26.19	NUM
dpc-4151	77	28	%	%	NOUN
dpc-4151	77	29	)	)	PUNCT
dpc-4151	77	30	generalized	generalize	VERB
dpc-4151	77	31	31	31	NUM
dpc-4151	77	32	(	(	PUNCT
dpc-4151	77	33	73.8	73.8	NUM
dpc-4151	77	34	%	%	NOUN
dpc-4151	77	35	)	)	PUNCT
dpc-4151	77	36	morphology	morphology	NOUN
dpc-4151	77	37	of	of	ADP
dpc-4151	77	38	lesions	lesion	NOUN
dpc-4151	77	39	papules	papule	NOUN
dpc-4151	77	40	35	35	NUM
dpc-4151	77	41	(	(	PUNCT
dpc-4151	77	42	83.33	83.33	NUM
dpc-4151	77	43	%	%	NOUN
dpc-4151	77	44	)	)	PUNCT
dpc-4151	77	45	micropapules	micropapule	VERB
dpc-4151	77	46	3	3	NUM
dpc-4151	77	47	(	(	PUNCT
dpc-4151	77	48	8.57	8.57	NUM
dpc-4151	77	49	%	%	NOUN
dpc-4151	77	50	)	)	PUNCT
dpc-4151	77	51	plaques	plaque	NOUN
dpc-4151	77	52	29	29	NUM
dpc-4151	77	53	(	(	PUNCT
dpc-4151	77	54	69	69	NUM
dpc-4151	77	55	%	%	NOUN
dpc-4151	77	56	)	)	PUNCT
dpc-4151	77	57	annular	annular	ADJ
dpc-4151	77	58	2	2	NUM
dpc-4151	77	59	(	(	PUNCT
dpc-4151	77	60	4.7	4.7	NUM
dpc-4151	77	61	%	%	NOUN
dpc-4151	77	62	)	)	PUNCT
dpc-4151	77	63	koebnerization	koebnerization	PROPN
dpc-4151	77	64	present	present	ADJ
dpc-4151	77	65	15	15	NUM
dpc-4151	77	66	(	(	PUNCT
dpc-4151	77	67	35.71	35.71	NUM
dpc-4151	77	68	%	%	NOUN
dpc-4151	77	69	)	)	PUNCT
dpc-4151	77	70	secondary	secondary	ADJ
dpc-4151	77	71	changes	change	NOUN
dpc-4151	77	72	(	(	PUNCT
dpc-4151	77	73	excoriations	excoriation	NOUN
dpc-4151	77	74	/	/	SYM
dpc-4151	77	75	erosions	erosion	NOUN
dpc-4151	77	76	/	/	SYM
dpc-4151	77	77	scaling	scaling	NOUN
dpc-4151	77	78	/	/	SYM
dpc-4151	77	79	crusting	crusting	NOUN
dpc-4151	77	80	)	)	PUNCT
dpc-4151	77	81	11	11	NUM
dpc-4151	77	82	(	(	PUNCT
dpc-4151	77	83	26.19	26.19	NUM
dpc-4151	77	84	%	%	NOUN
dpc-4151	77	85	)	)	PUNCT
dpc-4151	77	86	hair	hair	NOUN
dpc-4151	77	87	involvement	involvement	NOUN
dpc-4151	77	88	1	1	NUM
dpc-4151	77	89	(	(	PUNCT
dpc-4151	77	90	2.38	2.38	NUM
dpc-4151	77	91	%	%	NOUN
dpc-4151	77	92	)	)	PUNCT
dpc-4151	77	93	nail	nail	NOUN
dpc-4151	77	94	involvement	involvement	NOUN
dpc-4151	77	95	1	1	NUM
dpc-4151	77	96	(	(	PUNCT
dpc-4151	77	97	2.38	2.38	NUM
dpc-4151	77	98	%	%	NOUN
dpc-4151	77	99	)	)	PUNCT
dpc-4151	77	100	mucosal	mucosal	NOUN
dpc-4151	77	101	involvement	involvement	NOUN
dpc-4151	77	102	15	15	NUM
dpc-4151	77	103	(	(	PUNCT
dpc-4151	77	104	35.71	35.71	NUM
dpc-4151	77	105	%	%	NOUN
dpc-4151	77	106	)	)	PUNCT
dpc-4151	77	107	previous	previous	ADJ
dpc-4151	77	108	treatment	treatment	NOUN
dpc-4151	77	109	topical	topical	ADJ
dpc-4151	77	110	/	/	SYM
dpc-4151	77	111	intralesional	intralesional	ADJ
dpc-4151	77	112	corticosteroids	corticosteroid	NOUN
dpc-4151	77	113	20	20	NUM
dpc-4151	77	114	oral	oral	ADJ
dpc-4151	77	115	corticosteroids	corticosteroid	NOUN
dpc-4151	77	116	7	7	NUM
dpc-4151	77	117	dapsone	dapsone	NOUN
dpc-4151	77	118	7	7	NUM
dpc-4151	77	119	isotretinoin	isotretinoin	PROPN
dpc-4151	77	120	1	1	NUM
dpc-4151	77	121	apremilast	apremilast	NOUN
dpc-4151	77	122	1	1	NUM
dpc-4151	77	123	doxycycline	doxycycline	NOUN
dpc-4151	77	124	/	/	SYM
dpc-4151	77	125	minocycline	minocycline	ADJ
dpc-4151	77	126	3	3	NUM
dpc-4151	77	127	others	other	NOUN
dpc-4151	77	128	(	(	PUNCT
dpc-4151	77	129	ayurvedic	ayurvedic	NOUN
dpc-4151	77	130	/	/	SYM
dpc-4151	77	131	homeopathic	homeopathic	ADJ
dpc-4151	77	132	/	/	SYM
dpc-4151	77	133	antihistamines	antihistamine	NOUN
dpc-4151	77	134	/	/	SYM
dpc-4151	77	135	permethrin	permethrin	NOUN
dpc-4151	77	136	/	/	SYM
dpc-4151	77	137	salicylic	salicylic	NOUN
dpc-4151	77	138	acid	acid	NOUN
dpc-4151	77	139	)	)	PUNCT
dpc-4151	77	140	11	11	NUM
dpc-4151	77	141	none	none	NOUN
dpc-4151	77	142	7	7	NUM
dpc-4151	77	143	4	4	NUM
dpc-4151	77	144	original	original	ADJ
dpc-4151	77	145	article	article	NOUN
dpc-4151	77	146	|	|	ADV
dpc-4151	77	147	dermatol	dermatol	ADJ
dpc-4151	77	148	pract	pract	NOUN
dpc-4151	77	149	concept	concept	NOUN
dpc-4151	77	150	.	.	PUNCT
dpc-4151	78	1	2024;14(4):e2024220	2024;14(4):e2024220	NUM
dpc-4151	78	2	patients	patient	NOUN
dpc-4151	78	3	over	over	ADP
dpc-4151	78	4	a	a	DET
dpc-4151	78	5	mean	mean	NOUN
dpc-4151	78	6	of	of	ADP
dpc-4151	78	7	14.76	14.76	NUM
dpc-4151	78	8	weeks	week	NOUN
dpc-4151	78	9	.	.	PUNCT
dpc-4151	79	1	similarly	similarly	ADV
dpc-4151	79	2	,	,	PUNCT
dpc-4151	79	3	kanwar	kanwar	PROPN
dpc-4151	79	4	et	et	PROPN
dpc-4151	79	5	 	 	SPACE
dpc-4151	79	6	al	al	PROPN
dpc-4151	79	7	.	.	PUNCT
dpc-4151	80	1	[	[	X
dpc-4151	80	2	18	18	NUM
dpc-4151	80	3	]	]	PUNCT
dpc-4151	80	4	reported	report	VERB
dpc-4151	80	5	a	a	DET
dpc-4151	80	6	mean	mean	ADJ
dpc-4151	80	7	improvement	improvement	NOUN
dpc-4151	80	8	of	of	ADP
dpc-4151	80	9	79	79	NUM
dpc-4151	80	10	%	%	NOUN
dpc-4151	80	11	over	over	ADP
dpc-4151	80	12	12	12	NUM
dpc-4151	80	13	weeks	week	NOUN
dpc-4151	80	14	of	of	ADP
dpc-4151	80	15	mtx	mtx	NOUN
dpc-4151	80	16	in	in	ADP
dpc-4151	80	17	24	24	NUM
dpc-4151	80	18	patients	patient	NOUN
dpc-4151	80	19	and	and	CCONJ
dpc-4151	80	20	a	a	DET
dpc-4151	80	21	complete	complete	ADJ
dpc-4151	80	22	remission	remission	NOUN
dpc-4151	80	23	in	in	ADP
dpc-4151	80	24	58	58	NUM
dpc-4151	80	25	%	%	NOUN
dpc-4151	80	26	patients	patient	NOUN
dpc-4151	80	27	by	by	ADP
dpc-4151	80	28	24	24	NUM
dpc-4151	80	29	weeks	week	NOUN
dpc-4151	80	30	.	.	PUNCT
dpc-4151	81	1	the	the	DET
dpc-4151	81	2	cumulative	cumulative	ADJ
dpc-4151	81	3	dose	dose	NOUN
dpc-4151	81	4	of	of	ADP
dpc-4151	81	5	mtx	mtx	PROPN
dpc-4151	81	6	used	use	VERB
dpc-4151	81	7	was	be	AUX
dpc-4151	81	8	,	,	PUNCT
dpc-4151	81	9	however	however	ADV
dpc-4151	81	10	,	,	PUNCT
dpc-4151	81	11	much	much	ADV
dpc-4151	81	12	higher	high	ADJ
dpc-4151	81	13	than	than	ADP
dpc-4151	81	14	in	in	ADP
dpc-4151	81	15	our	our	PRON
dpc-4151	81	16	study	study	NOUN
dpc-4151	81	17	(	(	PUNCT
dpc-4151	81	18	306	306	NUM
dpc-4151	81	19	mg	mg	NOUN
dpc-4151	81	20	versus	versus	ADP
dpc-4151	81	21	153	153	NUM
dpc-4151	81	22	mg	mg	NOUN
dpc-4151	81	23	)	)	PUNCT
dpc-4151	81	24	.	.	PUNCT
dpc-4151	82	1	similar	similar	ADJ
dpc-4151	82	2	findings	finding	NOUN
dpc-4151	82	3	were	be	AUX
dpc-4151	82	4	noted	note	VERB
dpc-4151	82	5	in	in	ADP
dpc-4151	82	6	a	a	DET
dpc-4151	82	7	small	small	ADJ
dpc-4151	82	8	retrospective	retrospective	ADJ
dpc-4151	82	9	study	study	NOUN
dpc-4151	82	10	by	by	ADP
dpc-4151	82	11	turan	turan	PROPN
dpc-4151	82	12	et	et	PROPN
dpc-4151	82	13	al	al	PROPN
dpc-4151	82	14	.	.	PUNCT
dpc-4151	83	1	[	[	X
dpc-4151	83	2	19	19	NUM
dpc-4151	83	3	]	]	PUNCT
dpc-4151	83	4	investigating	investigate	VERB
dpc-4151	83	5	the	the	DET
dpc-4151	83	6	efficacy	efficacy	NOUN
dpc-4151	83	7	and	and	CCONJ
dpc-4151	83	8	safety	safety	NOUN
dpc-4151	83	9	of	of	ADP
dpc-4151	83	10	mtx	mtx	NOUN
dpc-4151	83	11	(	(	PUNCT
dpc-4151	83	12	15	15	NUM
dpc-4151	83	13	-	-	SYM
dpc-4151	83	14	20	20	NUM
dpc-4151	83	15	mg	mg	NUM
dpc-4151	83	16	/	/	SYM
dpc-4151	83	17	week	week	NOUN
dpc-4151	83	18	)	)	PUNCT
dpc-4151	83	19	in	in	ADP
dpc-4151	83	20	11	11	NUM
dpc-4151	83	21	generalized	generalized	ADJ
dpc-4151	83	22	lp	lp	ADJ
dpc-4151	83	23	patients	patient	NOUN
dpc-4151	83	24	,	,	PUNCT
dpc-4151	83	25	with	with	ADP
dpc-4151	83	26	improvement	improvement	NOUN
dpc-4151	83	27	in	in	ADP
dpc-4151	83	28	mucocutaneous	mucocutaneous	ADJ
dpc-4151	83	29	lesions	lesion	NOUN
dpc-4151	83	30	as	as	ADV
dpc-4151	83	31	early	early	ADV
dpc-4151	83	32	as	as	ADP
dpc-4151	83	33	the	the	DET
dpc-4151	83	34	first	first	ADJ
dpc-4151	83	35	month	month	NOUN
dpc-4151	83	36	of	of	ADP
dpc-4151	83	37	treatment	treatment	NOUN
dpc-4151	83	38	initiation	initiation	NOUN
dpc-4151	83	39	.	.	PUNCT
dpc-4151	84	1	our	our	PRON
dpc-4151	84	2	patients	patient	NOUN
dpc-4151	84	3	achieved	achieve	VERB
dpc-4151	84	4	control	control	NOUN
dpc-4151	84	5	in	in	ADP
dpc-4151	84	6	pruritus	pruritus	PROPN
dpc-4151	84	7	within	within	ADP
dpc-4151	84	8	a	a	DET
dpc-4151	84	9	mean	mean	ADJ
dpc-4151	84	10	duration	duration	NOUN
dpc-4151	84	11	of	of	ADP
dpc-4151	84	12	7.96	7.96	NUM
dpc-4151	84	13	weeks	week	NOUN
dpc-4151	84	14	,	,	PUNCT
dpc-4151	84	15	cessation	cessation	NOUN
dpc-4151	84	16	of	of	ADP
dpc-4151	84	17	new	new	ADJ
dpc-4151	84	18	lesions	lesion	NOUN
dpc-4151	84	19	within	within	ADP
dpc-4151	84	20	4.45	4.45	NUM
dpc-4151	84	21	weeks	week	NOUN
dpc-4151	84	22	,	,	PUNCT
dpc-4151	84	23	and	and	CCONJ
dpc-4151	84	24	complete	complete	ADJ
dpc-4151	84	25	resolution	resolution	NOUN
dpc-4151	84	26	of	of	ADP
dpc-4151	84	27	lesion	lesion	NOUN
dpc-4151	84	28	within	within	ADP
dpc-4151	84	29	14.76	14.76	NUM
dpc-4151	84	30	weeks	week	NOUN
dpc-4151	84	31	(	(	PUNCT
dpc-4151	84	32	in	in	ADP
dpc-4151	84	33	93	93	NUM
dpc-4151	84	34	%	%	NOUN
dpc-4151	84	35	patients	patient	NOUN
dpc-4151	84	36	)	)	PUNCT
dpc-4151	84	37	(	(	PUNCT
dpc-4151	84	38	table	table	NOUN
dpc-4151	84	39	2	2	NUM
dpc-4151	84	40	)	)	PUNCT
dpc-4151	84	41	.	.	PUNCT
dpc-4151	85	1	post	post	ADJ
dpc-4151	85	2	-	-	ADJ
dpc-4151	85	3	discontinuation	discontinuation	NOUN
dpc-4151	85	4	recurrences	recurrence	NOUN
dpc-4151	85	5	were	be	AUX
dpc-4151	85	6	,	,	PUNCT
dpc-4151	85	7	however	however	ADV
dpc-4151	85	8	,	,	PUNCT
dpc-4151	85	9	noted	note	VERB
dpc-4151	85	10	in	in	ADP
dpc-4151	85	11	43.3	43.3	NUM
dpc-4151	85	12	%	%	NOUN
dpc-4151	85	13	patients	patient	NOUN
dpc-4151	85	14	after	after	ADP
dpc-4151	85	15	a	a	DET
dpc-4151	85	16	mean	mean	ADJ
dpc-4151	85	17	duration	duration	NOUN
dpc-4151	85	18	of	of	ADP
dpc-4151	85	19	17	17	NUM
dpc-4151	85	20	months	month	NOUN
dpc-4151	85	21	.	.	PUNCT
dpc-4151	86	1	relapses	relapse	VERB
dpc-4151	86	2	post	post	ADJ
dpc-4151	86	3	-	-	ADJ
dpc-4151	86	4	cure	cure	ADJ
dpc-4151	86	5	is	be	AUX
dpc-4151	86	6	an	an	DET
dpc-4151	86	7	important	important	ADJ
dpc-4151	86	8	concern	concern	NOUN
dpc-4151	86	9	in	in	ADP
dpc-4151	86	10	clinical	clinical	ADJ
dpc-4151	86	11	practice	practice	NOUN
dpc-4151	86	12	;	;	PUNCT
dpc-4151	86	13	however	however	ADV
dpc-4151	86	14	,	,	PUNCT
dpc-4151	86	15	there	there	PRON
dpc-4151	86	16	is	be	VERB
dpc-4151	86	17	only	only	ADV
dpc-4151	86	18	limited	limited	ADJ
dpc-4151	86	19	literature	literature	NOUN
dpc-4151	86	20	documenting	document	VERB
dpc-4151	86	21	the	the	DET
dpc-4151	86	22	same	same	ADJ
dpc-4151	86	23	.	.	PUNCT
dpc-4151	87	1	kanwar	kanwar	PROPN
dpc-4151	87	2	et	et	PROPN
dpc-4151	87	3	al	al	PROPN
dpc-4151	87	4	.	.	PUNCT
dpc-4151	88	1	[	[	X
dpc-4151	88	2	17	17	NUM
dpc-4151	88	3	]	]	PUNCT
dpc-4151	88	4	and	and	CCONJ
dpc-4151	88	5	turan	turan	VERB
dpc-4151	88	6	et	et	PROPN
dpc-4151	88	7	al	al	PROPN
dpc-4151	88	8	.	.	PUNCT
dpc-4151	89	1	[	[	X
dpc-4151	89	2	18	18	NUM
dpc-4151	89	3	]	]	PUNCT
dpc-4151	89	4	reported	report	VERB
dpc-4151	89	5	relapses	relapse	NOUN
dpc-4151	89	6	in	in	ADP
dpc-4151	89	7	none	none	NOUN
dpc-4151	89	8	[	[	X
dpc-4151	89	9	17	17	NUM
dpc-4151	89	10	]	]	PUNCT
dpc-4151	89	11	and	and	CCONJ
dpc-4151	89	12	one	one	NUM
dpc-4151	89	13	[	[	X
dpc-4151	89	14	18	18	NUM
dpc-4151	89	15	]	]	X
dpc-4151	89	16	patient	patient	NOUN
dpc-4151	89	17	,	,	PUNCT
dpc-4151	89	18	respectively	respectively	ADV
dpc-4151	89	19	,	,	PUNCT
dpc-4151	89	20	after	after	ADP
dpc-4151	89	21	three	three	NUM
dpc-4151	89	22	months	month	NOUN
dpc-4151	89	23	and	and	CCONJ
dpc-4151	89	24	six	six	NUM
dpc-4151	89	25	months	month	NOUN
dpc-4151	89	26	post	post	ADJ
dpc-4151	89	27	-	-	ADJ
dpc-4151	89	28	treatment	treatment	NOUN
dpc-4151	89	29	discontinuation	discontinuation	NOUN
dpc-4151	89	30	.	.	PUNCT
dpc-4151	90	1	these	these	DET
dpc-4151	90	2	follow	follow	VERB
dpc-4151	90	3	-	-	PUNCT
dpc-4151	90	4	up	up	ADP
dpc-4151	90	5	periods	period	NOUN
dpc-4151	90	6	are	be	AUX
dpc-4151	90	7	notably	notably	ADV
dpc-4151	90	8	short	short	ADJ
dpc-4151	90	9	and	and	CCONJ
dpc-4151	90	10	hence	hence	ADV
dpc-4151	90	11	may	may	AUX
dpc-4151	90	12	have	have	AUX
dpc-4151	90	13	led	lead	VERB
dpc-4151	90	14	to	to	ADP
dpc-4151	90	15	estimation	estimation	NOUN
dpc-4151	90	16	of	of	ADP
dpc-4151	90	17	falsely	falsely	ADV
dpc-4151	90	18	low	low	ADJ
dpc-4151	90	19	relapse	relapse	NOUN
dpc-4151	90	20	rates	rate	NOUN
dpc-4151	90	21	.	.	PUNCT
dpc-4151	91	1	notably	notably	ADV
dpc-4151	91	2	,	,	PUNCT
dpc-4151	91	3	mtx	mtx	NOUN
dpc-4151	91	4	has	have	AUX
dpc-4151	91	5	been	be	AUX
dpc-4151	91	6	shown	show	VERB
dpc-4151	91	7	to	to	PART
dpc-4151	91	8	achieve	achieve	VERB
dpc-4151	91	9	a	a	DET
dpc-4151	91	10	comparable	comparable	ADJ
dpc-4151	91	11	response	response	NOUN
dpc-4151	91	12	to	to	ADP
dpc-4151	91	13	oral	oral	ADJ
dpc-4151	91	14	steroids	steroid	NOUN
dpc-4151	91	15	.	.	PUNCT
dpc-4151	92	1	hazra	hazra	VERB
dpc-4151	92	2	et	et	PROPN
dpc-4151	92	3	al	al	PROPN
dpc-4151	92	4	.	.	PUNCT
dpc-4151	93	1	[	[	X
dpc-4151	93	2	3	3	NUM
dpc-4151	93	3	]	]	PUNCT
dpc-4151	93	4	compared	compare	VERB
dpc-4151	93	5	12	12	NUM
dpc-4151	93	6	 	 	SPACE
dpc-4151	93	7	weeks	week	NOUN
dpc-4151	93	8	of	of	ADP
dpc-4151	93	9	oral	oral	ADJ
dpc-4151	93	10	mini	mini	NOUN
dpc-4151	93	11	-	-	NOUN
dpc-4151	93	12	pulse	pulse	ADJ
dpc-4151	93	13	(	(	PUNCT
dpc-4151	93	14	oral	oral	ADJ
dpc-4151	93	15	betamethasone	betamethasone	NOUN
dpc-4151	93	16	5	5	NUM
dpc-4151	93	17	mg	mg	ADV
dpc-4151	93	18	twice	twice	DET
dpc-4151	93	19	a	a	DET
dpc-4151	93	20	week	week	NOUN
dpc-4151	93	21	)	)	PUNCT
dpc-4151	93	22	with	with	ADP
dpc-4151	93	23	mtx	mtx	NOUN
dpc-4151	93	24	10	10	NUM
dpc-4151	93	25	mg	mg	NOUN
dpc-4151	93	26	weekly	weekly	NOUN
dpc-4151	93	27	in	in	ADP
dpc-4151	93	28	44	44	NUM
dpc-4151	93	29	patients	patient	NOUN
dpc-4151	93	30	and	and	CCONJ
dpc-4151	93	31	found	find	VERB
dpc-4151	93	32	and	and	CCONJ
dpc-4151	93	33	interleukin-17	interleukin-17	PROPN
dpc-4151	93	34	(	(	PUNCT
dpc-4151	93	35	il-17	il-17	NUM
dpc-4151	93	36	)	)	PUNCT
dpc-4151	93	37	while	while	SCONJ
dpc-4151	93	38	the	the	DET
dpc-4151	93	39	key	key	ADJ
dpc-4151	93	40	effector	effector	NOUN
dpc-4151	93	41	cells	cell	NOUN
dpc-4151	93	42	cd8	cd8	PROPN
dpc-4151	93	43	+	+	PROPN
dpc-4151	93	44	lymphocytes	lymphocyte	VERB
dpc-4151	93	45	(	(	PUNCT
dpc-4151	93	46	tc1	tc1	NOUN
dpc-4151	93	47	and	and	CCONJ
dpc-4151	93	48	tc17	tc17	PROPN
dpc-4151	93	49	lines	line	NOUN
dpc-4151	93	50	)	)	PUNCT
dpc-4151	93	51	mediate	mediate	VERB
dpc-4151	93	52	epidermal	epidermal	ADJ
dpc-4151	93	53	injury	injury	NOUN
dpc-4151	93	54	primarily	primarily	ADV
dpc-4151	93	55	by	by	ADP
dpc-4151	93	56	engaging	engage	VERB
dpc-4151	93	57	cytotoxic	cytotoxic	ADJ
dpc-4151	93	58	mechanisms	mechanism	NOUN
dpc-4151	93	59	through	through	ADP
dpc-4151	93	60	granule	granule	NOUN
dpc-4151	93	61	exocytosis	exocytosis	NOUN
dpc-4151	93	62	and	and	CCONJ
dpc-4151	93	63	also	also	ADV
dpc-4151	93	64	by	by	ADP
dpc-4151	93	65	the	the	DET
dpc-4151	93	66	fas	fas	PROPN
dpc-4151	93	67	-	-	PUNCT
dpc-4151	93	68	fasl	fasl	NOUN
dpc-4151	93	69	and	and	CCONJ
dpc-4151	93	70	tnf	tnf	PROPN
dpc-4151	93	71	-	-	PUNCT
dpc-4151	93	72	α	α	PROPN
dpc-4151	93	73	-	-	PUNCT
dpc-4151	93	74	tnf	tnf	VERB
dpc-4151	93	75	-	-	PUNCT
dpc-4151	93	76	α	α	NOUN
dpc-4151	93	77	receptors	receptor	NOUN
dpc-4151	93	78	interaction	interaction	NOUN
dpc-4151	93	79	.	.	PUNCT
dpc-4151	94	1	the	the	DET
dpc-4151	94	2	release	release	NOUN
dpc-4151	94	3	of	of	ADP
dpc-4151	94	4	cytotoxic	cytotoxic	ADJ
dpc-4151	94	5	molecules	molecule	NOUN
dpc-4151	94	6	such	such	ADJ
dpc-4151	94	7	as	as	ADP
dpc-4151	94	8	perforin	perforin	NOUN
dpc-4151	94	9	,	,	PUNCT
dpc-4151	94	10	granzyme	granzyme	NOUN
dpc-4151	94	11	b	b	NUM
dpc-4151	94	12	,	,	PUNCT
dpc-4151	94	13	and	and	CCONJ
dpc-4151	94	14	granulysin	granulysin	NOUN
dpc-4151	94	15	causes	cause	VERB
dpc-4151	94	16	keratinocyte	keratinocyte	NOUN
dpc-4151	94	17	apoptosis	apoptosis	NOUN
dpc-4151	94	18	,	,	PUNCT
dpc-4151	94	19	with	with	ADP
dpc-4151	94	20	consequent	consequent	ADJ
dpc-4151	94	21	epidermal	epidermal	ADJ
dpc-4151	94	22	and	and	CCONJ
dpc-4151	94	23	dermal	dermal	ADJ
dpc-4151	94	24	changes	change	NOUN
dpc-4151	94	25	and	and	CCONJ
dpc-4151	94	26	the	the	DET
dpc-4151	94	27	development	development	NOUN
dpc-4151	94	28	of	of	ADP
dpc-4151	94	29	specific	specific	ADJ
dpc-4151	94	30	lp	lp	ADJ
dpc-4151	94	31	lesions	lesion	NOUN
dpc-4151	94	32	.	.	PUNCT
dpc-4151	95	1	other	other	ADJ
dpc-4151	95	2	inflammatory	inflammatory	ADJ
dpc-4151	95	3	cells	cell	NOUN
dpc-4151	95	4	such	such	ADJ
dpc-4151	95	5	as	as	ADP
dpc-4151	95	6	dendritic	dendritic	ADJ
dpc-4151	95	7	cells	cell	NOUN
dpc-4151	95	8	,	,	PUNCT
dpc-4151	95	9	macrophages	macrophage	NOUN
dpc-4151	95	10	,	,	PUNCT
dpc-4151	95	11	and	and	CCONJ
dpc-4151	95	12	natural	natural	ADJ
dpc-4151	95	13	killer	killer	NOUN
dpc-4151	95	14	cells	cell	NOUN
dpc-4151	95	15	also	also	ADV
dpc-4151	95	16	initiate	initiate	VERB
dpc-4151	95	17	and	and	CCONJ
dpc-4151	95	18	maintain	maintain	VERB
dpc-4151	95	19	the	the	DET
dpc-4151	95	20	inflammatory	inflammatory	ADJ
dpc-4151	95	21	process	process	NOUN
dpc-4151	95	22	.	.	PUNCT
dpc-4151	96	1	regulatory	regulatory	ADJ
dpc-4151	96	2	t	t	PROPN
dpc-4151	96	3	(	(	PUNCT
dpc-4151	96	4	treg	treg	PROPN
dpc-4151	96	5	)	)	PUNCT
dpc-4151	96	6	cells	cell	NOUN
dpc-4151	96	7	are	be	AUX
dpc-4151	96	8	defective	defective	ADJ
dpc-4151	96	9	and	and	CCONJ
dpc-4151	96	10	hence	hence	ADV
dpc-4151	96	11	unable	unable	ADJ
dpc-4151	96	12	to	to	PART
dpc-4151	96	13	control	control	VERB
dpc-4151	96	14	the	the	DET
dpc-4151	96	15	inflammatory	inflammatory	ADJ
dpc-4151	96	16	process	process	NOUN
dpc-4151	96	17	,	,	PUNCT
dpc-4151	96	18	while	while	SCONJ
dpc-4151	96	19	tissue	tissue	NOUN
dpc-4151	96	20	-	-	PUNCT
dpc-4151	96	21	resident	resident	NOUN
dpc-4151	96	22	memory	memory	NOUN
dpc-4151	96	23	cells	cell	NOUN
dpc-4151	96	24	(	(	PUNCT
dpc-4151	96	25	trm	trm	NOUN
dpc-4151	96	26	)	)	PUNCT
dpc-4151	96	27	are	be	AUX
dpc-4151	96	28	responsible	responsible	ADJ
dpc-4151	96	29	for	for	ADP
dpc-4151	96	30	reactivations	reactivation	NOUN
dpc-4151	96	31	and	and	CCONJ
dpc-4151	96	32	flares	flare	NOUN
dpc-4151	96	33	[	[	X
dpc-4151	96	34	12	12	NUM
dpc-4151	96	35	]	]	PUNCT
dpc-4151	96	36	.	.	PUNCT
dpc-4151	97	1	mtx	mtx	NOUN
dpc-4151	97	2	is	be	AUX
dpc-4151	97	3	mechanistically	mechanistically	ADV
dpc-4151	97	4	a	a	DET
dpc-4151	97	5	rational	rational	ADJ
dpc-4151	97	6	choice	choice	NOUN
dpc-4151	97	7	for	for	ADP
dpc-4151	97	8	lp	lp	NOUN
dpc-4151	97	9	owing	owe	VERB
dpc-4151	97	10	to	to	ADP
dpc-4151	97	11	its	its	PRON
dpc-4151	97	12	profound	profound	ADJ
dpc-4151	97	13	effects	effect	NOUN
dpc-4151	97	14	on	on	ADP
dpc-4151	97	15	t	t	PROPN
dpc-4151	97	16	lymphocytes	lymphocyte	VERB
dpc-4151	97	17	[	[	X
dpc-4151	97	18	13	13	NUM
dpc-4151	97	19	]	]	PUNCT
dpc-4151	97	20	.	.	PUNCT
dpc-4151	98	1	mtx	mtx	NOUN
dpc-4151	98	2	suppresses	suppress	VERB
dpc-4151	98	3	th1	th1	NOUN
dpc-4151	98	4	cell	cell	NOUN
dpc-4151	98	5	line	line	NOUN
dpc-4151	98	6	,	,	PUNCT
dpc-4151	98	7	with	with	ADP
dpc-4151	98	8	simultaneous	simultaneous	ADJ
dpc-4151	98	9	increase	increase	NOUN
dpc-4151	98	10	in	in	ADP
dpc-4151	98	11	treg	treg	PROPN
dpc-4151	98	12	cell	cell	PROPN
dpc-4151	98	13	differentiation	differentiation	NOUN
dpc-4151	98	14	,	,	PUNCT
dpc-4151	98	15	both	both	DET
dpc-4151	98	16	actions	action	NOUN
dpc-4151	98	17	causing	cause	VERB
dpc-4151	98	18	attenuation	attenuation	NOUN
dpc-4151	98	19	of	of	ADP
dpc-4151	98	20	the	the	DET
dpc-4151	98	21	ongoing	ongoing	ADJ
dpc-4151	98	22	inflammation	inflammation	NOUN
dpc-4151	98	23	[	[	X
dpc-4151	98	24	13	13	NUM
dpc-4151	98	25	-	-	SYM
dpc-4151	98	26	15	15	NUM
dpc-4151	98	27	]	]	PUNCT
dpc-4151	98	28	.	.	PUNCT
dpc-4151	99	1	ifn	ifn	PROPN
dpc-4151	99	2	-	-	PUNCT
dpc-4151	99	3	γ	γ	X
dpc-4151	99	4	induced	induce	VERB
dpc-4151	99	5	chemokine	chemokine	ADJ
dpc-4151	99	6	cxcl10	cxcl10	NOUN
dpc-4151	99	7	is	be	AUX
dpc-4151	99	8	strongly	strongly	ADV
dpc-4151	99	9	expressed	express	VERB
dpc-4151	99	10	in	in	ADP
dpc-4151	99	11	serum	serum	NOUN
dpc-4151	99	12	of	of	ADP
dpc-4151	99	13	patients	patient	NOUN
dpc-4151	99	14	with	with	ADP
dpc-4151	99	15	lp	lp	NOUN
dpc-4151	99	16	as	as	ADV
dpc-4151	99	17	well	well	ADV
dpc-4151	99	18	as	as	ADP
dpc-4151	99	19	in	in	ADP
dpc-4151	99	20	both	both	PRON
dpc-4151	99	21	skin	skin	NOUN
dpc-4151	99	22	and	and	CCONJ
dpc-4151	99	23	mucosal	mucosal	NOUN
dpc-4151	99	24	lesions	lesion	NOUN
dpc-4151	99	25	[	[	X
dpc-4151	99	26	16	16	NUM
dpc-4151	99	27	]	]	PUNCT
dpc-4151	99	28	.	.	PUNCT
dpc-4151	100	1	cxcl10	cxcl10	NOUN
dpc-4151	100	2	is	be	AUX
dpc-4151	100	3	a	a	DET
dpc-4151	100	4	major	major	ADJ
dpc-4151	100	5	mediator	mediator	NOUN
dpc-4151	100	6	of	of	ADP
dpc-4151	100	7	chronic	chronic	ADJ
dpc-4151	100	8	cytotoxic	cytotoxic	ADJ
dpc-4151	100	9	inflammation	inflammation	NOUN
dpc-4151	100	10	which	which	PRON
dpc-4151	100	11	is	be	AUX
dpc-4151	100	12	downregulated	downregulate	VERB
dpc-4151	100	13	by	by	ADP
dpc-4151	100	14	mtx	mtx	NOUN
dpc-4151	100	15	[	[	X
dpc-4151	100	16	16	16	NUM
dpc-4151	100	17	]	]	PUNCT
dpc-4151	100	18	.	.	PUNCT
dpc-4151	101	1	interestingly	interestingly	ADV
dpc-4151	101	2	,	,	PUNCT
dpc-4151	101	3	mtx	mtx	NOUN
dpc-4151	101	4	also	also	ADV
dpc-4151	101	5	has	have	VERB
dpc-4151	101	6	an	an	DET
dpc-4151	101	7	inhibitory	inhibitory	ADJ
dpc-4151	101	8	effect	effect	NOUN
dpc-4151	101	9	on	on	ADP
dpc-4151	101	10	jak	jak	PROPN
dpc-4151	101	11	stat	stat	PROPN
dpc-4151	101	12	pathway	pathway	NOUN
dpc-4151	101	13	,	,	PUNCT
dpc-4151	101	14	which	which	PRON
dpc-4151	101	15	has	have	AUX
dpc-4151	101	16	been	be	AUX
dpc-4151	101	17	shown	show	VERB
dpc-4151	101	18	to	to	PART
dpc-4151	101	19	be	be	AUX
dpc-4151	101	20	relevant	relevant	ADJ
dpc-4151	101	21	to	to	ADP
dpc-4151	101	22	the	the	DET
dpc-4151	101	23	immunopathogenesis	immunopathogenesis	NOUN
dpc-4151	101	24	of	of	ADP
dpc-4151	101	25	lp	lp	NOUN
dpc-4151	101	26	in	in	ADP
dpc-4151	101	27	recent	recent	ADJ
dpc-4151	101	28	reports	report	NOUN
dpc-4151	101	29	[	[	X
dpc-4151	101	30	17	17	NUM
dpc-4151	101	31	]	]	PUNCT
dpc-4151	101	32	.	.	PUNCT
dpc-4151	102	1	we	we	PRON
dpc-4151	102	2	found	find	VERB
dpc-4151	102	3	low	low	ADJ
dpc-4151	102	4	-	-	PUNCT
dpc-4151	102	5	dose	dose	NOUN
dpc-4151	102	6	mtx	mtx	NOUN
dpc-4151	102	7	to	to	PART
dpc-4151	102	8	produce	produce	VERB
dpc-4151	102	9	a	a	DET
dpc-4151	102	10	satisfactory	satisfactory	ADJ
dpc-4151	102	11	response	response	NOUN
dpc-4151	102	12	in	in	ADP
dpc-4151	102	13	most	most	ADJ
dpc-4151	102	14	patients	patient	NOUN
dpc-4151	102	15	,	,	PUNCT
dpc-4151	102	16	with	with	ADP
dpc-4151	102	17	complete	complete	ADJ
dpc-4151	102	18	clearance	clearance	NOUN
dpc-4151	102	19	in	in	ADP
dpc-4151	102	20	93	93	NUM
dpc-4151	102	21	%	%	NOUN
dpc-4151	102	22	table	table	NOUN
dpc-4151	102	23	2	2	NUM
dpc-4151	102	24	.	.	PUNCT
dpc-4151	102	25	therapeutic	therapeutic	ADJ
dpc-4151	102	26	parameters	parameter	NOUN
dpc-4151	102	27	.	.	PUNCT
dpc-4151	103	1	mean	mean	VERB
dpc-4151	103	2	initial	initial	ADJ
dpc-4151	103	3	dose	dose	NOUN
dpc-4151	103	4	of	of	ADP
dpc-4151	103	5	methotrexate	methotrexate	NOUN
dpc-4151	103	6	(	(	PUNCT
dpc-4151	103	7	mg	mg	PROPN
dpc-4151	103	8	)	)	PUNCT
dpc-4151	103	9	9.46	9.46	NUM
dpc-4151	103	10	(	(	PUNCT
dpc-4151	103	11	5	5	NUM
dpc-4151	103	12	-	-	SYM
dpc-4151	103	13	10	10	NUM
dpc-4151	103	14	)	)	PUNCT
dpc-4151	103	15	mean	mean	VERB
dpc-4151	103	16	highest	high	ADJ
dpc-4151	103	17	dose	dose	NOUN
dpc-4151	103	18	of	of	ADP
dpc-4151	103	19	methotrexate	methotrexate	NOUN
dpc-4151	103	20	(	(	PUNCT
dpc-4151	103	21	mg	mg	PROPN
dpc-4151	103	22	)	)	PUNCT
dpc-4151	103	23	11.64	11.64	NUM
dpc-4151	103	24	(	(	PUNCT
dpc-4151	103	25	10	10	NUM
dpc-4151	103	26	-	-	SYM
dpc-4151	103	27	15	15	NUM
dpc-4151	103	28	)	)	PUNCT
dpc-4151	103	29	*	*	NOUN
dpc-4151	103	30	duration	duration	NOUN
dpc-4151	103	31	of	of	ADP
dpc-4151	103	32	treatment	treatment	NOUN
dpc-4151	103	33	(	(	PUNCT
dpc-4151	103	34	weeks	week	NOUN
dpc-4151	103	35	)	)	PUNCT
dpc-4151	103	36	to	to	PART
dpc-4151	103	37	achieve	achieve	VERB
dpc-4151	103	38	pruritus	pruritus	NOUN
dpc-4151	103	39	score	score	NOUN
dpc-4151	103	40	0	0	NUM
dpc-4151	103	41	7.96	7.96	NUM
dpc-4151	103	42	(	(	PUNCT
dpc-4151	103	43	2	2	NUM
dpc-4151	103	44	-	-	SYM
dpc-4151	103	45	32	32	NUM
dpc-4151	103	46	)	)	PUNCT
dpc-4151	103	47	to	to	PART
dpc-4151	103	48	achieve	achieve	VERB
dpc-4151	103	49	cessation	cessation	NOUN
dpc-4151	103	50	of	of	ADP
dpc-4151	103	51	appearance	appearance	NOUN
dpc-4151	103	52	of	of	ADP
dpc-4151	103	53	new	new	ADJ
dpc-4151	103	54	lesions	lesion	NOUN
dpc-4151	103	55	4.45	4.45	NUM
dpc-4151	103	56	(	(	PUNCT
dpc-4151	103	57	2	2	NUM
dpc-4151	103	58	-	-	SYM
dpc-4151	103	59	18	18	NUM
dpc-4151	103	60	)	)	PUNCT
dpc-4151	103	61	to	to	PART
dpc-4151	103	62	achieve	achieve	VERB
dpc-4151	103	63	50	50	NUM
dpc-4151	103	64	%	%	NOUN
dpc-4151	103	65	improvement	improvement	NOUN
dpc-4151	103	66	in	in	ADP
dpc-4151	103	67	disease	disease	NOUN
dpc-4151	103	68	5.43	5.43	NUM
dpc-4151	103	69	(	(	PUNCT
dpc-4151	103	70	2	2	NUM
dpc-4151	103	71	-	-	SYM
dpc-4151	103	72	12	12	NUM
dpc-4151	103	73	)	)	PUNCT
dpc-4151	103	74	to	to	PART
dpc-4151	103	75	achieve	achieve	VERB
dpc-4151	103	76	grade	grade	NOUN
dpc-4151	103	77	4	4	NUM
dpc-4151	103	78	flattening	flattening	NOUN
dpc-4151	103	79	of	of	ADP
dpc-4151	103	80	lesions	lesion	NOUN
dpc-4151	103	81	#	#	NOUN
dpc-4151	103	82	9.5	9.5	NUM
dpc-4151	103	83	(	(	PUNCT
dpc-4151	103	84	2	2	NUM
dpc-4151	103	85	-	-	SYM
dpc-4151	103	86	24	24	NUM
dpc-4151	103	87	)	)	PUNCT
dpc-4151	103	88	*	*	PUNCT
dpc-4151	103	89	*	*	PUNCT
dpc-4151	103	90	to	to	PART
dpc-4151	103	91	achieve	achieve	VERB
dpc-4151	103	92	complete	complete	ADJ
dpc-4151	103	93	resolution	resolution	NOUN
dpc-4151	103	94	(	(	PUNCT
dpc-4151	103	95	n=	n=	ADJ
dpc-4151	103	96	29/32	29/32	NUM
dpc-4151	103	97	)	)	PUNCT
dpc-4151	103	98	14.76	14.76	NUM
dpc-4151	103	99	(	(	PUNCT
dpc-4151	103	100	4	4	NUM
dpc-4151	103	101	-	-	SYM
dpc-4151	103	102	32	32	NUM
dpc-4151	103	103	)	)	PUNCT
dpc-4151	103	104	cumulative	cumulative	ADJ
dpc-4151	103	105	dose	dose	NOUN
dpc-4151	103	106	of	of	ADP
dpc-4151	103	107	methotrexate	methotrexate	NOUN
dpc-4151	103	108	(	(	PUNCT
dpc-4151	103	109	mg	mg	PROPN
dpc-4151	103	110	)	)	PUNCT
dpc-4151	103	111	153.58	153.58	NUM
dpc-4151	103	112	(	(	PUNCT
dpc-4151	103	113	50	50	NUM
dpc-4151	103	114	-	-	PUNCT
dpc-4151	103	115	375	375	NUM
dpc-4151	103	116	)	)	PUNCT
dpc-4151	103	117	side	side	NOUN
dpc-4151	103	118	effects	effect	NOUN
dpc-4151	103	119	12/32	12/32	NUM
dpc-4151	103	120	(	(	PUNCT
dpc-4151	103	121	37.5	37.5	NUM
dpc-4151	103	122	%	%	NOUN
dpc-4151	103	123	)	)	PUNCT
dpc-4151	103	124	transient	transient	ADJ
dpc-4151	103	125	exacerbation	exacerbation	NOUN
dpc-4151	103	126	(	(	PUNCT
dpc-4151	103	127	while	while	SCONJ
dpc-4151	103	128	on	on	ADP
dpc-4151	103	129	treatment	treatment	NOUN
dpc-4151	103	130	)	)	PUNCT
dpc-4151	103	131	3	3	NUM
dpc-4151	103	132	(	(	PUNCT
dpc-4151	103	133	9.37	9.37	NUM
dpc-4151	103	134	%	%	NOUN
dpc-4151	103	135	)	)	PUNCT
dpc-4151	103	136	relapse	relapse	NOUN
dpc-4151	103	137	13	13	NUM
dpc-4151	103	138	(	(	PUNCT
dpc-4151	103	139	40.6	40.6	NUM
dpc-4151	103	140	%	%	NOUN
dpc-4151	103	141	)	)	PUNCT
dpc-4151	103	142	mean	mean	VERB
dpc-4151	103	143	time	time	NOUN
dpc-4151	103	144	to	to	PART
dpc-4151	103	145	relapse	relapse	VERB
dpc-4151	103	146	post	post	ADJ
dpc-4151	103	147	-	-	NOUN
dpc-4151	103	148	treatment	treatment	ADJ
dpc-4151	103	149	(	(	PUNCT
dpc-4151	103	150	months	month	NOUN
dpc-4151	103	151	)	)	PUNCT
dpc-4151	103	152	17.33	17.33	NUM
dpc-4151	103	153	(	(	PUNCT
dpc-4151	103	154	5	5	NUM
dpc-4151	103	155	-	-	SYM
dpc-4151	103	156	36	36	NUM
dpc-4151	103	157	)	)	PUNCT
dpc-4151	103	158	mean	mean	VERB
dpc-4151	103	159	duration	duration	NOUN
dpc-4151	103	160	of	of	ADP
dpc-4151	103	161	remission	remission	NOUN
dpc-4151	103	162	(	(	PUNCT
dpc-4151	103	163	months	month	NOUN
dpc-4151	103	164	)	)	PUNCT
dpc-4151	103	165	29.43	29.43	NUM
dpc-4151	103	166	(	(	PUNCT
dpc-4151	103	167	5	5	NUM
dpc-4151	103	168	-	-	SYM
dpc-4151	103	169	60	60	NUM
dpc-4151	103	170	)	)	PUNCT
dpc-4151	103	171	physician	physician	NOUN
dpc-4151	103	172	global	global	ADJ
dpc-4151	103	173	assessment	assessment	NOUN
dpc-4151	103	174	(	(	PUNCT
dpc-4151	103	175	16	16	NUM
dpc-4151	103	176	weeks	week	NOUN
dpc-4151	103	177	)	)	PUNCT
dpc-4151	103	178	poor	poor	ADJ
dpc-4151	103	179	2	2	NUM
dpc-4151	103	180	(	(	PUNCT
dpc-4151	103	181	4.76	4.76	NUM
dpc-4151	103	182	%	%	NOUN
dpc-4151	103	183	)	)	PUNCT
dpc-4151	103	184	average	average	ADJ
dpc-4151	103	185	4	4	NUM
dpc-4151	103	186	(	(	PUNCT
dpc-4151	103	187	9.52	9.52	NUM
dpc-4151	103	188	%	%	NOUN
dpc-4151	103	189	)	)	PUNCT
dpc-4151	103	190	good	good	ADJ
dpc-4151	103	191	10	10	NUM
dpc-4151	103	192	(	(	PUNCT
dpc-4151	103	193	23.8	23.8	NUM
dpc-4151	103	194	%	%	NOUN
dpc-4151	103	195	)	)	PUNCT
dpc-4151	104	1	excellent	excellent	ADJ
dpc-4151	104	2	16	16	NUM
dpc-4151	104	3	(	(	PUNCT
dpc-4151	104	4	38	38	NUM
dpc-4151	104	5	%	%	NOUN
dpc-4151	104	6	)	)	PUNCT
dpc-4151	105	1	*	*	PUNCT
dpc-4151	105	2	10	10	NUM
dpc-4151	105	3	patients	patient	NOUN
dpc-4151	105	4	lost	lose	VERB
dpc-4151	105	5	to	to	PART
dpc-4151	105	6	follow	follow	VERB
dpc-4151	105	7	-	-	PUNCT
dpc-4151	105	8	up	up	NOUN
dpc-4151	105	9	.	.	PUNCT
dpc-4151	106	1	#	#	SYM
dpc-4151	106	2	grading	grade	VERB
dpc-4151	106	3	of	of	ADP
dpc-4151	106	4	flattening	flattening	NOUN
dpc-4151	106	5	of	of	ADP
dpc-4151	106	6	lesions	lesion	NOUN
dpc-4151	106	7	(	(	PUNCT
dpc-4151	106	8	grade	grade	NOUN
dpc-4151	106	9	120	120	NUM
dpc-4151	106	10	%	%	NOUN
dpc-4151	106	11	;	;	PUNCT
dpc-4151	106	12	220	220	NUM
dpc-4151	106	13	-	-	SYM
dpc-4151	106	14	50	50	NUM
dpc-4151	106	15	%	%	NOUN
dpc-4151	106	16	;	;	PUNCT
dpc-4151	106	17	3	3	NUM
dpc-4151	106	18	-	-	SYM
dpc-4151	106	19	50	50	NUM
dpc-4151	106	20	-	-	SYM
dpc-4151	106	21	90	90	NUM
dpc-4151	106	22	%	%	NOUN
dpc-4151	106	23	,	,	PUNCT
dpc-4151	106	24	4->90	4->90	ADJ
dpc-4151	106	25	%	%	NOUN
dpc-4151	106	26	)	)	PUNCT
dpc-4151	106	27	.	.	PUNCT
dpc-4151	107	1	*	*	PUNCT
dpc-4151	107	2	*	*	SYM
dpc-4151	107	3	2	2	NUM
dpc-4151	107	4	patients	patient	NOUN
dpc-4151	107	5	failed	fail	VERB
dpc-4151	107	6	methotrexate	methotrexate	INTJ
dpc-4151	107	7	(	(	PUNCT
dpc-4151	107	8	did	do	AUX
dpc-4151	107	9	not	not	PART
dpc-4151	107	10	achieve	achieve	VERB
dpc-4151	107	11	complete	complete	ADJ
dpc-4151	107	12	flattening	flattening	NOUN
dpc-4151	107	13	of	of	ADP
dpc-4151	107	14	lesions	lesion	NOUN
dpc-4151	107	15	and	and	CCONJ
dpc-4151	107	16	developed	develop	VERB
dpc-4151	107	17	new	new	ADJ
dpc-4151	107	18	lesions	lesion	NOUN
dpc-4151	107	19	while	while	SCONJ
dpc-4151	107	20	on	on	ADP
dpc-4151	107	21	treatment	treatment	NOUN
dpc-4151	107	22	)	)	PUNCT
dpc-4151	107	23	.	.	PUNCT
dpc-4151	108	1	original	original	ADJ
dpc-4151	108	2	article	article	NOUN
dpc-4151	108	3	|	|	ADV
dpc-4151	108	4	dermatol	dermatol	ADJ
dpc-4151	108	5	pract	pract	NOUN
dpc-4151	108	6	concept	concept	NOUN
dpc-4151	108	7	.	.	PUNCT
dpc-4151	109	1	2024;14(4):e2024220	2024;14(4):e2024220	NUM
dpc-4151	109	2	5	5	NUM
dpc-4151	109	3	5	5	NUM
dpc-4151	109	4	.	.	PUNCT
dpc-4151	110	1	sardana	sardana	PROPN
dpc-4151	110	2	k	k	PROPN
dpc-4151	110	3	,	,	PUNCT
dpc-4151	110	4	gupta	gupta	PROPN
dpc-4151	110	5	a.	a.	NOUN
dpc-4151	110	6	a	a	DET
dpc-4151	110	7	recalcitrant	recalcitrant	ADJ
dpc-4151	110	8	case	case	NOUN
dpc-4151	110	9	of	of	ADP
dpc-4151	110	10	ulcerative	ulcerative	ADJ
dpc-4151	110	11	lichen	lichen	NOUN
dpc-4151	110	12	planus	planus	NOUN
dpc-4151	110	13	responsive	responsive	ADJ
dpc-4151	110	14	to	to	PART
dpc-4151	110	15	leflunomide	leflunomide	VERB
dpc-4151	110	16	.	.	PUNCT
dpc-4151	111	1	clin	clin	PROPN
dpc-4151	111	2	exp	exp	NOUN
dpc-4151	111	3	dermatol	dermatol	NOUN
dpc-4151	111	4	.	.	PUNCT
dpc-4151	112	1	2020;45(3	2020;45(3	NUM
dpc-4151	112	2	):	):	PUNCT
dpc-4151	112	3	340	340	NUM
dpc-4151	112	4	-	-	SYM
dpc-4151	112	5	41	41	NUM
dpc-4151	112	6	.	.	PUNCT
dpc-4151	113	1	doi:10.1111	doi:10.1111	ADJ
dpc-4151	113	2	/	/	SYM
dpc-4151	113	3	ced.14069	ced.14069	PROPN
dpc-4151	113	4	.	.	NOUN
dpc-4151	113	5	6	6	NUM
dpc-4151	113	6	.	.	X
dpc-4151	113	7	abduelmula	abduelmula	PROPN
dpc-4151	114	1	a	a	PRON
dpc-4151	114	2	,	,	PUNCT
dpc-4151	114	3	bagit	bagit	ADV
dpc-4151	114	4	a	a	X
dpc-4151	114	5	,	,	PUNCT
dpc-4151	114	6	mufti	mufti	PROPN
dpc-4151	114	7	a	a	PROPN
dpc-4151	114	8	,	,	PUNCT
dpc-4151	114	9	et	et	PROPN
dpc-4151	114	10	al	al	PROPN
dpc-4151	114	11	.	.	PUNCT
dpc-4151	115	1	the	the	DET
dpc-4151	115	2	use	use	NOUN
dpc-4151	115	3	of	of	ADP
dpc-4151	115	4	janus	janus	PROPN
dpc-4151	115	5	kinase	kinase	PROPN
dpc-4151	115	6	inhibitors	inhibitor	NOUN
dpc-4151	115	7	for	for	ADP
dpc-4151	115	8	lichen	lichen	NOUN
dpc-4151	115	9	planus	planus	NOUN
dpc-4151	115	10	:	:	PUNCT
dpc-4151	115	11	an	an	DET
dpc-4151	115	12	evidence	evidence	NOUN
dpc-4151	115	13	-	-	PUNCT
dpc-4151	115	14	based	base	VERB
dpc-4151	115	15	review	review	NOUN
dpc-4151	115	16	.	.	PUNCT
dpc-4151	116	1	j	j	PROPN
dpc-4151	116	2	cutan	cutan	PROPN
dpc-4151	116	3	med	med	ADJ
dpc-4151	116	4	surg	surg	NOUN
dpc-4151	116	5	.	.	PUNCT
dpc-4151	117	1	2023;27(3):271	2023;27(3):271	NUM
dpc-4151	117	2	-	-	SYM
dpc-4151	117	3	76	76	NUM
dpc-4151	117	4	.	.	PUNCT
dpc-4151	118	1	doi	doi	NOUN
dpc-4151	118	2	:	:	PUNCT
dpc-4151	118	3	10.1177/12034	10.1177/12034	NUM
dpc-4151	118	4	754231156100	754231156100	NUM
dpc-4151	118	5	.	.	PUNCT
dpc-4151	119	1	7	7	X
dpc-4151	119	2	.	.	X
dpc-4151	119	3	atzmony	atzmony	PROPN
dpc-4151	119	4	l	l	PROPN
dpc-4151	119	5	,	,	PUNCT
dpc-4151	119	6	reiter	reiter	PROPN
dpc-4151	119	7	o	o	PROPN
dpc-4151	119	8	,	,	PUNCT
dpc-4151	119	9	hodak	hodak	PROPN
dpc-4151	119	10	e	e	NOUN
dpc-4151	119	11	,	,	PUNCT
dpc-4151	119	12	et	et	PROPN
dpc-4151	119	13	al	al	PROPN
dpc-4151	119	14	.	.	PROPN
dpc-4151	120	1	treatments	treatment	NOUN
dpc-4151	120	2	for	for	ADP
dpc-4151	120	3	cutaneous	cutaneous	ADJ
dpc-4151	120	4	lichen	lichen	NOUN
dpc-4151	120	5	planus	planus	NOUN
dpc-4151	120	6	:	:	PUNCT
dpc-4151	120	7	a	a	DET
dpc-4151	120	8	systematic	systematic	ADJ
dpc-4151	120	9	review	review	NOUN
dpc-4151	120	10	and	and	CCONJ
dpc-4151	120	11	meta	meta	ADJ
dpc-4151	120	12	-	-	PUNCT
dpc-4151	120	13	analysis	analysis	NOUN
dpc-4151	120	14	.	.	PUNCT
dpc-4151	121	1	am	be	AUX
dpc-4151	121	2	j	j	PROPN
dpc-4151	121	3	clin	clin	PROPN
dpc-4151	121	4	dermatol	dermatol	NOUN
dpc-4151	121	5	.	.	PUNCT
dpc-4151	122	1	2016;17(1):11	2016;17(1):11	NUM
dpc-4151	122	2	-	-	SYM
dpc-4151	122	3	22	22	NUM
dpc-4151	122	4	.	.	PUNCT
dpc-4151	123	1	doi:10.1007	doi:10.1007	VERB
dpc-4151	123	2	/	/	SYM
dpc-4151	123	3	s40257	s40257	PROPN
dpc-4151	123	4	-	-	PUNCT
dpc-4151	123	5	015	015	NUM
dpc-4151	123	6	-0160	-0160	PROPN
dpc-4151	123	7	-	-	PUNCT
dpc-4151	123	8	6	6	NUM
dpc-4151	123	9	.	.	NOUN
dpc-4151	123	10	8	8	NUM
dpc-4151	123	11	.	.	X
dpc-4151	124	1	jeffes	jeffes	PROPN
dpc-4151	124	2	ew	ew	PROPN
dpc-4151	124	3	,	,	PUNCT
dpc-4151	124	4	mccullough	mccullough	PROPN
dpc-4151	124	5	jl	jl	PROPN
dpc-4151	124	6	,	,	PUNCT
dpc-4151	124	7	pittelkow	pittelkow	PROPN
dpc-4151	124	8	mr	mr	PROPN
dpc-4151	124	9	,	,	PUNCT
dpc-4151	124	10	et	et	PROPN
dpc-4151	124	11	al	al	PROPN
dpc-4151	124	12	.	.	PROPN
dpc-4151	124	13	methotrexate	methotrexate	PROPN
dpc-4151	124	14	therapy	therapy	NOUN
dpc-4151	124	15	of	of	ADP
dpc-4151	124	16	psoriasis	psoriasis	NOUN
dpc-4151	124	17	:	:	PUNCT
dpc-4151	124	18	differential	differential	ADJ
dpc-4151	124	19	sensitivity	sensitivity	NOUN
dpc-4151	124	20	of	of	ADP
dpc-4151	124	21	proliferating	proliferate	VERB
dpc-4151	124	22	lymphoid	lymphoid	NOUN
dpc-4151	124	23	and	and	CCONJ
dpc-4151	124	24	epithelial	epithelial	ADJ
dpc-4151	124	25	cells	cell	NOUN
dpc-4151	124	26	to	to	ADP
dpc-4151	124	27	cytotoxic	cytotoxic	ADJ
dpc-4151	124	28	and	and	CCONJ
dpc-4151	124	29	growth	growth	VERB
dpc-4151	124	30	inhibitory	inhibitory	ADJ
dpc-4151	124	31	effects	effect	NOUN
dpc-4151	124	32	of	of	ADP
dpc-4151	124	33	methotrexate	methotrexate	NOUN
dpc-4151	124	34	.	.	PUNCT
dpc-4151	125	1	j	j	PROPN
dpc-4151	125	2	invest	invest	VERB
dpc-4151	125	3	dermatol	dermatol	NOUN
dpc-4151	125	4	.	.	PUNCT
dpc-4151	126	1	1995;104(2):183	1995;104(2):183	NUM
dpc-4151	126	2	-	-	SYM
dpc-4151	126	3	8	8	NUM
dpc-4151	126	4	.	.	PUNCT
dpc-4151	126	5	doi:10.1111/1523	doi:10.1111/1523	NOUN
dpc-4151	126	6	-	-	PUNCT
dpc-4151	126	7	1747.ep12612745	1747.ep12612745	ADJ
dpc-4151	126	8	.	.	PUNCT
dpc-4151	127	1	9	9	X
dpc-4151	127	2	.	.	X
dpc-4151	127	3	nylander	nylander	PROPN
dpc-4151	127	4	lundqvist	lundqvist	PROPN
dpc-4151	127	5	e	e	PROPN
dpc-4151	127	6	,	,	PUNCT
dpc-4151	127	7	wahlin	wahlin	PROPN
dpc-4151	127	8	yb	yb	PROPN
dpc-4151	127	9	,	,	PUNCT
dpc-4151	127	10	hofer	hofer	PROPN
dpc-4151	127	11	pa	pa	PROPN
dpc-4151	127	12	.	.	PROPN
dpc-4151	127	13	methotrexate	methotrexate	PROPN
dpc-4151	127	14	supplemented	supplement	VERB
dpc-4151	127	15	with	with	ADP
dpc-4151	127	16	steroid	steroid	NOUN
dpc-4151	127	17	ointments	ointment	NOUN
dpc-4151	127	18	for	for	ADP
dpc-4151	127	19	the	the	DET
dpc-4151	127	20	treatment	treatment	NOUN
dpc-4151	127	21	of	of	ADP
dpc-4151	127	22	severe	severe	ADJ
dpc-4151	127	23	erosive	erosive	NOUN
dpc-4151	127	24	lichen	lichen	NOUN
dpc-4151	127	25	ruber	ruber	PROPN
dpc-4151	127	26	.	.	PUNCT
dpc-4151	128	1	acta	acta	PROPN
dpc-4151	128	2	derm	derm	PROPN
dpc-4151	128	3	venereol	venereol	NOUN
dpc-4151	128	4	.	.	PUNCT
dpc-4151	129	1	2002;82(1):63	2002;82(1):63	NUM
dpc-4151	129	2	-	-	SYM
dpc-4151	129	3	4	4	NUM
dpc-4151	129	4	.	.	PUNCT
dpc-4151	129	5	doi:10.1080/000155502753600966	doi:10.1080/000155502753600966	X
dpc-4151	129	6	.	.	PUNCT
dpc-4151	130	1	10	10	NUM
dpc-4151	130	2	.	.	PUNCT
dpc-4151	131	1	mignogna	mignogna	PROPN
dpc-4151	131	2	md	md	PROPN
dpc-4151	131	3	,	,	PUNCT
dpc-4151	131	4	lo	lo	PROPN
dpc-4151	131	5	russo	russo	PROPN
dpc-4151	131	6	l	l	PROPN
dpc-4151	131	7	,	,	PUNCT
dpc-4151	131	8	fedele	fedele	PROPN
dpc-4151	131	9	s	s	PART
dpc-4151	131	10	,	,	PUNCT
dpc-4151	131	11	et	et	PROPN
dpc-4151	131	12	al	al	PROPN
dpc-4151	131	13	.	.	PUNCT
dpc-4151	132	1	clinical	clinical	ADJ
dpc-4151	132	2	behaviour	behaviour	NOUN
dpc-4151	132	3	of	of	ADP
dpc-4151	132	4	malignant	malignant	ADJ
dpc-4151	132	5	transforming	transform	VERB
dpc-4151	132	6	oral	oral	ADJ
dpc-4151	132	7	lichen	lichen	NOUN
dpc-4151	132	8	planus	planus	NOUN
dpc-4151	132	9	.	.	PUNCT
dpc-4151	133	1	eur	eur	PROPN
dpc-4151	133	2	j	j	PROPN
dpc-4151	133	3	surg	surg	PROPN
dpc-4151	133	4	oncol	oncol	PROPN
dpc-4151	133	5	.	.	PUNCT
dpc-4151	134	1	2002;28(8	2002;28(8	NUM
dpc-4151	134	2	):	):	PUNCT
dpc-4151	134	3	838–43	838–43	PROPN
dpc-4151	134	4	.	.	PUNCT
dpc-4151	135	1	doi:10.1053	doi:10.1053	PROPN
dpc-4151	135	2	/	/	SYM
dpc-4151	135	3	ejso.2002.1302	ejso.2002.1302	PROPN
dpc-4151	135	4	.	.	PUNCT
dpc-4151	136	1	11	11	NUM
dpc-4151	136	2	.	.	PUNCT
dpc-4151	137	1	ioannides	ioannide	NOUN
dpc-4151	137	2	d	d	PROPN
dpc-4151	137	3	,	,	PUNCT
dpc-4151	137	4	vakirlis	vakirlis	ADJ
dpc-4151	137	5	e	e	NOUN
dpc-4151	137	6	,	,	PUNCT
dpc-4151	137	7	kemeny	kemeny	PROPN
dpc-4151	137	8	l	l	PROPN
dpc-4151	137	9	,	,	PUNCT
dpc-4151	137	10	et	et	PROPN
dpc-4151	137	11	al	al	PROPN
dpc-4151	137	12	.	.	PUNCT
dpc-4151	138	1	european	european	PROPN
dpc-4151	138	2	s1	s1	PROPN
dpc-4151	138	3	guidelines	guideline	NOUN
dpc-4151	138	4	on	on	ADP
dpc-4151	138	5	the	the	DET
dpc-4151	138	6	management	management	NOUN
dpc-4151	138	7	of	of	ADP
dpc-4151	138	8	lichen	lichen	NOUN
dpc-4151	138	9	planus	planus	NOUN
dpc-4151	138	10	:	:	PUNCT
dpc-4151	138	11	a	a	DET
dpc-4151	138	12	cooperation	cooperation	NOUN
dpc-4151	138	13	of	of	ADP
dpc-4151	138	14	the	the	DET
dpc-4151	138	15	european	european	ADJ
dpc-4151	138	16	dermatology	dermatology	PROPN
dpc-4151	138	17	forum	forum	PROPN
dpc-4151	138	18	with	with	ADP
dpc-4151	138	19	the	the	DET
dpc-4151	138	20	european	european	PROPN
dpc-4151	138	21	academy	academy	PROPN
dpc-4151	138	22	of	of	ADP
dpc-4151	138	23	dermatology	dermatology	NOUN
dpc-4151	138	24	and	and	CCONJ
dpc-4151	138	25	venereology	venereology	NOUN
dpc-4151	138	26	.	.	PUNCT
dpc-4151	139	1	j	j	PROPN
dpc-4151	139	2	eur	eur	PROPN
dpc-4151	139	3	acad	acad	PROPN
dpc-4151	139	4	dermatol	dermatol	NOUN
dpc-4151	139	5	venereol	venereol	NOUN
dpc-4151	139	6	.	.	PUNCT
dpc-4151	140	1	2020;34(7):1403	2020;34(7):1403	NUM
dpc-4151	140	2	-	-	SYM
dpc-4151	140	3	14	14	NUM
dpc-4151	140	4	.	.	PUNCT
dpc-4151	140	5	 	 	SPACE
dpc-4151	141	1	doi:10.1111	doi:10.1111	PROPN
dpc-4151	141	2	/	/	SYM
dpc-4151	141	3	jdv.16464	jdv.16464	PROPN
dpc-4151	141	4	.	.	PROPN
dpc-4151	142	1	12	12	NUM
dpc-4151	142	2	.	.	PUNCT
dpc-4151	143	1	vičić	vičić	PROPN
dpc-4151	143	2	m	m	PROPN
dpc-4151	143	3	,	,	PUNCT
dpc-4151	143	4	hlača	hlača	PROPN
dpc-4151	143	5	n	n	CCONJ
dpc-4151	143	6	,	,	PUNCT
dpc-4151	143	7	kaštelan	kaštelan	PROPN
dpc-4151	143	8	m	m	PROPN
dpc-4151	143	9	,	,	PUNCT
dpc-4151	143	10	et	et	PROPN
dpc-4151	143	11	al	al	PROPN
dpc-4151	143	12	.	.	PROPN
dpc-4151	143	13	comprehensive	comprehensive	PROPN
dpc-4151	143	14	insight	insight	NOUN
dpc-4151	143	15	into	into	ADP
dpc-4151	143	16	lichen	lichen	NOUN
dpc-4151	143	17	planus	planus	PROPN
dpc-4151	143	18	immunopathogenesis	immunopathogenesis	NOUN
dpc-4151	143	19	.	.	PUNCT
dpc-4151	143	20	  	  	SPACE
dpc-4151	144	1	int	int	PROPN
dpc-4151	144	2	j	j	PROPN
dpc-4151	144	3	mol	mol	ADP
dpc-4151	144	4	sci	sci	PROPN
dpc-4151	144	5	.	.	PROPN
dpc-4151	144	6	2023	2023	NUM
dpc-4151	144	7	;	;	PUNCT
dpc-4151	144	8	24(3):3038	24(3):3038	NUM
dpc-4151	144	9	.	.	PUNCT
dpc-4151	145	1	doi:10.3390	doi:10.3390	PROPN
dpc-4151	145	2	/	/	SYM
dpc-4151	145	3	ijms24033038	ijms24033038	PROPN
dpc-4151	145	4	.	.	PUNCT
dpc-4151	146	1	13	13	NUM
dpc-4151	146	2	.	.	X
dpc-4151	147	1	sardana	sardana	PROPN
dpc-4151	147	2	k.	k.	PROPN
dpc-4151	148	1	immunosupressive	immunosupressive	ADJ
dpc-4151	148	2	drugs	drug	NOUN
dpc-4151	148	3	.	.	PUNCT
dpc-4151	149	1	in	in	ADP
dpc-4151	149	2	:	:	PUNCT
dpc-4151	149	3	sardana	sardana	PROPN
dpc-4151	149	4	k	k	PROPN
dpc-4151	149	5	,	,	PUNCT
dpc-4151	149	6	arora	arora	PROPN
dpc-4151	149	7	p	p	PROPN
dpc-4151	149	8	,	,	PUNCT
dpc-4151	149	9	kandhari	kandhari	PROPN
dpc-4151	149	10	s	s	PROPN
dpc-4151	149	11	,	,	PUNCT
dpc-4151	149	12	mathachan	mathachan	PROPN
dpc-4151	149	13	sr	sr	PROPN
dpc-4151	149	14	,	,	PUNCT
dpc-4151	149	15	agrawal	agrawal	PROPN
dpc-4151	149	16	d	d	PROPN
dpc-4151	149	17	eds	eds	PROPN
dpc-4151	149	18	.	.	PUNCT
dpc-4151	150	1	systemic	systemic	ADJ
dpc-4151	150	2	drugs	drug	NOUN
dpc-4151	150	3	in	in	ADP
dpc-4151	150	4	dermatology	dermatology	NOUN
dpc-4151	150	5	.	.	PUNCT
dpc-4151	151	1	2nd	2nd	ADJ
dpc-4151	151	2	ed	ed	NOUN
dpc-4151	151	3	.	.	PUNCT
dpc-4151	152	1	new	new	ADJ
dpc-4151	152	2	delhi	delhi	PROPN
dpc-4151	152	3	:	:	PUNCT
dpc-4151	152	4	jaypee	jaypee	PROPN
dpc-4151	152	5	brothers	brothers	PROPN
dpc-4151	152	6	medical	medical	ADJ
dpc-4151	152	7	publishers	publisher	NOUN
dpc-4151	152	8	;	;	PUNCT
dpc-4151	152	9	2022.p.548	2022.p.548	X
dpc-4151	152	10	-	-	SYM
dpc-4151	152	11	51	51	NUM
dpc-4151	152	12	.	.	PUNCT
dpc-4151	152	13	14	14	NUM
dpc-4151	152	14	.	.	PUNCT
dpc-4151	153	1	thomas	thomas	PROPN
dpc-4151	153	2	s	s	PROPN
dpc-4151	153	3	,	,	PUNCT
dpc-4151	153	4	fisher	fisher	PROPN
dpc-4151	153	5	kh	kh	PROPN
dpc-4151	153	6	,	,	PUNCT
dpc-4151	153	7	snowden	snowden	PROPN
dpc-4151	153	8	ja	ja	PROPN
dpc-4151	153	9	,	,	PUNCT
dpc-4151	153	10	et	et	PROPN
dpc-4151	153	11	al	al	PROPN
dpc-4151	153	12	.	.	PROPN
dpc-4151	153	13	methotrexate	methotrexate	PROPN
dpc-4151	153	14	is	be	AUX
dpc-4151	153	15	a	a	DET
dpc-4151	153	16	jak	jak	PROPN
dpc-4151	153	17	/	/	SYM
dpc-4151	153	18	stat	stat	PROPN
dpc-4151	153	19	pathway	pathway	NOUN
dpc-4151	153	20	inhibitor	inhibitor	NOUN
dpc-4151	153	21	.	.	PUNCT
dpc-4151	154	1	plos	plos	PROPN
dpc-4151	154	2	one	one	NUM
dpc-4151	154	3	.	.	PUNCT
dpc-4151	155	1	2015;10(7):e0130078	2015;10(7):e0130078	NUM
dpc-4151	155	2	.	.	PUNCT
dpc-4151	156	1	doi	doi	NOUN
dpc-4151	156	2	:	:	PUNCT
dpc-4151	156	3	10.1371	10.1371	NUM
dpc-4151	156	4	/	/	SYM
dpc-4151	156	5	journal.pone.0130078	journal.pone.0130078	PROPN
dpc-4151	156	6	.	.	NOUN
dpc-4151	157	1	15	15	NUM
dpc-4151	157	2	.	.	PUNCT
dpc-4151	158	1	thomas	thomas	PROPN
dpc-4151	158	2	s	s	PROPN
dpc-4151	158	3	,	,	PUNCT
dpc-4151	158	4	fisher	fisher	PROPN
dpc-4151	158	5	k	k	PROPN
dpc-4151	158	6	,	,	PUNCT
dpc-4151	158	7	snowden	snowden	PROPN
dpc-4151	158	8	j	j	PROPN
dpc-4151	158	9	,	,	PUNCT
dpc-4151	158	10	et	et	PROPN
dpc-4151	158	11	al	al	PROPN
dpc-4151	158	12	.	.	PROPN
dpc-4151	158	13	effect	effect	NOUN
dpc-4151	158	14	of	of	ADP
dpc-4151	158	15	methotrexate	methotrexate	NOUN
dpc-4151	158	16	on	on	ADP
dpc-4151	158	17	jak	jak	PROPN
dpc-4151	158	18	/	/	SYM
dpc-4151	158	19	stat	stat	PROPN
dpc-4151	158	20	pathway	pathway	NOUN
dpc-4151	158	21	activation	activation	NOUN
dpc-4151	158	22	in	in	ADP
dpc-4151	158	23	myeloproliferative	myeloproliferative	ADJ
dpc-4151	158	24	neoplasms	neoplasm	NOUN
dpc-4151	158	25	.	.	PUNCT
dpc-4151	159	1	lancet	lancet	PROPN
dpc-4151	159	2	.	.	PUNCT
dpc-4151	160	1	2015;385	2015;385	NUM
dpc-4151	161	1	suppl	suppl	ADJ
dpc-4151	161	2	1	1	NUM
dpc-4151	161	3	:	:	PUNCT
dpc-4151	161	4	s98	s98	NOUN
dpc-4151	161	5	.	.	PUNCT
dpc-4151	162	1	doi	doi	NOUN
dpc-4151	162	2	:	:	PUNCT
dpc-4151	162	3	10.1016	10.1016	NUM
dpc-4151	162	4	/	/	SYM
dpc-4151	162	5	s0140	s0140	PROPN
dpc-4151	162	6	-6736(15)60413	-6736(15)60413	NOUN
dpc-4151	162	7	-	-	PUNCT
dpc-4151	162	8	5	5	NUM
dpc-4151	162	9	.	.	NOUN
dpc-4151	162	10	16	16	NUM
dpc-4151	162	11	.	.	PUNCT
dpc-4151	162	12	di	di	PROPN
dpc-4151	162	13	lernia	lernia	PROPN
dpc-4151	162	14	v.	v.	ADP
dpc-4151	162	15	targeting	target	VERB
dpc-4151	162	16	the	the	DET
dpc-4151	162	17	ifn	ifn	PROPN
dpc-4151	162	18	-	-	PUNCT
dpc-4151	162	19	γ	γ	NOUN
dpc-4151	162	20	/	/	SYM
dpc-4151	162	21	cxcl10	cxcl10	NOUN
dpc-4151	162	22	pathway	pathway	NOUN
dpc-4151	162	23	in	in	ADP
dpc-4151	162	24	lichen	lichen	NOUN
dpc-4151	162	25	planus	planus	NOUN
dpc-4151	162	26	.	.	PUNCT
dpc-4151	163	1	med	med	ADJ
dpc-4151	163	2	hypotheses	hypothesis	NOUN
dpc-4151	163	3	.	.	PUNCT
dpc-4151	164	1	2016;92:60	2016;92:60	NUM
dpc-4151	164	2	-	-	SYM
dpc-4151	164	3	1	1	NUM
dpc-4151	164	4	.	.	PUNCT
dpc-4151	164	5	 	 	SPACE
dpc-4151	164	6	doi	doi	NOUN
dpc-4151	164	7	:	:	PUNCT
dpc-4151	164	8	10.1016	10.1016	NUM
dpc-4151	164	9	/	/	SYM
dpc-4151	164	10	j.mehy.2016	j.mehy.2016	PROPN
dpc-4151	164	11	.04.042	.04.042	PUNCT
dpc-4151	164	12	.	.	PROPN
dpc-4151	165	1	17	17	NUM
dpc-4151	165	2	.	.	PUNCT
dpc-4151	166	1	shao	shao	PROPN
dpc-4151	166	2	s	s	PROPN
dpc-4151	166	3	,	,	PUNCT
dpc-4151	166	4	tsoi	tsoi	PROPN
dpc-4151	166	5	lc	lc	PROPN
dpc-4151	166	6	,	,	PUNCT
dpc-4151	166	7	sarkar	sarkar	PROPN
dpc-4151	166	8	mk	mk	PROPN
dpc-4151	166	9	,	,	PUNCT
dpc-4151	166	10	et	et	PROPN
dpc-4151	166	11	al	al	PROPN
dpc-4151	166	12	.	.	PUNCT
dpc-4151	167	1	ifn	ifn	PROPN
dpc-4151	167	2	-	-	PUNCT
dpc-4151	167	3	γ	γ	PROPN
dpc-4151	167	4	enhances	enhance	NOUN
dpc-4151	167	5	cellmediated	cellmediate	VERB
dpc-4151	167	6	cytotoxicity	cytotoxicity	NOUN
dpc-4151	167	7	against	against	ADP
dpc-4151	167	8	keratinocytes	keratinocyte	NOUN
dpc-4151	167	9	via	via	ADP
dpc-4151	167	10	jak2	jak2	PROPN
dpc-4151	167	11	/	/	SYM
dpc-4151	167	12	stat1	stat1	PROPN
dpc-4151	167	13	in	in	ADP
dpc-4151	167	14	lichen	lichen	NOUN
dpc-4151	167	15	planus	planus	NOUN
dpc-4151	167	16	.	.	PUNCT
dpc-4151	168	1	sci	sci	PROPN
dpc-4151	168	2	transl	transl	PROPN
dpc-4151	168	3	med.2019;11(511):eaav7561	med.2019;11(511):eaav7561	PROPN
dpc-4151	168	4	.	.	PUNCT
dpc-4151	169	1	doi	doi	NOUN
dpc-4151	169	2	:	:	PUNCT
dpc-4151	169	3	10.1126	10.1126	NUM
dpc-4151	169	4	/scitranslmed.aav7561	/scitranslmed.aav7561	SYM
dpc-4151	169	5	.	.	PUNCT
dpc-4151	170	1	18	18	NUM
dpc-4151	170	2	.	.	PUNCT
dpc-4151	170	3	kanwar	kanwar	PROPN
dpc-4151	170	4	aj	aj	PROPN
dpc-4151	170	5	,	,	PUNCT
dpc-4151	170	6	de	de	PROPN
dpc-4151	170	7	d.	d.	PROPN
dpc-4151	170	8	methotrexate	methotrexate	VERB
dpc-4151	170	9	for	for	ADP
dpc-4151	170	10	treatment	treatment	NOUN
dpc-4151	170	11	of	of	ADP
dpc-4151	170	12	lichen	lichen	NOUN
dpc-4151	170	13	planus	planus	NOUN
dpc-4151	170	14	:	:	PUNCT
dpc-4151	170	15	old	old	ADJ
dpc-4151	170	16	drug	drug	NOUN
dpc-4151	170	17	,	,	PUNCT
dpc-4151	170	18	new	new	ADJ
dpc-4151	170	19	indication	indication	NOUN
dpc-4151	170	20	.	.	PUNCT
dpc-4151	171	1	j	j	PROPN
dpc-4151	171	2	eur	eur	PROPN
dpc-4151	171	3	acad	acad	PROPN
dpc-4151	171	4	dermatol	dermatol	NOUN
dpc-4151	171	5	venereol	venereol	NOUN
dpc-4151	171	6	.	.	PUNCT
dpc-4151	172	1	2013;27(3):e410	2013;27(3):e410	NUM
dpc-4151	172	2	-	-	SYM
dpc-4151	172	3	3	3	NUM
dpc-4151	172	4	.	.	PUNCT
dpc-4151	172	5	doi	doi	NOUN
dpc-4151	172	6	:	:	PUNCT
dpc-4151	172	7	10.1111	10.1111	NUM
dpc-4151	172	8	/	/	SYM
dpc-4151	172	9	j.1468	j.1468	NOUN
dpc-4151	172	10	-	-	PUNCT
dpc-4151	172	11	3083.2012.04654.x	3083.2012.04654.x	NUM
dpc-4151	172	12	.	.	PUNCT
dpc-4151	173	1	19	19	NUM
dpc-4151	173	2	.	.	PUNCT
dpc-4151	173	3	turan	turan	PROPN
dpc-4151	173	4	h	h	PROPN
dpc-4151	173	5	,	,	PUNCT
dpc-4151	173	6	baskan	baskan	PROPN
dpc-4151	173	7	eb	eb	PROPN
dpc-4151	173	8	,	,	PUNCT
dpc-4151	173	9	tunali	tunali	VERB
dpc-4151	173	10	s	s	PART
dpc-4151	173	11	,	,	PUNCT
dpc-4151	173	12	et	et	PROPN
dpc-4151	173	13	al	al	PROPN
dpc-4151	173	14	.	.	PROPN
dpc-4151	173	15	methotrexate	methotrexate	VERB
dpc-4151	173	16	for	for	ADP
dpc-4151	173	17	the	the	DET
dpc-4151	173	18	treatment	treatment	NOUN
dpc-4151	173	19	of	of	ADP
dpc-4151	173	20	generalized	generalized	ADJ
dpc-4151	173	21	lichen	lichen	NOUN
dpc-4151	173	22	planus	planus	NOUN
dpc-4151	173	23	.	.	PUNCT
dpc-4151	174	1	j	j	PROPN
dpc-4151	174	2	am	be	AUX
dpc-4151	174	3	acad	acad	ADJ
dpc-4151	174	4	dermatol	dermatol	NOUN
dpc-4151	174	5	.	.	PUNCT
dpc-4151	175	1	2009;60(1):164	2009;60(1):164	NOUN
dpc-4151	175	2	-	-	PUNCT
dpc-4151	175	3	6	6	NUM
dpc-4151	175	4	.	.	PUNCT
dpc-4151	175	5	doi	doi	NOUN
dpc-4151	175	6	:	:	PUNCT
dpc-4151	175	7	10.1016	10.1016	NUM
dpc-4151	175	8	/	/	SYM
dpc-4151	175	9	j.jaad.2008.09.054	j.jaad.2008.09.054	PROPN
dpc-4151	175	10	.	.	PROPN
dpc-4151	176	1	20	20	NUM
dpc-4151	176	2	.	.	PUNCT
dpc-4151	176	3	bakhtiar	bakhtiar	NOUN
dpc-4151	176	4	r	r	NOUN
dpc-4151	176	5	,	,	PUNCT
dpc-4151	176	6	noor	noor	PROPN
dpc-4151	176	7	sm	sm	PROPN
dpc-4151	176	8	,	,	PUNCT
dpc-4151	176	9	paracha	paracha	ADJ
dpc-4151	176	10	mm	mm	PROPN
dpc-4151	176	11	.	.	PUNCT
dpc-4151	176	12	effectiveness	effectiveness	NOUN
dpc-4151	176	13	of	of	ADP
dpc-4151	176	14	oral	oral	ADJ
dpc-4151	176	15	methotrexate	methotrexate	NOUN
dpc-4151	176	16	therapy	therapy	NOUN
dpc-4151	176	17	versus	versus	ADP
dpc-4151	176	18	systemic	systemic	ADJ
dpc-4151	176	19	corticosteroid	corticosteroid	ADJ
dpc-4151	176	20	therapy	therapy	NOUN
dpc-4151	176	21	in	in	ADP
dpc-4151	176	22	treatment	treatment	NOUN
dpc-4151	176	23	of	of	ADP
dpc-4151	176	24	generalised	generalised	ADJ
dpc-4151	176	25	lichen	lichen	NOUN
dpc-4151	176	26	planus	planus	NOUN
dpc-4151	176	27	.	.	PUNCT
dpc-4151	177	1	j	j	PROPN
dpc-4151	177	2	coll	coll	PROPN
dpc-4151	177	3	physicians	physicians	PROPN
dpc-4151	177	4	surg	surg	PROPN
dpc-4151	177	5	pak	pak	PROPN
dpc-4151	177	6	.	.	PUNCT
dpc-4151	178	1	2018;28(7):505	2018;28(7):505	NUM
dpc-4151	178	2	-	-	SYM
dpc-4151	178	3	08	08	NUM
dpc-4151	178	4	.	.	PUNCT
dpc-4151	179	1	doi	doi	NOUN
dpc-4151	179	2	:	:	PUNCT
dpc-4151	179	3	10.29271	10.29271	NUM
dpc-4151	179	4	/	/	SYM
dpc-4151	179	5	jcpsp.2018.07.505	jcpsp.2018.07.505	NOUN
dpc-4151	179	6	.	.	PUNCT
dpc-4151	180	1	no	no	DET
dpc-4151	180	2	significant	significant	ADJ
dpc-4151	180	3	difference	difference	NOUN
dpc-4151	180	4	in	in	ADP
dpc-4151	180	5	response	response	NOUN
dpc-4151	180	6	rates	rate	NOUN
dpc-4151	180	7	between	between	ADP
dpc-4151	180	8	the	the	DET
dpc-4151	180	9	two	two	NUM
dpc-4151	180	10	groups	group	NOUN
dpc-4151	180	11	.	.	PUNCT
dpc-4151	181	1	similarly	similarly	ADV
dpc-4151	181	2	,	,	PUNCT
dpc-4151	181	3	bakhtiar	bakhtiar	NOUN
dpc-4151	181	4	et	et	PROPN
dpc-4151	181	5	al	al	PROPN
dpc-4151	181	6	.	.	PUNCT
dpc-4151	182	1	[	[	X
dpc-4151	182	2	20	20	NUM
dpc-4151	182	3	]	]	PUNCT
dpc-4151	182	4	found	find	VERB
dpc-4151	182	5	an	an	DET
dpc-4151	182	6	insignificant	insignificant	ADJ
dpc-4151	182	7	difference	difference	NOUN
dpc-4151	182	8	in	in	ADP
dpc-4151	182	9	efficacy	efficacy	NOUN
dpc-4151	182	10	of	of	ADP
dpc-4151	182	11	oral	oral	ADJ
dpc-4151	182	12	steroids	steroid	NOUN
dpc-4151	182	13	(	(	PUNCT
dpc-4151	182	14	72	72	NUM
dpc-4151	182	15	%	%	NOUN
dpc-4151	182	16	;	;	PUNCT
dpc-4151	182	17	with	with	ADP
dpc-4151	182	18	40	40	NUM
dpc-4151	182	19	mg	mg	NOUN
dpc-4151	182	20	daily	daily	ADV
dpc-4151	182	21	for	for	ADP
dpc-4151	182	22	eight	eight	NUM
dpc-4151	182	23	weeks	week	NOUN
dpc-4151	182	24	followed	follow	VERB
dpc-4151	182	25	by	by	ADP
dpc-4151	182	26	tapering	taper	VERB
dpc-4151	182	27	)	)	PUNCT
dpc-4151	182	28	and	and	CCONJ
dpc-4151	182	29	mtx	mtx	NOUN
dpc-4151	182	30	(	(	PUNCT
dpc-4151	182	31	80	80	NUM
dpc-4151	182	32	%	%	NOUN
dpc-4151	182	33	;	;	PUNCT
dpc-4151	182	34	with	with	ADP
dpc-4151	182	35	10	10	NUM
dpc-4151	182	36	mg	mg	PROPN
dpc-4151	182	37	weekly	weekly	NOUN
dpc-4151	182	38	for	for	ADP
dpc-4151	182	39	eight	eight	NUM
dpc-4151	182	40	weeks	week	NOUN
dpc-4151	182	41	)	)	PUNCT
dpc-4151	182	42	.	.	PUNCT
dpc-4151	183	1	we	we	PRON
dpc-4151	183	2	observed	observe	VERB
dpc-4151	183	3	only	only	ADJ
dpc-4151	183	4	minor	minor	ADJ
dpc-4151	183	5	side	side	NOUN
dpc-4151	183	6	effects	effect	NOUN
dpc-4151	183	7	in	in	ADP
dpc-4151	183	8	37	37	NUM
dpc-4151	183	9	%	%	NOUN
dpc-4151	183	10	of	of	ADP
dpc-4151	183	11	patients	patient	NOUN
dpc-4151	183	12	,	,	PUNCT
dpc-4151	183	13	and	and	CCONJ
dpc-4151	183	14	the	the	DET
dpc-4151	183	15	drug	drug	NOUN
dpc-4151	183	16	was	be	AUX
dpc-4151	183	17	not	not	PART
dpc-4151	183	18	discontinued	discontinue	VERB
dpc-4151	183	19	due	due	ADJ
dpc-4151	183	20	to	to	ADP
dpc-4151	183	21	adverse	adverse	ADJ
dpc-4151	183	22	events	event	NOUN
dpc-4151	183	23	in	in	ADP
dpc-4151	183	24	any	any	DET
dpc-4151	183	25	patient	patient	NOUN
dpc-4151	183	26	.	.	PUNCT
dpc-4151	184	1	the	the	DET
dpc-4151	184	2	adverse	adverse	ADJ
dpc-4151	184	3	effect	effect	NOUN
dpc-4151	184	4	profile	profile	NOUN
dpc-4151	184	5	of	of	ADP
dpc-4151	184	6	mtx	mtx	NOUN
dpc-4151	184	7	is	be	AUX
dpc-4151	184	8	much	much	ADV
dpc-4151	184	9	more	more	ADV
dpc-4151	184	10	favorable	favorable	ADJ
dpc-4151	184	11	than	than	ADP
dpc-4151	184	12	daily	daily	ADJ
dpc-4151	184	13	or	or	CCONJ
dpc-4151	184	14	even	even	ADV
dpc-4151	184	15	twice	twice	ADV
dpc-4151	184	16	-	-	PUNCT
dpc-4151	184	17	weekly	weekly	ADJ
dpc-4151	184	18	oral	oral	ADJ
dpc-4151	184	19	steroids	steroid	NOUN
dpc-4151	184	20	(	(	PUNCT
dpc-4151	184	21	oral	oral	ADJ
dpc-4151	184	22	mini	mini	NOUN
dpc-4151	184	23	-	-	NOUN
dpc-4151	184	24	pulse	pulse	NOUN
dpc-4151	184	25	)	)	PUNCT
dpc-4151	184	26	,	,	PUNCT
dpc-4151	184	27	as	as	SCONJ
dpc-4151	184	28	is	be	AUX
dpc-4151	184	29	evident	evident	ADJ
dpc-4151	184	30	from	from	ADP
dpc-4151	184	31	existing	exist	VERB
dpc-4151	184	32	literature	literature	NOUN
dpc-4151	184	33	[	[	X
dpc-4151	184	34	3	3	NUM
dpc-4151	184	35	]	]	PUNCT
dpc-4151	184	36	and	and	CCONJ
dpc-4151	184	37	from	from	ADP
dpc-4151	184	38	our	our	PRON
dpc-4151	184	39	results	result	NOUN
dpc-4151	184	40	as	as	ADV
dpc-4151	184	41	well	well	ADV
dpc-4151	184	42	.	.	PUNCT
dpc-4151	185	1	recurrence	recurrence	NOUN
dpc-4151	185	2	remains	remain	VERB
dpc-4151	185	3	an	an	DET
dpc-4151	185	4	important	important	ADJ
dpc-4151	185	5	concern	concern	NOUN
dpc-4151	185	6	with	with	ADP
dpc-4151	185	7	any	any	DET
dpc-4151	185	8	treatment	treatment	NOUN
dpc-4151	185	9	given	give	VERB
dpc-4151	185	10	the	the	DET
dpc-4151	185	11	role	role	NOUN
dpc-4151	185	12	of	of	ADP
dpc-4151	185	13	tissue	tissue	NOUN
dpc-4151	185	14	resident	resident	NOUN
dpc-4151	185	15	memory	memory	NOUN
dpc-4151	185	16	t	t	NOUN
dpc-4151	185	17	cells	cell	NOUN
dpc-4151	185	18	in	in	ADP
dpc-4151	185	19	pathogenesis	pathogenesis	NOUN
dpc-4151	185	20	of	of	ADP
dpc-4151	185	21	lp	lp	NOUN
dpc-4151	186	1	[	[	X
dpc-4151	186	2	20	20	NUM
dpc-4151	186	3	]	]	PUNCT
dpc-4151	186	4	.	.	PUNCT
dpc-4151	187	1	notably	notably	ADV
dpc-4151	187	2	,	,	PUNCT
dpc-4151	187	3	seven	seven	NUM
dpc-4151	187	4	patients	patient	NOUN
dpc-4151	187	5	in	in	ADP
dpc-4151	187	6	our	our	PRON
dpc-4151	187	7	study	study	NOUN
dpc-4151	187	8	had	have	AUX
dpc-4151	187	9	previously	previously	ADV
dpc-4151	187	10	been	be	AUX
dpc-4151	187	11	treated	treat	VERB
dpc-4151	187	12	with	with	ADP
dpc-4151	187	13	oral	oral	ADJ
dpc-4151	187	14	steroids	steroid	NOUN
dpc-4151	187	15	,	,	PUNCT
dpc-4151	187	16	and	and	CCONJ
dpc-4151	187	17	5/7	5/7	NUM
dpc-4151	187	18	patients	patient	NOUN
dpc-4151	187	19	reported	report	VERB
dpc-4151	187	20	prompt	prompt	ADJ
dpc-4151	187	21	relapse	relapse	NOUN
dpc-4151	187	22	on	on	ADP
dpc-4151	187	23	stopping	stop	VERB
dpc-4151	187	24	steroids	steroid	NOUN
dpc-4151	187	25	.	.	PUNCT
dpc-4151	188	1	relapses	relapse	VERB
dpc-4151	188	2	post	post	ADJ
dpc-4151	188	3	-	-	ADJ
dpc-4151	188	4	dose	dose	ADJ
dpc-4151	188	5	lowering	lowering	NOUN
dpc-4151	188	6	/	/	SYM
dpc-4151	188	7	stopping	stopping	NOUN
dpc-4151	188	8	of	of	ADP
dpc-4151	188	9	steroids	steroid	NOUN
dpc-4151	188	10	is	be	AUX
dpc-4151	188	11	a	a	DET
dpc-4151	188	12	well	well	ADV
dpc-4151	188	13	-	-	PUNCT
dpc-4151	188	14	established	establish	VERB
dpc-4151	188	15	clinical	clinical	ADJ
dpc-4151	188	16	phenomenon	phenomenon	NOUN
dpc-4151	188	17	,	,	PUNCT
dpc-4151	188	18	and	and	CCONJ
dpc-4151	188	19	requirement	requirement	NOUN
dpc-4151	188	20	of	of	ADP
dpc-4151	188	21	re	re	NOUN
dpc-4151	188	22	-	-	NOUN
dpc-4151	188	23	treatment	treatment	NOUN
dpc-4151	188	24	exposes	expose	VERB
dpc-4151	188	25	patients	patient	NOUN
dpc-4151	188	26	to	to	PART
dpc-4151	188	27	cumulative	cumulative	VERB
dpc-4151	188	28	adverse	adverse	ADJ
dpc-4151	188	29	effects	effect	NOUN
dpc-4151	188	30	[	[	X
dpc-4151	188	31	19	19	NUM
dpc-4151	188	32	]	]	PUNCT
dpc-4151	188	33	.	.	PUNCT
dpc-4151	189	1	conclusions	conclusion	NOUN
dpc-4151	189	2	and	and	CCONJ
dpc-4151	189	3	limitations	limitation	NOUN
dpc-4151	189	4	we	we	PRON
dpc-4151	189	5	demonstrate	demonstrate	VERB
dpc-4151	189	6	the	the	DET
dpc-4151	189	7	high	high	ADJ
dpc-4151	189	8	efficacy	efficacy	NOUN
dpc-4151	189	9	and	and	CCONJ
dpc-4151	189	10	good	good	ADJ
dpc-4151	189	11	safety	safety	NOUN
dpc-4151	189	12	profile	profile	NOUN
dpc-4151	189	13	of	of	ADP
dpc-4151	189	14	mtx	mtx	NOUN
dpc-4151	189	15	for	for	ADP
dpc-4151	189	16	extensive	extensive	ADJ
dpc-4151	189	17	recalcitrant	recalcitrant	ADJ
dpc-4151	189	18	lp	lp	NOUN
dpc-4151	189	19	,	,	PUNCT
dpc-4151	189	20	although	although	SCONJ
dpc-4151	189	21	the	the	DET
dpc-4151	189	22	retrospective	retrospective	ADJ
dpc-4151	189	23	nature	nature	NOUN
dpc-4151	189	24	of	of	ADP
dpc-4151	189	25	the	the	DET
dpc-4151	189	26	study	study	NOUN
dpc-4151	189	27	and	and	CCONJ
dpc-4151	189	28	a	a	DET
dpc-4151	189	29	significant	significant	ADJ
dpc-4151	189	30	loss	loss	NOUN
dpc-4151	189	31	to	to	PART
dpc-4151	189	32	follow	follow	VERB
dpc-4151	189	33	-	-	PUNCT
dpc-4151	189	34	up	up	NOUN
dpc-4151	189	35	in	in	ADP
dpc-4151	189	36	analyzed	analyze	VERB
dpc-4151	189	37	records	record	NOUN
dpc-4151	189	38	are	be	AUX
dpc-4151	189	39	significant	significant	ADJ
dpc-4151	189	40	limitations	limitation	NOUN
dpc-4151	189	41	.	.	PUNCT
dpc-4151	190	1	reasonably	reasonably	ADV
dpc-4151	190	2	high	high	ADJ
dpc-4151	190	3	efficacy	efficacy	NOUN
dpc-4151	190	4	,	,	PUNCT
dpc-4151	190	5	in	in	ADP
dpc-4151	190	6	addition	addition	NOUN
dpc-4151	190	7	to	to	ADP
dpc-4151	190	8	the	the	DET
dpc-4151	190	9	low	low	ADJ
dpc-4151	190	10	cost	cost	NOUN
dpc-4151	190	11	,	,	PUNCT
dpc-4151	190	12	makes	make	VERB
dpc-4151	190	13	mtx	mtx	NOUN
dpc-4151	190	14	a	a	DET
dpc-4151	190	15	desirable	desirable	ADJ
dpc-4151	190	16	treatment	treatment	NOUN
dpc-4151	190	17	option	option	NOUN
dpc-4151	190	18	for	for	ADP
dpc-4151	190	19	extensive	extensive	ADJ
dpc-4151	190	20	cutaneous	cutaneous	ADJ
dpc-4151	190	21	lp	lp	NOUN
dpc-4151	190	22	.	.	PUNCT
dpc-4151	191	1	however	however	ADV
dpc-4151	191	2	,	,	PUNCT
dpc-4151	191	3	larger	large	ADJ
dpc-4151	191	4	head	head	NOUN
dpc-4151	191	5	-	-	PUNCT
dpc-4151	191	6	to	to	ADP
dpc-4151	191	7	-	-	PUNCT
dpc-4151	191	8	head	head	NOUN
dpc-4151	191	9	trials	trial	NOUN
dpc-4151	191	10	with	with	ADP
dpc-4151	191	11	other	other	ADJ
dpc-4151	191	12	potentially	potentially	ADV
dpc-4151	191	13	effective	effective	ADJ
dpc-4151	191	14	systemic	systemic	ADJ
dpc-4151	191	15	drugs	drug	NOUN
dpc-4151	191	16	in	in	ADP
dpc-4151	191	17	lp	lp	NOUN
dpc-4151	191	18	are	be	AUX
dpc-4151	191	19	urgently	urgently	ADV
dpc-4151	191	20	required	require	VERB
dpc-4151	191	21	to	to	PART
dpc-4151	191	22	firmly	firmly	ADV
dpc-4151	191	23	establish	establish	VERB
dpc-4151	191	24	the	the	DET
dpc-4151	191	25	role	role	NOUN
dpc-4151	191	26	of	of	ADP
dpc-4151	191	27	mtx	mtx	NOUN
dpc-4151	191	28	in	in	ADP
dpc-4151	191	29	management	management	NOUN
dpc-4151	191	30	of	of	ADP
dpc-4151	191	31	extensive	extensive	ADJ
dpc-4151	191	32	lp	lp	NOUN
dpc-4151	191	33	.	.	PUNCT
dpc-4151	192	1	ethics	ethic	NOUN
dpc-4151	192	2	approval	approval	NOUN
dpc-4151	192	3	:	:	PUNCT
dpc-4151	193	1	ethical	ethical	ADJ
dpc-4151	193	2	clearance	clearance	NOUN
dpc-4151	193	3	obtained	obtain	VERB
dpc-4151	193	4	from	from	ADP
dpc-4151	193	5	institutional	institutional	ADJ
dpc-4151	193	6	ethics	ethic	NOUN
dpc-4151	193	7	committee	committee	NOUN
dpc-4151	193	8	[	[	X
dpc-4151	193	9	vide	vide	NOUN
dpc-4151	193	10	letter	letter	NOUN
dpc-4151	193	11	number	number	NOUN
dpc-4151	193	12	631	631	NUM
dpc-4151	193	13	(	(	PUNCT
dpc-4151	193	14	74/2022)/	74/2022)/	NUM
dpc-4151	193	15	iec	iec	NOUN
dpc-4151	193	16	/	/	SYM
dpc-4151	193	17	abvims	abvim	NOUN
dpc-4151	193	18	/	/	SYM
dpc-4151	193	19	rmlh/1134	rmlh/1134	NOUN
dpc-4151	193	20	]	]	PUNCT
dpc-4151	193	21	.	.	PUNCT
dpc-4151	194	1	references	reference	NOUN
dpc-4151	194	2	1	1	NUM
dpc-4151	194	3	.	.	PUNCT
dpc-4151	194	4	hunt	hunt	NOUN
dpc-4151	194	5	km	km	PROPN
dpc-4151	194	6	,	,	PUNCT
dpc-4151	194	7	klager	klager	NOUN
dpc-4151	194	8	s	s	PROPN
dpc-4151	194	9	,	,	PUNCT
dpc-4151	194	10	kwak	kwak	PROPN
dpc-4151	194	11	yj	yj	PROPN
dpc-4151	194	12	,	,	PUNCT
dpc-4151	194	13	sami	sami	PROPN
dpc-4151	194	14	n.	n.	PROPN
dpc-4151	194	15	successful	successful	ADJ
dpc-4151	194	16	systemic	systemic	ADJ
dpc-4151	194	17	treatment	treatment	NOUN
dpc-4151	194	18	outcomes	outcome	NOUN
dpc-4151	194	19	of	of	ADP
dpc-4151	194	20	lichen	lichen	NOUN
dpc-4151	194	21	planus	planus	NOUN
dpc-4151	194	22	:	:	PUNCT
dpc-4151	194	23	a	a	DET
dpc-4151	194	24	single	single	ADJ
dpc-4151	194	25	-	-	PUNCT
dpc-4151	194	26	center	center	NOUN
dpc-4151	194	27	retrospective	retrospective	ADJ
dpc-4151	194	28	review	review	NOUN
dpc-4151	194	29	.	.	PUNCT
dpc-4151	194	30	  	  	SPACE
dpc-4151	195	1	dermatol	dermatol	NOUN
dpc-4151	195	2	ther	ther	ADV
dpc-4151	195	3	.	.	PUNCT
dpc-4151	196	1	2021;34(3):e14903	2021;34(3):e14903	X
dpc-4151	196	2	.	.	PUNCT
dpc-4151	197	1	doi:10.1111	doi:10.1111	PROPN
dpc-4151	197	2	/dth.14903	/dth.14903	PROPN
dpc-4151	197	3	.	.	PUNCT
dpc-4151	198	1	2	2	X
dpc-4151	198	2	.	.	X
dpc-4151	198	3	husein	husein	NOUN
dpc-4151	198	4	-	-	PUNCT
dpc-4151	198	5	elahmed	elahme	VERB
dpc-4151	198	6	h	h	NOUN
dpc-4151	198	7	,	,	PUNCT
dpc-4151	198	8	gieler	gieler	NOUN
dpc-4151	198	9	u	u	NOUN
dpc-4151	198	10	,	,	PUNCT
dpc-4151	198	11	steinhoff	steinhoff	ADJ
dpc-4151	198	12	m.	m.	NOUN
dpc-4151	198	13	lichen	lichen	NOUN
dpc-4151	198	14	planus	planus	PROPN
dpc-4151	198	15	:	:	PUNCT
dpc-4151	198	16	a	a	DET
dpc-4151	198	17	comprehensive	comprehensive	ADJ
dpc-4151	198	18	evidencebased	evidencebase	VERB
dpc-4151	198	19	analysis	analysis	NOUN
dpc-4151	198	20	of	of	ADP
dpc-4151	198	21	medical	medical	ADJ
dpc-4151	198	22	treatment	treatment	NOUN
dpc-4151	198	23	.	.	PUNCT
dpc-4151	199	1	j	j	PROPN
dpc-4151	199	2	eur	eur	PROPN
dpc-4151	199	3	acad	acad	PROPN
dpc-4151	199	4	dermatol	dermatol	NOUN
dpc-4151	199	5	venereol	venereol	NOUN
dpc-4151	199	6	.	.	PUNCT
dpc-4151	200	1	2019;33(10):1847	2019;33(10):1847	X
dpc-4151	200	2	-	-	SYM
dpc-4151	200	3	62	62	NUM
dpc-4151	200	4	.	.	PUNCT
dpc-4151	201	1	doi:10.1111	doi:10.1111	PROPN
dpc-4151	201	2	/jdv.15771	/jdv.15771	PROPN
dpc-4151	201	3	.	.	PUNCT
dpc-4151	202	1	3	3	X
dpc-4151	202	2	.	.	X
dpc-4151	202	3	hazra	hazra	PROPN
dpc-4151	202	4	sc	sc	PROPN
dpc-4151	202	5	,	,	PUNCT
dpc-4151	202	6	choudhury	choudhury	PROPN
dpc-4151	202	7	am	am	PROPN
dpc-4151	202	8	,	,	PUNCT
dpc-4151	202	9	khondker	khondker	PROPN
dpc-4151	202	10	l	l	PROPN
dpc-4151	202	11	,	,	PUNCT
dpc-4151	202	12	khan	khan	PROPN
dpc-4151	202	13	si	si	PROPN
dpc-4151	202	14	.	.	PROPN
dpc-4151	202	15	comparative	comparative	ADJ
dpc-4151	202	16	efficacy	efficacy	NOUN
dpc-4151	202	17	of	of	ADP
dpc-4151	202	18	methotrexate	methotrexate	NOUN
dpc-4151	202	19	and	and	CCONJ
dpc-4151	202	20	mini	mini	ADJ
dpc-4151	202	21	pulse	pulse	NOUN
dpc-4151	202	22	betamethasone	betamethasone	NOUN
dpc-4151	202	23	in	in	ADP
dpc-4151	202	24	the	the	DET
dpc-4151	202	25	treatment	treatment	NOUN
dpc-4151	202	26	of	of	ADP
dpc-4151	202	27	lichen	lichen	NOUN
dpc-4151	202	28	planus	planus	NOUN
dpc-4151	202	29	.	.	PUNCT
dpc-4151	203	1	mymensingh	mymensingh	PROPN
dpc-4151	203	2	med	med	PROPN
dpc-4151	203	3	j.	j.	PROPN
dpc-4151	203	4	2013(4);22:787–97	2013(4);22:787–97	PROPN
dpc-4151	203	5	.	.	PROPN
dpc-4151	203	6	4	4	NUM
dpc-4151	203	7	.	.	PUNCT
dpc-4151	204	1	arora	arora	PROPN
dpc-4151	204	2	p	p	X
dpc-4151	204	3	,	,	PUNCT
dpc-4151	204	4	sardana	sardana	PROPN
dpc-4151	204	5	k	k	PROPN
dpc-4151	204	6	,	,	PUNCT
dpc-4151	204	7	gautam	gautam	PROPN
dpc-4151	204	8	rk	rk	PROPN
dpc-4151	204	9	,	,	PUNCT
dpc-4151	204	10	malhotra	malhotra	PROPN
dpc-4151	204	11	p.	p.	PROPN
dpc-4151	204	12	low	low	PROPN
dpc-4151	204	13	dose	dose	PROPN
dpc-4151	204	14	thalidomide	thalidomide	NOUN
dpc-4151	204	15	monotherapy	monotherapy	NOUN
dpc-4151	204	16	for	for	ADP
dpc-4151	204	17	the	the	DET
dpc-4151	204	18	treatment	treatment	NOUN
dpc-4151	204	19	of	of	ADP
dpc-4151	204	20	recalcitrant	recalcitrant	ADJ
dpc-4151	204	21	erosive	erosive	NOUN
dpc-4151	204	22	lichen	lichen	NOUN
dpc-4151	204	23	planus	planus	NOUN
dpc-4151	204	24	.	.	PUNCT
dpc-4151	205	1	dermatol	dermatol	NOUN
dpc-4151	205	2	ther	ther	ADV
dpc-4151	205	3	.	.	PUNCT
dpc-4151	206	1	2019;32(2):e12824	2019;32(2):e12824	NUM
dpc-4151	206	2	.	.	PUNCT
dpc-4151	206	3	doi:10.1111	doi:10.1111	PROPN
dpc-4151	206	4	/dth.12824	/dth.12824	PROPN
dpc-4151	206	5	.	.	PUNCT